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ABSTRACT OF THESIS

COLLAGEN CROSSLINKING REAGENT UTILIZED TO MODIFY THE MECHANICAL
PROPERTIES OF THE SOFT PALATE IN EQUINE SNORING AND APNEA
APPLICATIONS
Snoring is a sleep disruption that can lead to obstructive sleep apnea (OSA),
which interrupts breathing by obstructing the airway. Injecting a protein crosslinker, such
as genipin, into the soft palate could decrease the severity of snoring and OSA by
stiffening the soft palate. Equine soft palates modeled human palates due to a high
incidence of awake snoring and apnea.
The pilot in vivo study treated six horses with two 100 mM injections of the
buffered genipin reagent. The efficacy phase horses underwent respiratory audio
recordings to document snoring changes using Matlab and ImageJ in the time and
frequency domains. Histological analysis was completed on the safety phase palates
post treatment.
All horses were successfully treated with the genipin injections. At least one
horse showed high frequency amplitude reductions, and all horses had low frequency
amplitude reductions, correlating to a reduction in palatal displacement and snoring
loudness. One efficacy horse appears to have been completely cured. The histological
analysis presented tissue damage, mucosal tissue damage, and mild inflammation due
to palate expansion and errant injections.
Different injection volumes and techniques should be investigated next. Applying
this treatment to human studies for snoring and OSA applications is the ultimate goal.

KEYWORDS: Obstructive sleep apnea, snoring, soft palate stiffening, sound analysis of
snoring, biomechanical testing of soft tissue
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1. Introduction
Snoring is a highly prevalent condition that affects people of all ages, caused by
the vibration of the tissues in the airway of the nose and throat, especially the soft
palate. Conditions leading to snoring are exacerbated by obesity, allergies, aging,
medication use, or alcohol consumption. Snoring can lead to sleep cycle disruptions for
the snorer and their family, sleep deprivation, daytime lethargy, and drowsiness [1-4]. In
some instances, snoring can advance into a more serious, and sometimes life
threatening condition, obstructive sleep apnea (OSA). In OSA, breathing is interrupted
during sleep by physical obstruction of the airway caused by excessive compliance of
the soft palate and abnormalities in the geometry of air passages. Repeated trauma to
the soft palate caused by snoring can increase its passive deformability and damage its
muscle fibers and peripheral nerve fibers, increasing the chance of obstruction. OSA
can lead to respiratory and cardiovascular complications, such as high blood pressure,
stroke, heart failure, diabetes and depression [1-5].
Current treatments for snoring and OSA follow a 4-phase path. The first step is
simple lifestyle changes, such as weight loss or changing eating or drinking habits. The
second phase consists of over the counter medications, oral devices and nasal dilators.
One common example of over the counter products is nasal snoring strips. The third
phase consists of non-surgical devices, such as the continuous positive air pressure
machine (CPAP) that provides continuous air to the patient to counter the narrowing of
the air passage. The final phase consists of various surgical treatments aimed at either
removal of offending tissues or stiffening the soft palate through the formation of scar
tissue. Examples of common surgical procedures include radiofrequency ablation,
injection of sclerosants, uvulectomy surgery, and the Pillar procedure [1,4,5,6-15].
The treatments for both snoring and OSA are relatively unsuccessful. A majority
of the current surgery procedures rely on stiffening the soft palate to increase damping,
and therefore to improve airflow induced vibrations. Typically, the stiffening is the result
of fibrosis formation, which is an inflammatory wound-healing response resulting in
fibroblast activation and production of a poorly organized extracellular matrix [6-15].
Short-term results are promising for these treatments; however, fibrosis contributes to
mechanical degradation of the overloaded soft palate, leading to eventual loss of
treatment benefits. Generally, the collagen network created in fibrotic lesions is not the
same type of collagen originally present in the tissue, leading to degradation of the
1

mechanical properties and reduction of the tissue’s durability, or fatigue resistance [8,1517]. Additionally, the tissue-material interfaces produced in some procedures can cause
micro-motion, wear, particle-release, inflammatory or cellular responses and tissue
damage [13-16]. Treatments that rely on heat denaturation of the target tissue can
produce inferior mechanical properties, substandard molecular and micro-structural
geometries and loss of initial treatment-related benefits [6-12]. With less than ideal
results from current treatments, along with an increasing number of patients diagnosed
with snoring and OSA, a new treatment is necessary that can stiffen the soft palate while
improving the mechanical properties of the tissue.
The hypothesis of this study was that an injection of a non-toxic protein crosslinking reagent into the soft palate would augment the mechanical properties and reduce
deformation and vibration of the palate when subjected to physiologic air flow, thus
decreasing severity of snoring and the likelihood of airway collapse, while also
increasing the tissue’s resistance to mechanical degradation. Instead of creating scar
tissue that degrades over time, crosslink augmentation stabilizes the tissue while
preserving the microstructural and compositional integrity. More specifically, this method
can modify the viscoelastic, elastic-plastic, and durability properties by increasing the
strength, stiffness, fatigue resistance and energy required to permanently deform or fail
the tissue [18-26]. Compared to other treatments, protein crosslinking is less intrusive,
less expensive, faster (same-day benefit), and less harsh in regards to induction of
inflammatory responses.
An alternative to animal model research was unsuccessful in simulating the multifaceted conditions leading to soft palate degradation, tissue vibration and air passage
obstruction. Likewise, the inflammatory and immunogenic responses and the
mechanically activated cellular responses to a non-physiologically altered matrix cannot
be simulated to an acceptable level in a non-living model. Therefore, equine soft palates
were used as a relevant model to represent human snoring and OSA due to a high
incidence of awake snoring and apnea, otherwise known as dorsal displacement of the
soft palate, or DDSP. This disease is a naturally occurring soft palate disorder caused
by the displacement of the caudal edge of the soft palate, which interferes with normal
airflow through the nasopharynx, producing mechanical property deficiencies, snoring,
and temporary obstruction of the airway. DDSP occurs in 10 to 20% of competitive
horses; however, this is only an estimate because horses with this malady are often
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quietly euthanized [27]. Current treatments include the tie-forward procedure, laser
staphylectomy, myectomy, and the Cornell Collar that focus on immobilizing the larynx
or stiffening the soft palate to prevent displacement of the soft palate, all of which have
about a 50-60% success rate [27-33].
The hypotheses of this study were tested through in vivo and in vitro methods
using equine soft palates as a relevant model for human snoring and OSA. A pilot
equine in vivo study tested the efficacy and safety of genipin injection treatment of the
soft palate. The in vitro mechanical testing study used cadaveric equine soft palates to
determine the effects of the genipin treatment on the mechanical properties of the soft
palate. Together, these studies provided a glimpse into the potential treatment benefits
of injecting a genipin crosslinking reagent into the soft palate for treatment of human
snoring and OSA, as well as equine DDSP.
Prior to starting any work on the current study, a previous in vitro equine soft
palate study was completed by Dr. Jonathan Kuo and his team from Orthopeutics, LP in
Lexington, KY that was used to determine the concentrations of the genipin treatment
used in both the pilot in vivo study and the in vitro mechanical testing study. Kuo et al.
designed and constructed a custom wind tunnel, equipped with a mounting clamp that
mimicked the support provided to the soft palate by the hard palate and connective
tissues, to simulate the equine respiratory tract as shown in Figure 1.1 The wind tunnel
system produced transient and steady state wind flow up to 14 meters/second over the
mounted soft palate to simulate breathing conditions. A laser reflection transducer
(Keyence LK-081, Itaska, IL) was mounted above the samples to measure the
displacement amplitudes and vibration frequency and amplitudes of the specimens.
Three different concentrations for genipin injection were tested, including 50 mM, 100
mM and 150 mM. Additionally, untreated controls and 0.33% genipin soaked samples
were tested to serve as baselines for untreated tissue and maximum genipin crosslinked
tissue, respectively. Changes in displacement and frequency were measured and
compared between treated and untreated samples. The genipin injected soft palates
resulted in localized crosslinking around the injection side. The 50 mM, 100 mM and
150 mM genipin concentration injection had 44%, 46% and 64% respective decrease in
transient displacement of the soft palate compared to the untreated samples. For
steady state displacements (vibration amplitudes), there was a 36%, 23%, and 42%
decrease compared to the control samples for the 50 mM, 100 mM, and 150 mM genipin
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concentration injections, respectively. The genipin injections covered 40%, 49% and
51% of the soft palate for the 50 mM, 100 mM, and 150 mM genipin concentration
injections, respectively, based on the area of crosslinking region, which appears blue
due to the genipin reaction.

Figure 1.1: The wind tunnel was custom designed to mimic the equine breathing flow (left). It
consisted of a fan that blew wind over the soft palate to measure changes in the displacements
using a laser displacement measurement system. The wind tunnel supported the soft palate (right)
similar to how the hard palate and connective tissue support it in the horse’s airway.

Based on the results of the wind tunnel study, the 100 mM concentration of
genipin injections was used for the in vivo study for a variety of reasons. First, the 100
mM concentration showed a decrease in both deformation and vibration of the palate.
Also, it treated about half of the palate, as demonstrated by the area of the blue genipin
crosslinking region. The amount of area covered by the genipin was important in the
equine studies because the soft palate is larger, thus more coverage is needed to
effectively treat the tissue. Finally, a previous safety study completed by Orthopeutics,
LP, showed no adverse acute reactions at the 100 mM genipin concentration when
injecting it into the equine soft palate in vivo. Overall, the 100 mM concentration for the
genipin injections showed the most promise to produce a noticeable treatment effect for
horses afflicted with DDSP.
For the equine soft palate mechanical testing study, the 50 mM genipin
concentration was chosen because it was the preferred concentration for potential
human snoring and OSA applications. The 50 mM concentration was picked because it
had minimal toxicity based on previous studies while demonstrating a similar effect in the
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wind tunnel as higher concentrations. Also, no DMSO was required to solubilize the
genipin at a lower concentration.
The pilot equine in vivo study consisted of two phases: the efficacy phase, which
tested the success of the genipin injections for treating DDSP, and the safety phase,
which tested the short-term biological effects of the genipin injections on the soft palate.
The efficacy phase consisted of three horses diagnosed with DDSP, while the safety
phase consisted of three horses with no apparent breathing disorders. The efficacy
phase horses underwent dynamic endoscope examinations and respiratory audio
recordings prior to and after the soft palate injections to qualitatively and quantitatively
measure the effects of the genipin treatment. The respiratory audio recordings were
analyzed using Matlab in the time domain and frequency domain to determine if there
were any changes in the snoring loudness or frequency of DDSP associated with the
genipin treatment. At the completion of the study, the soft palates from the safety phase
horses were harvested for histological analysis using hematoxylin and eosin (H&E) stain
to determine any presence of inflammation or fibroplasia infiltrates.
The mechanical testing study used cadaveric equine soft palates to test the
effect of the genipin treatment on the mechanical properties of the tissue. Three test
groups, including untreated control samples, buffer-only injected samples, and buffered
genipin treated samples, underwent three mechanical tests using a universal testing
machine. Each sample underwent a cyclical loading (hysteresis), stress relaxation and
tensile loading to failure test in order to determine quantitative changes between the
treated samples and untreated samples. First cycle hysteresis, change in hysteresis,
hysteresis ratio, stress relaxation, relaxation modulus, normalized relaxation modulus,
ultimate tensile stress and strain, toe region slope, Young’s modulus, yield point stress
and strain, toughness, energy, and resilience were calculated from the results of the
mechanical tests. Statistical analysis was completed using the F-test, Student’s t-test
and the Mann-Whitney U non-parametric test to determine any statistically significant
differences between the three test groups.
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2. Background
2.1 Snoring and Obstructive Sleep Apnea
2.1.1

Overview

Snoring is a respiratory sound generated primarily by inspiration in the upper
airway during sleep [1]. The functions of the upper airway, which is the part of the
respiratory system between the nostrils and trachea, include air warming, humidification,
pathways for olfaction, coordination of ventilation with swallowing, protection from
aspiration of food, and primary defense against infection [2]. These functions are
controlled by the neuromuscular systems under both voluntary and involuntary control
[2]. Snoring is worsened by alcohol consumption, weight gain, sedative medications,
sleep deprivations, and supine sleeping positions. The symptoms of snoring include
drooling, dry mouth and restless sleep [3]. Additionally, patients experience excessive
daytime sleepiness (EDS), which is measured by the Epworth Sleepiness Scale (ESS)
[3]. Overall, snoring affects people of all ages, occurring in 35-45% of men and 15-28%
of women [4]. However, it is more prevalent in the elderly, occurring in 28-67% of elderly
men and in 20-54% of elderly women [4].
Obstructive sleep apnea (OSA) is a potentially life threatening condition caused
by repetitive partial or complete collapse of the upper airway during sleep. OSA occurs
when an imbalance persists between the forces dilating and occluding the pharynx due
to insufficiencies in luminal patency and airway stability, including slowly varying
vascular pressure and tissue elasticity and quickly varying muscular effects [1,34]. OSA
is a gradually progressive disease caused by a variety of factors, including palatal
denervation, a thickened soft palate, an enlarged tongue volume, a receding jaw, an
enlarge uvula or a lack of muscle tone in the throat [1-4]. Additionally, a lack of rigidity
caused by a decrease in mechanical properties of the pharyngeal tissues can also lead
to airway occlusion, including the upper airway muscles, larynx and soft palate [34].
These conditions lead to apneas - a cessation of breathing, or hypopneas - reduced
breathing phases [1]. During sleep, the upper airway is particularly vulnerable because
the reflexes are relaxed, leaving the airway susceptible to collapse, leading to OSA
conditions [2,4]. OSA occurs in about 2-11% of the population aged 16 or older, or
approximately 10 million individuals. Men are twice as likely to experience OSA than
women. Additionally, OSA is more common in Pacific Islanders, Hispanic Americans,
and African Americans [1,4,5].
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OSA is characterized by a loud snore alternating with 20- to 30- second intervals
of silence, terminated by loud snorts, gasps, moans or other vocalizations, and
sometimes in conjunction with brief awakenings and body movements [3]. Additionally,
18-31% of patients experience nocturnal dyspnea, or a sensation of choking or
suffocating, in relationship with OSA [3]. Nocturnal symptoms of OSA consist of
intermittent snoring, nocturnal enuresis, witnessed apneas, dyspnea, drooling, dry
mouth, bruxism, restless sleep/frequent arousals, gastroesophageal reflux and nocturia
[1,4]. Daytime symptoms include daytime sleepiness, diminished intellectual
performance, personality changes, morning headaches, diminished quality of life,
depression, anxiety, irritability, and sexual dysfunction [1,4].

Excessive body weight

and genetic factors play a role in OSA, as well [1,4]. As OSA worsens, it leads to more
serious respiratory and cardiovascular complications, including hypertension,
cardiovascular disease, stroke, obesity, insulin resistance, and myocardial infarction
[1,3,5].
OSA is diagnosed according to the apnea hypopnea index (AHI), physical
examinations, and patient symptoms [1,3]. AHI is defined as the number of apneas plus
the number of hypopneas per hour of sleep. Typically, if a patient experiences more than
five respiratory collapses per hour (AHI ≥ 5), they are diagnosed with OSA. OSA is then
categorized based on severity: mild OSA from 5 ≤ AHI < 20; moderate OSA from 20 ≤
AHI < 40; and severe OSA with AHI ≥ 40 [1,3]. Diagnosing sleep apnea through
symptoms alone is only successful about 50% of the time; therefore, sleep endoscopic
examinations or polysomnography tests are utilized for a more accurate diagnosis [3,5].
Sleep endoscopic examinations are completed using a flexible endoscope to view the
nasal passage while a patient is sleeping. There are a few disadvantages associated
with endoscopic examinations that interfere with the validity of the test, including
reduction of the cross-section of the airway by the endoscope, arousal reactions due to
mechanical stimulus, to visual obstruction by phlegm, and to simultaneous assessment
of only one level of the airway [1]. A polysomnography test, which is the current ‘gold
standard’ for diagnosing OSA, is a sleep study completed overnight that observes
various sleep irregularities. However, sleep studies are expensive and time consuming,
which dissuades patients from undergoing them [3]. In both techniques, an apnea is
identified as the cessation of airflow for at least ten seconds [6]. Additionally, according
to the American Academy of Sleep Medicine Task Force, hypopnea is defined as either
greater than 50% reduction in airflow, or less than 50% reduction in airflow associated
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with a desaturation of greater than 3%, or a moderate reduction in airflow with
associated arousal by electroencephalogram (EEG) [35].
2.1.2 Current Treatments
Current treatments for snoring and OSA range from conservative options to
apparatus therapies to invasive surgeries, all of which have respective advantages and
disadvantages. The goal of all snoring treatments is to reduce or stop vibration of the
relevant airway structures, while the goals of OSA treatments are to enlarge the airway
or to alter mechanical properties of the pharyngeal tissues to prevent collapse and
eliminate apneas, hypopneas, and other related symptoms [1,34,36]. The first treatment
option for both snoring and OSA are conservative treatments, which consist of weight
reduction, optimization of sleep hygiene, avoidance of certain sleeping positions, and
cessation of certain medication, alcohol and tobacco use [1,37].
The next phase consists of oral devices and apparatus therapies. One common
oral device is mandibular repositioning appliance (MRA), which manually moves the
mandible forward to improve the upper airway patency [37]. Typically, the MRA has a
50-70% success rate for mild to moderate severe OSA [1]. In general, the oral devices
are bulky and uncomfortable, leading to hypersalivation, xerostomy, jaw pain, dental
pain and permanent teeth misalignments [1,4].
The most widely used apparatus therapy is the continuous positive airway
pressure (CPAP) machine, which delivers a continuous flow of air through a nasal mask,
creating a constant pressure during the respiratory cycle to eliminate obstructive apneas,
as shown in Figure 2.1 [4]. The CPAP machine works by counteracting the negative
transmural pressure that promotes collapse and narrowing of the floppy-toned upper
airway pharyngeal musculature by pneumatically splinting open the upper airway via the
application of a positive pressure across the airway walls to prevent narrowing or
collapse [37]. With a potential success rate of 98%, the CPAP machine is the ‘gold
standard’ therapy in OSA treatments; however, there are patient compliance issues
resulting in only 60-80% of patients using it due to common side effects, including nasal
congestion, rhinorrhea, dryness, sneezing, complaints of machine noise, loss of mask
seal against face, and intolerance to the level of positive pressure [1-5].
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Figure 2.1: The CPAP machine is an external device used to treated OSA and severe snoring. The
machine is bulky and noisy, causing sleep cycle disruptions for the patient and their family.

Nasal surgery options are typically used in conjunction with the CPAP machine to
assist in snoring reduction and OSA. Common nasal surgeries include: septoplasty,
septorhinoplasty, turbinate reduction, and endoscopic sinus surgery [5]. Overall, nasal
surgeries are successful at reducing snoring 34-69% of the time and OSA 20% of the
time in combination with the CPAP machine [4].
When simple lifestyle changes and apparatus therapies fail, surgical procedures
focus on altering the soft palate and surrounding tissues for treatment of snoring and
OSA. The uvulopalatopharyngoplasty (UPPP) consists of ablating the excessive tissue
of posterior margin of the soft palate, uvula, and lateral pharyngeal wall with a laser,
cautery or cold knife to relieve oropharyngeal obstruction and to increase stiffness
through postoperative scarring [4,36,38]. Typically, the UPPP procedure is completed in
conjunction with a tonsillectomy [4]. In general, there is a long-term success rate of
70% for snoring and of 50% for OSA [5]. The success of the treatment relies on the
amount of soft palate tissue resected. Excessive resection can cause palatal
malfunction, and conservative resection can still produce snoring or OSA symptoms [38].
The procedure is considered to be relatively painful with high morbidity and mortality
rates and common side effects, including post-op bleeding, voice changes,
nasopharyngeal stenosis, persistent dry throat, swallowing abnormalities, respiratory
distress and palatal incompetence [4,5,38].
Another surgery treatment is the laser-assisted uvulopalatoplasty (LAUP), which
reduces snoring by trimming the palate and surrounding tissues and by increasing the
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stiffness through postoperative scarring [36]. The procedure consists of ablation of the
palate, velum, and uvula using a carbon dioxide laser under local anesthesia [4].
Overall, the side effects are minor with the biggest complaint being severe pain and
potential ineffectiveness [4]. The effectiveness was reported as 69% successful at 9
months and as 55% successful at 59 months post treatment. In general, success rates
deteriorated from 70% to 30% over time, with differences in laryngeal anatomy being the
biggest reason for failure [5]. In some cases, treatments can be repeated every six
weeks to improve effectiveness [5].
Many surgical treatments focus on stiffening the soft palate to prevent vibration
and obstruction, such as radiofrequency thermotherapy, the injection of sclerosants, the
Pillar procedure, and laser soft palate stiffening. Radiofrequency thermotherapy is
accomplished by using radiofrequency energy to create thermal lesions with subsequent
fibrosis leading to stiffening and some shrinkage of the palate and tongue base [5]. This
outpatient procedure works best for mild to moderate OSA, with effectiveness being
related to the total energy delivered and to the location of the lesions that increase scar
tissue [5,35]. Common complications include pain, dryness, or recurrence of snoring
[35]. Similarly, the injection of sclerosants stiffens the palate by injecting chemicals,
such as sodium tetradecyl sulphate, into the tissue to induce scarring and stiffening of
the palate [5]. Again, complications include pain, dryness, foreign body sensation, and
recurrence of snoring [36].
The Pillar procedure consists of inserting palatal implants into the soft palate to
reduce vibration and narrowing of the soft palate by increasing the stiffness of the palate
[5,36]. Three small, rectangular implants, made of a woven polyester material, are
inserted into the soft palate in a parallel orientation for the treatment of OSA [36].
Initially, the treatment reduces AHI in patients with mild to moderate OSA as long as the
implant stays in place. However, over time, the effectiveness decreases because the
fibrotic encapsulation around the implants leads to tissue degradation [36]. The most
common side effect of the Pillar procedure is the extrusion of the implant at a rate of 025% due to chronic inflammatory responses and fibrous capsule formation. This side
effect is remedied by replacing the implant [36].
Comparably, the laser soft palate stiffening procedure stiffens the palate using a
low power Nd:YAG laser of 1.44 micrometer as an alternative treatment to the UPPP
surgery. This procedure is less invasive than the UPPP because it is a form of
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“electrosurgery” that works by visibly shrinking the soft palate by breaking intrinsic
collagen crosslinking to shrink the collagenous matrix, with an average 3.0 mm
immediate reduction in length [38]. Histopathology results show no inflammation or
necrosis, with submucosal fibrosis and scarring produced about 1-1.5 mm deep [38].
The immediate response is mucosal shrinking, followed by a gradual tissue stiffening
over time with the formation of tissue fibrosis [38]. Long-term effectiveness for this
particular treatment have not been studied fully, but similar to other methods that stiffen
the palate through scar tissue formation, it can be assumed that the effectiveness will
decrease over time due to mechanical degradation in the soft palate.
Other treatments for snoring and OSA include skeletal facial corrections and
tracheotomy surgeries. The maxillomandibular advancement is a type of skeletal facial
correction that works by repositioning the jaw to allow for more airflow to prevent
obstruction [36]. A tracheotomy is an opening in the windpipe that alleviates breathing
obstructions [4,39]. Tracheotomy surgeries are generally viewed to be a mutilating
intervention because it creates an unsightly hole in the trachea [4]. In general, these two
treatments are the only treatments considered to be 100% effective at preventing OSA,
and are reserved for patients with severe OSA that are unsuitable for CPAP or other
surgical options due to severe life-threatening conditions or failure of previous surgical
approaches [4].
2.1.3

Acoustic Analyses of Snoring and Sleep Apnea

A review of the literature was conducted to determine common techniques for
detecting and analyzing snoring and OSA sounds. Relevant techniques could then be
applied to the equine in vivo study to record and analyze snoring sounds. Beck et al.
characterized snoring in the article title, “The acoustic properties of snoring.” In Beck’s
study, snoring was simulated in a canine model by placing a balloon above the larynx
and inflating it to create various levels of obstruction to simulate OSA [40]. Beck then
analyzed the snoring sounds from 75-2000 Hz in the time domain and frequency
domain. The canine snoring sounds resulted in complex waveforms in the low frequency
range associated with intermittent airway closure. The biggest difference between
Beck’s study and the current study is the animal model. Beck’s study used a canine
model that had an induced airway obstruction, whereas the equine model used in the
present study experienced a naturally occurring form of OSA and snoring. Regardless
of the animal model, Beck’s study reiterated the idea that complex snoring waveforms in
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the low frequency range are associated with airway obstruction, meaning that respiratory
recordings and analysis in the low frequency range are a viable way to determine
differences in snoring patterns.
Another article titled, “Is there a relationship between sound intensity and
frequency and OSAS severity?” by Acar et. al. explored the correlation between snoring
loudness and OSA severity through snoring analysis. Acar’s study consisted of patients
with various degrees of OSA, ranging from mild to severe [41]. This study analyzed the
snoring sounds using the fast Fourier transform function (FFT), and snoring was
quantified using average snoring sound intensity level (SSIL) and the maximal frequency
(Fmax). Acar determined that SSIL and Fmax increased with age, in females, and in
patients with severe OSA. Additionally, Acar concluded that SSIL and Fmax are strongly
correlated with AHI, and thus the severity of OSA. Acar’s study showed that the FFT is
a preferred way to analyze snoring sounds because it allows various peaks to be
determined. Acar also indicated that higher frequency peaks are characteristic of OSA
snoring, which can be carried over for the equine snoring analysis used in the present
study. In contrast, Acar’s study focused on determining specific parameters associated
with OSA, while the present study focused more on comparing a pre treatment
frequency domain curve against a post treatment frequency domain curve.
Another article by Azarbarzin and Moussavi, titled, “Snoring sounds variability as
a signature of obstructive sleep apnea,” worked to determine an association between
snoring sounds and the degree of OSA. Azarbarzin and Moussavi recorded snoring
sounds from patients with varying degrees of OSA and analyzed them using the time
domain and frequency domain [42]. In their study, the apneic events had a pattern of
high amplitude bands followed by apneic gaps without breathing in the time domain
graphs. These concepts can be used in the present equine in vivo study to determine
the location of an obstruction caused by DDSP in the time domain.
2.2 Dorsal Displacement of the Soft Palate
2.2.1

Overview

Equine soft palates were used as a relevant model to represent the multi-faceted
conditions leading to soft palate degradation, tissue vibration and air passage
obstruction in snoring and OSA due to a high incidence of a pathology involving awake
snoring and apnea, known as dorsal displacement of the soft palate, or DDSP. This
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disease is a naturally occurring soft palate disorder caused by the displacement of the
caudal edge of the soft palate, which interferes with normal airflow through the
nasopharynx. The disorder most commonly occurs when the head is in a flexed
position, or when the horse is fatigued during hard exercise [43]. The displacement can
usually be self-corrected by the animal by swallowing or by readjusting the head
position, however, it can occur several times during a single race or training session,
causing interruptions to normal breathing and consequently a significant decrease in
performance.
Horses breathe completely through their nostrils, meaning that they cannot
breathe through their mouths [43]. The soft palate is a musculomembranous tissue that
extends from the hard palate to the esophageal pharynx, separating the oral cavity from
the nasopharynx [44]. The epiglottis projects through the caudal notch, or free border, of
the palate [44]. Together, the soft palate and epiglottis form a seal to block off the nasal
cavity from the oral cavity. The free border of the palate should remain beneath the
epiglottis at all times, except during swallowing or coughing [44]. DDSP occurs when the
caudal edge of the soft palate displaces dorsally relative to the epiglottis, partially
blocking the nasal passage and creating air turbulence during inspiration and, primarily,
expiration, as demonstrated in Figure 2.2 [44]. When displaced, the soft palate reduces
the cross-sectional area of the nasopharnyx, causing an obstruction. The caudal edge
of the palate vibrates as air flows past it, producing a “gurgling” or “snoring” noise in 5080% of affected horses [29-33,44-46]. When the soft palate is displaced, minute
ventilation decreases by 13%, and maximal oxygen consumption decreases by 10%
[45]. Swallowing or head movements can return the palate to the normal position after
displacement [44]. In permanent cases, the palate is continuously displaced [27].
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Normal Anatomy

Epiglottis

Soft Palate

DDSP Anatomy

Soft Palate

Epiglottis
Figure 2.2: The normal airway anatomy (top) of a horse allows air to pass freely past the soft palate,
which is tucked underneath the epiglottis. In DDSP (bottom), the soft palate is displaced above the
epiglottis, blocking the airway as the horse exhales.

DDSP occurs in 10-40% of competitive horses, especially Thoroughbreds and
Standardbred racehorses [27-33]. There is no known correlation between age of the
horse and predisposition to DDSP, although younger horses seem more prone to the
malady [27,32]. Since the soft palate acts as a seal for the larynx, any factor that
disrupts the seal can cause the soft palate to displace. Therefore, retraction of the
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tongue can cause caudal displacement of the larynx, forcing the soft palate above the
epiglottis [24]. Structural abnormalities or physical obstruction due to masses,
granulomas or cysts can also interfere with soft palate position, causing DDSP [27,46].
In certain cases, hyper activation of the muscles responsible for the movement of the
larynx can cause the larynx to retract, thus displacing the palate. This condition
manifests in horses that are overly excitable or nervous [46].
DDSP is diagnosed through clinical observations and dynamic endoscopic
examinations. A loud “gurgling” or “snoring” noise, as well as the fluttering of the cheeks
as air is diverted beneath the displaced palate, are common symptoms of DDSP.
Additionally, affected horses demonstrate exercise intolerance, often described by
trainers as “choking down” or “swallowing their tongue” due to the temporary airway
obstruction [27].
Resting endoscopic evaluations are not useful in detecting DDSP because the
soft palate rarely displaces at rest; however, resting endoscopic evaluations are utilized
to assess the nasopharyngeal function and to rule out other upper airway disorders [27].
DDSP is diagnosed with a dynamic endoscopic examination performed on a treadmill or
over ground. The dynamic endoscope mimics showing or racing conditions that induce
the displacement as close as possible. For example, the horse is equipped with the
typical tack and/or devices utilized during showing or racing. An endoscope is advanced
through the nostril to the pharynx, then the horse is exercised at various speeds and
intensities until fatigue to induce DDSP conditions [27]. In some instances, the frequency
of swallowing increases immediately prior to displacement [27]. Additionally, some
horses experience a billowing of the caudal portion of the soft palate, causing palatal
instability, preceding displacement [27]. DDSP is diagnosed if the soft palate displaces
dorsally to the epiglottis for longer than eight seconds during the dynamic endoscopic
evaluations [27].
2.2.2 Current Treatments
Because there are a variety of conditions that lead to DDSP, potential treatments
vary significantly, from simple external devices or tack adjustments to complex surgical
procedures. The simplest treatment for DDSP is a tongue-tie during exercise, in which
the tongue is physically tied to the lower jaw using a leather strap or fabric strip. The
tongue is indirectly connected to the larynx, so tying it prevents caudal retraction of the
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larynx, and thus applying dorsal pressure to the soft palate in order to prevent
displacement [44,46,47]. Tying the tongue does not always prevent displacement, and
in some cases, multiple tongue-ties are required to prevent displacement. Similarly,
changing the tack can help with the management of DDSP. Commonly used tack
options include a Z-bit or a leverage bit to hold the head and neck in certain positions to
decrease the possibility of displacement [27,44]. Also, figure 8 nosebands are often used
to prevent air from flowing into the orthopharynx by applying ventral pressure to the soft
palate [46]. Finally, an external device can be added to assist in prevention of DDSP.
As shown in Figure 2.3, the Cornell Collar applies pressure to the caudal aspect of the
basihyoid bone and ventral aspect of the thyroid cartilage to pull the larynx more rostral,
reducing the possibility of soft palate displacement [47].

Figure 2.3: The Cornell Collar is an external device that applies pressure to the basihyoid bone to
elevate the larynx and reduce potential soft palate displacements.

When conservative treatments fail at preventing DDSP, more invasive surgical
procedures are sometimes attempted. Surgical treatments range from muscle
transection to soft palate shortening to soft palate stiffening. Overall, surgical treatments
have a 58-78% success rate [48].
A sternothyrohyoid myectomy transects the “strap” muscles via a bilateral partial
tenomyectomy to increase upper airway pressure and to provide stability to the
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nasopharyngeal structures. The “strap” muscles, which are responsible for caudal
retraction of the larynx, include the sternohyoideus, sternothyroideus and omohyoideus
muscles, commonly referred to as sternothyrohyoid muscles [44,47]. One potential
benefit of this procedure is that it can be performed under light anesthesia with the horse
remaining standing. Similarly, there is a relatively short recovery period of about 14
days with minimal complications [27,44,46]. Overall, the sternothyrohyoid myectomy has
a reported 58-73% success rate [27,46,49,50].
A staphylectomy consists of removing a portion of the caudal margin of the soft
palate to prevent airway obstruction [44]. Although the staphylectomy is a relatively
straightforward procedure, it can have severe complications and a 4-6 week recovery
period. If the soft palate is cut too short, it may allow food and water contents to enter
the nasopharynx during swallowing, leading to coughing, sneezing, or aspiration
pneumonia [46]. The success rate of 40-60% is based on the reduction of the amount
of tissue blocking the airway when the soft palate displaces [46,49].
The laryngeal tie-forward procedure mimics the effects of the Cornell Collar by
permanently positioning the larynx dorsally to the basihyoid bone by suturing the larynx
to the bone [27]. This procedure attempts to correct DDSP by reducing caudal
movement of the larynx [50]. Post-operatively, there are minimal complications, and
horses can return to work within 10-14 days [27]. Overall, there is about a 60-80%
success rate, with failure typically being the result of breakdown of the suture [49,50].
Similar to treatment in human snoring and OSA, one common treatment for
DDSP is stiffening the soft palate through laser treatments or palatal sclerotherapy. In
laser palatoplasty, the caudal edge of the soft palate is stiffened though laser induced
fibrosis during an outpatient procedure [27]. Minimal inflammatory complications occur
post-operatively, and most horses can return to work within one month [27]. Similarly,
caudal soft palate photothermoplasty stiffens the caudal edge of the soft palate by
creating a large area of fibrosis through laser ablation of strips of the oral mucosa and
submucosa [48]. Overall, stiffening the soft palate through various laser treatments had
an immediate success rate of 60-92% to prevent DDSP [48-50]. Likewise, to stiffen the
palate using sclerotherapy, a sclerosing agent, such as sodium tetradecyl sulfate, is
injected into the submucosal layer of the soft palate to induce fibrosis [49]. Overall, a
small study showed that sclerotherapy is a relatively simple procedure with minimal side
effects and a short-term success rate of about 75% [49]. In general, the short-term
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results show that stiffening the soft palate through the formation of scar tissue can
prevent displacement and vibration of the palate; however, long-term results show that
fibrous formation degrades the soft palate and is mechanically insufficient compared to
healthy tissue, leading to treatment failure [48-50].
A common approach to DDSP treatment is a combination of two or more
procedures. Composite surgeries offer the benefit of minimizing anesthesia and
surgery, while increasing the chances for DDSP prevention [51]. One common
composite surgery is the Llewellyn procedure, which combines the myectomy with a
staphlectomy to transect the sternothyrohoid muscles and shorten the caudal edge of
the soft palate. The Llewellyn procedure has an initial 60-92% success rate, but similar
to the previous procedures, it becomes less effective over time due to degradation of the
soft palate [49,50].
2.2.3 Review of Equine Soft Palate Stiffening, Testing, and Sound Analysis
A review was completed of literature associated with stiffening the equine soft
palate for prevention of DDSP to compare and contrast the procedure and results with
the present study. One study, completed by Munoz et al, was titled, “Histological and
biomechanical effects of palatal sclerotherapy in the horse using sodium tetradecyl
sulfate.” Munoz et al. used healthy horses to inject tetradecyl sulfate into the distal
portion of the soft palate to stiffen it [52]. During the injections, a bubble was created at
the injection site, leading to hard nodule formation in at least one of the horses [52]. A
study by Alkabes et al. titled, “Evaluation of the effects of transendoscopic diode laser
palatoplasty on clinical, histologic, magnetic resonance imaging, and biomechanical
findings,” was also reviewed. Alkabes’ study, which used healthy horses, stiffened the
soft palate through scar tissue formation via the laser palatoplasty procedure [53].
Alkabes treated the horses with either a low-dose or a high-dose laser treatment, with
edemas forming initially in each horse. Over time, the edema decreased, and scarring
of the soft palate increased [53]. Similar to the present study, both reviewed studies
aimed to stiffen the soft palate to prevent DDSP. However, both of these studies relied
to some extent on scar tissue formation, whereas the current study relies on
crosslinking. Another major difference between the present study and these two studies
is that the horses used in these studies were not diagnosed with DDSP and had normal
soft palates. Using horses with normal soft palates could lead to very different results
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when compared to using horses with abnormal soft palates, due the pre-existing
degradation and instability of the DDSP afflicted soft palate.
Both of the studies in the literature analyzed the soft palate tissue through
histological analysis and biomechanical testing. Munoz evaluated the tissue using H&E
staining, and did not find any significant necrosis, inflammation, or fibrosis in the treated
or control palates [52]. Alkabes analyzed the tissue using H&E staining, and discovered
inflammation caused by infiltration of lymphocytes and plasma cells. The high-dose
laser treated horses also had multiple fibrotic bands present [53]. Similar to the present
study, both of these studies used H&E staining for the histological analysis. As
predicted, Alkabes’ study showed presence of fibrotic tissue formation, which is not the
intended target in the current study that aims to stiffen and to strengthen the soft palate
through crosslinking.
The studies in the literature also biomechanically evaluated the treated tissues.
Munoz tested each sample in tension until failure at a rate of 10 mm/s to determine the
slope of the deformation curve, tensile stress and tensile strain [52]. In Munoz’s study,
80% of the samples failed near the grips with no significant differences in stiffness,
tensile strain or stress between the treated and control samples [52]. Alkabes
examined the samples in compression using a deformation rod connected to a 100-g
load cell at a rate of 3 mm/s [53]. Alkabes’ study showed a decrease in the elastic
modulus of the high-dose laser treated horses compared to the control horses [53]. For
the present study, compression testing was not used because the equine soft palate
experiences minimal compressive loads; therefore, Alkabes’ biomechanical testing was
not relevant to the present study. On the other hand, Munoz’s biomechanical testing
was similar to the present study because they tested the samples in tension to find
Young’s Modulus, tensile stress and tensile strain. However, the current study loaded
the samples at a slower rate of 1 mm/s as described in the procedure in Section 3.3.4,
rather than the rate of 10 mm/s used in Munoz’s study. One major issue with Munoz’s
biomechanical testing was that a majority of the samples failed near the grips rather than
in the middle; consequently, steps were taken in the current study to neck down the
samples to half of their original width to ensure failure in the middle of the sample.
Three articles were reviewed to compare techniques for recording and analyzing
respiratory sounds in horses. The first paper by Derksen et al was titled, “Spectrum
analysis of respiratory sounds in exercising horses with experimentally induced laryngeal
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hemiplegia or dorsal displacement of the soft palate.” Derksen induced DDSP in horses
and recorded the respiratory sounds using a tape recorder positioned 4 cm from the
horse’s nostril [53]. Abnormal respiratory noises were easily recorded in exercising
horses in Derksen’s study, proving that it would be possible to record respiratory noises
in the present study to determine differences in snoring before and after treatment.
Two articles by Franklin et al. were reviewed because they analyzed respiratory
noises in horses with breathing disorders. These articles were titled, “Spectral analysis
of respiratory noise in horses with upper airway disorders,” and “The displaced equine
soft palate as a source of abnormal respiratory noise during expiration.” Franklin’s
studies recorded abnormal respiratory noises through an in vivo study with exercising
horses diagnosed with DDSP and through an in situ study using cadaveric equine heads
to simulate DDSP conditions [55,56]. In each of Franklin’s studies, the respiratory audio
was recorded using a microphone placed halfway between the horse’s nostrils to avoid
interference noises at a sampling rate of 10 kHz [55,56]. Both of these studies analyzed
respiratory recordings by breaking the signals into individual inspiratory and expiratory
segments and transforming them into the frequency domain using the fast Fourier
transform (FFT) to determine an expiration to inspiration ratio for comparison with control
horse respiratory audio [55,56]. One of the biggest differences was that Franklin
compared the control horse respiratory audio to the DDSP horse respiratory audio using
the expiration to inspiration ratio. In the present study, the amplitude peaks were
compared in the pre treatment and post treatment frequency domain graphs instead.
For both the in vivo and in situ study, the snoring frequencies occurred in a low
frequency range from 50-150 Hz, while a common ‘DDSP peak’ existed in the range
from 20 to 80 Hz that could be potentially used to diagnose DDSP [55,56]. A very
important finding from the Franklin studies was the existence of a ‘DDSP peak’ seen in
all horses with DDSP, as well as in the cadaveric horse heads. This finding provided a
potential metric to use in the current study to determine the success of the genipin
treatments based on the appearance or disappearance of the ‘DDSP peak’ in the 20-80
Hz range.
2.3 Genipin Crosslinking
2.3.1 Overview
Protein crosslinking is used to modify mechanical properties of biomaterials by
augmenting the native collagenous crosslinks by adding additional crosslinking bonds
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through direct injection of crosslinking agents [57,58]. Native collagenous crosslinks
connect lysine or hydroxylysine residues within tropocollagen molecules or between
different molecules [58]. Exogenous crosslinks can be added to create intrahelical
crosslinks between the tropocollagen molecules within individual helical strands or to
create interhelical crosslinks between adjacent molecules. Additionally, intermicrofibrillar
crosslinks can be formed between two adjacent microfibrils if the distance between the
microfibrils is smaller than the length of the crosslinking agent [58], or in the case of selfpolymerizing crosslinkers such as glutaraldehyde and genipin, if the distance between
potential binding sites is smaller than the chain length of the crosslinker.
One of the most commonly used crosslinkers is glutaraldehyde, but it has many
adverse side effects, including acute toxicity and calcification of the treated collagen [59].
Therefore, other alternatives are being used as crosslinking reagents. Genipin is a
naturally occurring, minimally toxic crosslinker extracted from geniposide, a major
ingredient in the fruit from the Gardenia jasminoides plant, which grows in Central Asia
[57]. Genipin is commonly used with a phosphate buffered saline (PBS) solution to
crosslink biomaterials and implants [57]. Genipin reacts with the free amino groups of
lysine, hydroxylysine or arginine within biological tissue to produce a covalent bond, and
a blue coloration with the simplest primary amine, methylamine. The genipinmethylamine monomer is formed through a nucleophilic attack by methylamine on the
olefinic carbon at C-3 of genipin, followed by the opening of the dihydropyran ring and
attack of the resulting aldehyde group by the secondary amino group. The blue
pigments are formed through oxygen radical-induced polymerization and
dehydrogenation of several intermediary pigments [60]. As a result, after crosslink
fixation, the tissue turns a dark blue, with the darkness of the blue coloration reflecting
the density of the genipin crosslink bonds in the tissue [61]. Genipin crosslinking forms
intrahelical, interhelical crosslinks, or intermicrofibrillar crosslinks [58]. Fixation by
genipin crosslinking depends on the amount of genipin and the type of tissue. As the
genipin diffuses through the tissue, the fixation reaction occurs immediately. If a limited
amount of genipin is present, complete fixation can occur in a few minutes, but if a larger
amount of genipin is present, unreacted genipin can continue to diffuse and react with
available amines throughout the adjacent tissue such that complete fixation can take
hours. In general, fixation is usually complete within 24 hours [61].
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Figure 2.4: Molecular structure of genipin.

Using genipin as a crosslinking agent creates stable collagenous matrices,
making the tissue less susceptible to enzymatic degradation [57,59-62]. Similarly,
genipin treatment causes a three-fold reduction in fatigue induced mechanical
degradation of the tissue [62]. Additionally, compared to glutaraldehyde, genipin
crosslinking induces a smaller inflammatory reaction and calcium concentration in the
fixed tissue [60,61,64].
2.3.2 Mechanical Properties and Biocompatibility
Crosslinking a tissue with genipin alters the strength, stiffness, and other
mechanical properties of the tissue. Genipin treated tissues sometimes experience an
increase in tensile strength and modulus caused by an increase in crosslinking density
[59,63]. Additionally, genipin crosslinking produces inter-fibrillar crosslinks, which may
reduce the ability of the collagen fibers to slide past each other. Therefore, the tissue
can be less extensible, which could decrease the overall strain and increase the stiffness
of the tissue, depending on the degree of crosslinking and the structure of the tissue
[58,59,65]. Finally, genipin crosslinking also increases the tear resistance by 40% and
the number of fatigue cycles to achieve failure [62].
Biocompatibility studies have shown that genipin crosslinking is 2000-3000 times
less cytotoxic than glutaraldehyde [60,64]. Additionally, genipin exposure is not
associated with any abnormal symptoms in the liver or kidney, or in hematological or
histological analysis [64]. However, genipin crosslinking is sensitive to pH changes, with
the degree of genipin crosslinking concentrations varying at different pH values.
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Genipin crosslinking at a basic pH is greater than crosslinking at a neutral pH, which is
greater than crosslinking at an acidic pH [61]. In general, the higher the pH, the more
reactive the genipin is for crosslinking [61].
2.3.3 Other uses
Genipin has successfully crosslinked many other collagenous tissues. It is being
investigated for the treatment of osteoarthritis by preventing chemical degradation and
mechanical wear of articular cartilage [65]. Also, it has been used to treat injuries to the
tendon and ligaments of horses [62]. Likewise, genipin crosslinking has been
investigated for treatment of the pericardium, aortic valves, spinal discs, cellular
scaffolds, knee meniscus injuries, tendons, and ligaments [57,62]. Traditionally, genipin
has been used for herbal medications, Chinese medicine, treatments of jaundice, and
various inflammatory and hepatic diseases [63]. Also, the dark blue pigment can be
derived through the reaction of genipin with an amino acid and used in the fabrication of
food dyes [60,61].
3. Methods
3.1 Pilot in vivo Study Preparation
3.1.1 Study Design
The purpose of the in vivo study was to determine the safety and efficacy of
injecting the equine soft palate with a genipin reagent. The study was broken down into
two parts: a safety phase and an efficacy phase. The safety phase utilized three control
horses to test the biological effects of the genipin reagent injections, while the efficacy
phase utilized three DDSP horses to test the success of reducing soft palate vibrations
and displacements with the genipin reagent injections.
To set up the experiment, Dr. Kimberly Sprayberry, DVM from Cal Poly San Luis
Obispo, provided expert advice for the in vivo study. Dr. Sprayberry helped by
answering specific questions about the injection method, finding the DDSP horses, and
quantifying the snoring sounds. Working with Dr. Sprayberry, the requirements for the
pre treatment examinations were set to include both a dynamic endoscope examination
and a breathing audio recording to confirm DDSP diagnoses and to record the abnormal
breathing patterns, respectively. To view the questions and answers in full, see
Appendix A1.
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Dr. Brett Woodie, DVM, MS, Dipl. ACVS from Rood and Riddle Equine Hospital,
assisted with diagnosing the DDSP horses through dynamic endoscope examinations.
Dr. Woodie also recommended enrolling horses older than two years old to ensure full
development of the soft palate.
For the sound analysis portion of the study, Dr. Abhijit Patwardhan, Ph.D., a
professor from the Department of Biomedical Engineering at the University of Kentucky
with considerable signal-processing expertise, helped guide the appropriate steps. Dr.
Patwardhan advised to record all respiratory audio in a non lossy format, such as
Windows Media Audio (WMA), to avoid automatic data compression of the audio signal
by the digital voice recorder, which was important because the distinguishing parameters
between the pre-treatment recordings and the post-treatment recordings were unknown
at the start of the study. The goals for the sound analysis, outlined with Dr. Patwardhan’s
assistance, were to objectively measure the snoring volume and to differentiate between
low frequency and high frequency amplitudes in order to determine shifts in the posttreatment audio amplitudes from the pre-treatment audio amplitudes.
3.1.2 Voice Recorder Design
In order to quantify the DDSP snoring noise, a digital voice recorder was utilized
to record the horses while exercising. The recordings were then analyzed using the time
domain and the frequency domain in Matlab to determine any irregular breathing
patterns and any changes in loudness or frequency of the snoring sounds. The audio
recording mechanism consisted of a digital voice recorder, a microphone, and a sturdy
base.
The digital voice recorder had a few specific requirements. First, it had to pick up
sounds in a difficult environment with background noise and wind present. It was crucial
that voice activated recording (VAR) feature, which is common in most recording
devices, could be disabled. This feature causes the recorder to only record when it
detects frequencies associated with human speech, and since the recorder needed to
pick up breathing noise, the VAR feature had to be disabled. Likewise, the recorder had
to record in WMA or a similar non lossy recording format. Finally, the ideal recorder
needed to have a microphone jack, a rechargeable battery, and an USB import jack.
The RCA VR5330R digital voice recorder was chosen because it fit all of the
aforementioned requirements. The recorder was set to record in the high quality (HQ)
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setting at a sampling rate of 8000 Hz. The specifications for the digital voice recorder
are in Appendix A2.
The original recording device design consisted of a headstall with a wire attached
to support the microphone as shown in Figure 3.1. The actual device was created using
wooden shims, duct tape and vet wrap. Two wooden shims were secured together with
duct tape to create a sturdy base for the recorder. Then, the microphone wire was run
along the length of the wooden shims with the microphone secured at one end. The
wooden shims and microphone cord were fully wrapped in vet wrap to cover all rough
edges of the wood and to protect the microphone cord. The voice recorder was
attached on the opposite end of the microphone by wrapping vet wrap around the
carrying case, ensuring to leave enough room to insert the recorder. The entire device
was attached to the halter or bridle using zip ties. Two to three zip ties were secured on
either end of the recorder, making sure it was securely attached. The recorder was firmly
attached on the front of the head or side of the head depending on the horse’s tack with
the microphone as close to one nostril as possible to minimize background noise as
shown in Figure 3.2. The microphone placement was uniform for each individual horse
throughout the study.

Figure 3.1: The recording device schematic consisted of a headstall or halter with a sturdy wire to
support the microphone, which was placed near the horse’s nostril. The digital recorder was
attached to the horse’s neck or further up the halter.
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Microphone

Microphone

Figure 3.2: The recording device was created with wooden shims and vet wrap and attached to either
the side or front of the horse’s tack using zip ties to hold it firmly in place. The microphone
placement was consistent for each individual horse throughout the study.

The recorder’s design integrity was tested using eight non-study horses. These
horses were exercised at a variety of speeds with numerous outdoor situations, including
windy and calm days, to test the effectiveness of the device to record all breathing
noises. For all of the test horses, the recorder was attached to the halter on the side of
the head with the microphone near the nostril, and the horse was exercised at a walk,
trot and canter. The recordings were then studied to ensure that a variety of breathing
noises could be heard.
3.1.3 Study Enrollment
Before enrolling any horses in the study, a consent form and a donation form
were created. The consent form was used for the efficacy phase horses because the
original owner maintained ownership throughout the study. The donation form was used
for the safety phase horses because the owner relinquished ownership to Orthopeutics,
LP for the study. Both forms described the study in detail, including the background of
genipin, the procedure, and the associated risks. Additionally, the forms requested
information about the owner, the horse, and the horse’s veterinary history. The consent
form required further information describing the horse’s DDSP history, including the date
of DDSP onset, the frequency of displacement, the loudness of DDSP snoring, and
previous surgeries related to DDSP. It was required that all horses had a completed
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consent or donation form on file prior to starting the study. See Appendix A3 for the
consent form and Appendix A4 for the donation form.
The efficacy phase horses were located by calling or emailing a list of over 300
qualified equine veterinarians in Kentucky provided by Dr. Sprayberry to help locate
three horses diagnosed with DDSP. The requirements for the DDSP horses were that
they must be at least two years old, be either thoroughbreds or Standardbred
racehorses, and be free of any breathing abnormalities except for DDSP. Ideally, the
DDSP horses would not have any previous surgeries or treatments for DDSP that would
affect the structural or biological composition of the soft palate. See Appendix A5 for the
sample transcript of the emails and phone calls made to the veterinarians.
The safety phase control horse requirements included having no breathing
issues, being older than two years old, and being thoroughbreds, Standardbred
racehorses, or similar breeds. Originally, the plan was to purchase cheap yearling
thoroughbreds that were not eligible to enter the thoroughbred sale for racing, and that
were designated for euthanasia by their owners. However, per Dr. Woodie’s
recommendation, horses younger than two years old were not enrolled in the study
because their soft palates may not be fully developed at an immature age. Therefore,
donated horses or purchased horses meeting the requirements were accepted as
control horses.
Once all of the horses were enrolled, pre treatment examinations were
completed. First, each efficacy phase horse underwent either a dynamic endoscope
examination or provided previous documentation of a DDSP diagnosis from within one
calendar year of the projected study start date. Dr. Woodie completed the dynamic
endoscopic examinations using either a treadmill located at Rood and Riddle Equine
Hospital or using a portable dynamic endoscope at a remote location.
The second stage of the pre treatment testing was to record each DDSP horse
while exercising to document abnormal respiratory noises. The goal was to record any
roars, snores, vibrations, or breathing gaps associated with soft palate displacement.
Each horse was recorded for 20 minutes at a walk, trot, and canter to ensure adequate
snoring and palate displacements.
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3.1.4 Reagent Preparation
The genipin reagent used in the treatment consisted of two parts contained in
two different vials: the genipin powder and the buffer solution. The reagent was a 100
mM concentration of genipin powder in a 10% Dimethyl sulfoxide (DMSO), 45 mM 3-[4(2-Hydroxyethyl)-1-piperazyl]propane sulfonic acid phosphate (EPPS-P) buffered
solution. Assistance in preparing the reagent components was received from Dr.
Matthew Brown of Orthopeutics, LP/Crosscoat Medical, LLC in Lexington, KY.
To prepare the genipin vials, the vials, caps and lids were sterilized using
autoclave sterilization. Then, 45.24 ± 0.05 mg of cGMP genipin powder (CAS# 6902-778) from Wilshire Technologies was placed into each vial with a disposable scoop to
create a 100 mM buffer solution. The rubber cap was placed in the bottle and crimped
shut. A total of 12 vials of genipin powder were prepared and shipped to STERIS
Isomedix Services for terminal gamma irradiation for sterilization.
To prepare the 45 mM EPPS-P buffer solution with 10% DMSO added, the vials,
caps and lids were sterilized using autoclave sterilization. Then 22.5 mL of 100 mM
EPPS-P buffer, 22.5 mL of deionized water, and 5 mL of DMSO were combined into a
bottle, through a 0.2µm sterile filter in a sterile hood. Then, 2 mL of the buffer solution
was distributed into 12 sterile vials. The DMSO was added to the buffer to increase
solubility of the genipin. Phosphate was added to the EPPS solution initially to catalyze
the genipin crosslinking reaction.
Adding 2 mL from one buffer vial to one genipin power vial would produce 2 mL
of the 100 mM buffered genipin reagent. One reagent vial was sufficient for two 1 mL
injections for the soft palate. Appendix A6 shows the calculations for the genipin powder
and buffer solution.
3.2 Pilot in vivo Study
3.2.1 Study Logistics
Due to grant requirements, the pilot in vivo study had to be completed in an
Association for Assessment and Accreditation of Laboratory Animal Care International
(AALAC) and Office of Laboratory Animal Welfare (OLAW) approved facility. Therefore,
the in vivo study was conducted at Sinclair Research Center (SRC), in Columbia
Missouri. All of the study horses had to be shipped to SRC, and the efficacy phase
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horses had to be shipped back from SRC upon study completion. All six horses arrived
to SRC by September 15, 2014, allowing for a one-week acclimation phase. Overall, the
study lasted three weeks, with one week of acclimation, one injection day, three
observation recovery days, and one week of post study recovery.
3.2.2

Equine Arrival and Acclimation

Upon arrival at SRC, SRC personnel performed full veterinary examinations on
each horse. During the one-week acclimation phase, the horses were individually
housed in appropriately sized box stalls within an enclosed large animal facility
according to floor space criteria provided by the USDA animal welfare requirements.
Horses were fed grain supplied by their owners as directed, and given unlimited access
to fresh water and hay ad libitum. The horses were hand walked twice per day for
exercise. Generalized exams and observations were completed twice a day throughout
the course of the study.
3.2.3

Soft Palate Treatment

Dr. Fabio Aristizabal, DVM from UC Davis, completed all soft palate injections.
SRC veterinarians monitored the horses throughout the injection process. Dr. Thomas
Hedman, Ph.D. of Orthopeutics, LP/Crosscoat Medical, LLC and SRC personnel were
also present to assist and to observe the procedures.
To begin the injections, a SRC veterinarian examined each horse. After receiving
a clean bill of health, the horse was sedated with the appropriate dose of intravenous
detomidine and butorphanol according to the animal’s weight. The horse was then led
into a stockade and given ample time to ensure full sedation. Then, a 1-meter long, 9
mm-outer diameter fiberoptic endoscope was inserted into one nostril and advanced into
the larynx. Dr. Aristizabal examined the soft palate to ensure there were no
abnormalities. Approximately 10 to 20 mL of 2% lidocaine was then sprayed onto the
surface of the caudal margin of the soft palate through the injection port of the
endoscope to induce topical local anesthesia.
Concurrently, the genipin buffered reagent was prepared. For each injection, 2
mL of the 45 mM EPPS-P buffer solution with 10% DMSO was injected into one vial of
the genipin powder. The solution was then shaken vigorously for about ten minutes until
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all of the particles were fully dissolved. Throughout the procedure, the buffer and
genipin vials were stored at room temperature.
After allowing several minutes for the lidocaine to take effect, the soft palate
injections were completed. The endoscope was advanced through one nostril to the soft
palate, and a transendoscopic injection needle was passed through the endoscope’s
biopsy port and positioned over the area on the opposite side of the soft palate to inject
the reagent. Each horse was injected with two 1 mL injections of the genipin buffered
reagent in the 5:00 and 7:00 positions on the soft palate, with the epiglottis occupying
the 6:00 position, as shown in Figure 3.3. The first horse received two 1.5 mL injections
of the genipin buffered reagent due to accidentally injecting too much reagent. After
ensuring the needle was in the correct position, 1.5 mL of the reagent was drawn up into
the syringe, and the needle was primed. The transendoscopic needle maintained a
loading volume of 0.5 mL in the tube, so it was crucial to load 1.5 mL of the reagent
solution into the syringe to ensure the desired 1 ml of the reagent was injected into the
soft palate. The needle was then pushed forward into the tissue with a quick, controlled
thrust in order to penetrate the epidermal covering of the palate. Once the needle was
placed in the proper location in the soft palate, the reagent was injected using 1 mL of
air. The endoscope was then removed and reinserted through the other nostril for the
second injection. After both injections were complete, the horse was led back into the
stall for recovery. This procedure was repeated for all six horses.

Figure 3.3: The 5:00 and 7:00 injection positions are represented by the black dots on the soft palate
when viewed through an endoscope inserted from the nasal cavity of the horse.
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For the first 72 hours post treatment, the horses were monitored around the clock
with veterinary examinations every hour. Food and water were withheld until the horse
was fully recovered from the sedation. The horses remained at SRC for one-week post
treatment to allow for full recovery before traveling.
The three safety phase horses were euthanized seven days post treatment, and
their soft palates were harvested. The horses were sedated with Detomidine (0.02
mg/kg) and Butorphanol (0.03 mg/kg) intravenously. Fatal Plus (1mL/4.5 kg) was
injected for final euthanasia. The soft palates were harvested, stored on dry ice, and
shipped to Orthopeutics, LP in Lexington, KY for further analysis. The horses were
properly disposed of by SRC.
The three efficacy phase horses were returned to their owners 12 days posttreatment for post-treatment examinations.
3.2.4

Post Treatment Examinations

Two weeks post treatment, the efficacy phase horse owners reported on the
exercise tolerance, breathing sounds, and general well-being of each horse compared to
pre treatment conditions.
Post treatment dynamic endoscope examinations were conducted on the efficacy
phase horses. Additionally, respiratory recordings were completed post treatment for 20
minutes at full speed for each individual horse. The dynamic endoscope examinations
and the breathing recordings were delayed until approximately six weeks post treatment
to allow the horses to be trained back into the same exercise condition as demonstrated
in the pre treatment examinations
3.2.5

Respiratory Audio Analysis

The sound analysis was completed using MATLAB. As per Dr. Patwardhan’s
suggestions, the sound analysis was broken down into the time domain and frequency
domain in low frequency ranges and high frequency ranges. The specific steps to
analyze the breathing audio were determined as follows. First, have a DDSP
professional classify the snoring sound for validation. Then, create a data set with
control and DDSP horse breathing. Next, analyze the audio in the time domain and
frequency domain. Finally, complete blind testing to determine the results of the
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program. Figure 3.4 represents the respiratory audio analysis steps completed using
Matlab.

Figure 3.4: Each sound file was broken down into 1, 3 and 20 exhale groups for analysis in the time
domain and frequency domain in Matlab.

The audio samples were about 20 minutes long, recording from the time when the
recorder was attached until it was removed. Therefore, the samples were cut down
using Audacity 2.1.1 (Computer Program, 2015), an audio editor and recording program,
to remove the excess audio that was not required, leaving only the audio from the horse
exercising at full speed. Each recording was approximately five minutes long after
removing the excess audio. Then, the time locations of palate displacements were
determined by noting where loud snores or where gaps in breathing occurred. The loud
snores and breathing gaps indicated a palate displacement because the wind pipe was
obstructed. Using the palate displacement time locations, the samples were further
broken down into 1, 3, and 20 exhale recordings for various analyses. The one exhale
(1E) recordings were analyzed using the frequency domain only. The three exhales (3E)
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recordings were analyzed using the time domain, spectrograms, and the frequency
domain. The 20 exhales (20E) recordings were analyzed using the time domain.
Individual programs were created in Matlab (Mathworks Matlab, R2014a Student
Version) to analyze 1E, 3E, and 20E recordings, with the 3E program shown as an
example in Appendix A7. After the programs were finalized and validated using control
respiratory recordings, the pre treatment and post treatment sound recordings for each
horse in the efficacy phase of the pilot in vivo study were analyzed. For all programs, the
first step was to import the desired files. Then, the length and time of the files were
determined.
Next, the 3E and 20E programs analyzed the files in the time domain. The time
domain was used to locate any gaps in the breathing pattern caused by a soft palate
obstruction. Additionally, the pattern and amplitudes of each exhale was compared for
pre and post-treatment recordings. To do this, the moving average was used to filter the
data, which is done by creating a series of averages for different divisions and shifting it
along the full data set to filter the file. For each audio file, the divisions used for
averaging were one-fourth of the entire data set, with a=1 and b= [¼ ¼ ¼ ¼ ] for the
filter function in Matlab. Then, the time domain for pre treatment recordings and post
treatment recordings were plotted in one window for easy comparisons with time on the
x-axis and amplitude on the y-axis.
Then, the 3E programs plotted spectrogram graphs to visually determine changes
in sound amplitude across all frequency ranges. Spectrogram graphs were not plotted
for the 1E programs because there was insufficient data with only a single exhale shown
in the spectrogram. Additionally, the 20E spectrogram graphs were not plotted because
they did not provide any additional information compared to the 3E spectrogram graphs.
The spectrograms were plotted using the spectrogram function with a window (nwin) of
1024 samples and an overlap (noverlap) of 768 samples. For each graph, the x-axis
represented time, the y-axis represented frequency, and the color intensity represented
amplitude from -40 to -120 V as demonstrated in Figure 3.5. The spectrogram graphs
for pre treatment and post treatment recordings were plotted in one window for
comparison.
After creating the spectrogram graphs in Matlab, the total red area representing
high amplitudes was analyzed using ImageJ software to determine the percent
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difference between pre and post treatment recordings. To do this, the Matlab
spectrogram was saved as a JPEG and imported into ImageJ. Once imported, the
graph was split into three 8-bit images representing the red, green and blue color
channels. When separating color channels, a filter is applied to the image to
differentiate red, green and blue colors. For example, for the green color channel, a filter
is applied that blocks any green pixel from passing through, causing it to appear white in
the final picture. The filter allows any pixel that is not green to pass through,
representing it as black or as a shade of gray. Therefore, the green channel best
mapped the red high amplitude pixels in the spectrogram graph because the red area
appeared as black after the channel filter was applied as illustrated in Figure 3.6. Then,
the threshold was adjusted using the default values to intensify the pixels, which fall into
the intensity range from 0 to 160. Pixels with an intensity of 0 represented black and an
intensity of 255 represented white [65]. Finally, the total area and percent area of the
number of pixels were calculated through the analyze particles feature in ImageJ. These
steps were completed for all the pre treatment and post treatment spectrograms, and a
detailed protocol is shown in Appendix A8. The percent difference was calculated to
determine the change in the total area of the high amplitude red squares in the
spectrogram graphs using Equation 1.
%𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =

𝑃𝑜𝑠𝑡 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝑟𝑒𝑎 − 𝑃𝑟𝑒 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝑟𝑒𝑎
𝑥 100% (𝐸𝑞. 1)
𝑃𝑟𝑒 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝑟𝑒𝑎

Figure 3.5: An example spectrogram graph shows the various colors present with red representing
the high amplitude noises and blue representing the low amplitude noises.

34

Figure 3.6: The red (left), blue (middle), and green (right) channel graphs produced by ImageJ
display the different color pixels depending on which filter is applied to the original image. In this
case, the green channel best represents the shape of red squares in the original spectrogram graph.

Finally, the 1E and 3E programs were analyzed using the frequency domain.
First, the recordings were transformed into the frequency domain using the fast Fourier
transform (FFT). Once in the frequency domain, the entire pre treatment and post
treatment graphs were plotted with frequency on the x-axis and amplitude on the y-axis.
Then, the frequency domain signals were filtered using the moving average to remove
noise. The original frequency domain graph and the filtered graph were plotted on a
single graph for comparison for both the pre treatment and post treatment files.
The high amplitude frequency range was analyzed in relation to palatal
displacement “whistling” noises. The filtered signals for the pre and post treatment audio
was plotted from 500 to 4000 Hz. The low-end frequency was set to 500 Hz because
that was the cutoff frequency for the laser non-contact displacement measuring system
used in the wind tunnel study. With a data collection rate of 8 kHz, the Nyquist
frequency for the samples was 4000 Hz, so that was used as the maximum point in the
graph.
The low amplitude frequency range was analyzed in relation to snoring loudness
because typical snoring sounds occur below 200 Hz. First, frequency domain graphs
were created from 0 to 500 Hz because frequencies less than 500 Hz would contain the
sounds related to snoring caused by vibration of the soft palate according to Dr.
Patwardhan. Also, 500 Hz was the cutoff frequency for the laser system used during
the wind tunnel study. Next, the frequency domain graphs were plotted from 0 to 200
Hz because 200 Hz is the typical maximum frequency used for human snoring analysis
[39,40]. Then, the frequency domain graphs were plotted form 0 to 100 Hz to
correspond with palatal vibrations. For the low frequency domain graphs, the area
under the curve was used to determine the percent difference between the pre-treatment
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and post-treatment audio recordings. The area under the curve was calculated using
the trapz function in Matlab and plotted on the corresponding graph as demonstrated by
Figure 3.7. Percent difference was calculated using Equation 1.

Figure 3.7: For each pre treatment and post treatment frequency domain graph, the area under the
curve was calculated and highlighted as demonstrated in the graph above.

Finally, as previously mentioned, a study completed by Franklin et al. discovered
a peak in the frequency domain corresponding to DDSP. Based on their results, the
peak appeared at 41±21Hz for the in vitro horses and 53±24 Hz for in vivo study horses
with DDSP, as shown in Figure 3.8 [55]. Therefore, the 1E frequency domain graphs
were analyzed from 20 Hz to 80 Hz to include the average ‘DDSP Peak’ location plus
one standard deviation on either side. Only 1E was analyzed in this range to best
compare to the results from the previous study, which only analyzed one exhale at a
time. These graphs were used to determine if the ‘DDSP Peak’ existed before or after
treatment with the genipin injections in relation to the study completed by Franklin et al.
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Figure 3.8: The DDSP peak occurs in the 20-80 Hz range in the frequency domain as demonstrated
by the peaks from the cadaveric in vitro DDSP study results (top) and the in vivo study results
(bottom) [55].

3.2.6

Histological Analysis

The three soft palates harvested from the safety phase horses were thawed for 24
hours and sectioned for histological analysis. Each palate was cut in half along the
median, and then three sections were cut perpendicular to the median from each lateral
half palate, producing six samples for each palate for a total of 18 samples. Two
samples from treated regions of tissue as determined by the visual observation of the
blue coloration due to genipin crosslinking, and one sample from an apparently
untreated region of tissue were sectioned from each soft palate half. Figure 3.9 shows
the specific sections used for each palate. Samples were taken from the internal portion
of the sample along the sagittal plane so that each histology slice would contain both the
oral and respiratory mucosal layer. A suture was placed in each sample on the opposite
side of the cutting plane. The samples were labeled according to the original location on
the soft palate and placed in beakers with 100 mL of 10% formalin for six days. Then,
the samples were packaged into separate 50 mL tubes of 70% ethanol and shipped via
FedEx ground to IDEXX BioResearch Pathology Services (IDEXX) in Columbia, MO for
histological analysis.
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Figure 3.9: Each soft palate was divided in half and then three sections were cut from each half in
the general areas shown in the figure. At least one of the samples from each side was cut from a
perceived untreated section of the palate.

Dr. Cynthia Besch-Williford, a licensed veterinary pathologist, at IDEXX completed
the histological analysis. All biopsies were sectioned in the sagittal plane such that both
mucosal surfaces along with the submucosal and muscular components were
represented. Tissues were processed for paraffin infiltration, blocked, sectioned,
stained with H&E and examined microscopically. Observed microscopic changes were
described as to the extent and grade of inflammation and fibroplasia using terms
including minimal, mild, moderate, and marked.
3.3 Soft Palate Mechanical Testing
3.3.1 Study Preparation
The soft palate mechanical testing study was completed to determine any
mechanical property changes in the soft palate after injecting it with 50 mM genipin
solution. The genipin was mixed with a saline solution that would be available in most
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hospital or laboratory settings. Phosphate was added to the solution to catalyze the
reaction.
A total of 12 cadaveric equine soft palates were separated into four sections and
put into three testing groups: control (no injection), buffer-only injection or genipin
injection. The samples were mechanically tested to compare the hysteresis, stress
relaxation and tensile properties of each sample.
3.3.2 Reagent Preparation
The genipin powder was premeasured and placed into individual glass vials.
Each vial contained 22.6 ± 0.5 mg of genipin (CAS#6902-77-8) from Wilshire
Technologies in order to create a concentration of 50 mM when mixed with 2 mL of the
buffer solution. A total of 10 vials were created.
To make the buffer solution, saline was combined with phosphate to create a 50
mM phosphate solution. First, the 0.9% saline was made by adding 9.0 grams of NaCl
(CAS#7647-14-5) to 1000 mL of deionized water and shaking vigorously until fully
dissolved. Then, 19.0 grams of sodium phosphate tribasic dodecahydrate (CAS#
10101-89-0) was added to the 1000 mL saline solution, creating saline with a 50 mM
phosphate concentration. See Appendix B1 for full calculations for the genipin and
buffer solution.
3.3.3 Sample Preparation
Twelve frozen cadaveric equine soft palates were received from Conboy
Enterprises, Inc. in Lexington, KY. The soft palates included the entire upper respiratory
tract, including the trachea, larynx, epiglottis, soft palate, and the surrounding bones,
muscles, tendons and ligaments. The palates were thawed for 24 hours. After thawing,
the soft palates were excised from the surrounding tissue. To remove, the tissue above
the palate was cut in half along the median to expose the epiglottis and soft palate. The
epiglottis was placed below the notch in the soft palate. Then, the palate was removed
by cutting along the outside edge of the palate. The edges of the V-notch of the palate
were removed by cutting along the bones. Once the palate was removed, it was
examined and trimmed to ensure only the soft palate was present. The other tissue was
discarded appropriately. See Appendix B2 for the soft palate extraction protocol
supplemented with pictures.
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The soft palate was then divided into four samples, cut along the V-notch of the
palate. First, the soft palate was divided along the midline, and then two samples,
approximately 2 cm wide, were cut along the V-notch, or free edge, of the palate. The
samples cut from the first spot next to the free edge of the palate were labeled as tops,
and the samples cut closer to the hard palate were labeled as bottoms, as demonstrated
in Figure 3.10. The samples were divided among the three groups according to the chart
in Figure 3.11.

Figure 3.10: The two samples, #1 and #2, sectioned from the free edge of the palate were labeled as
tops. Section #3 and #4 were labeled as bottoms. The excess tissue near the hard palate was
discarded.
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Figure 3.11: Each soft palate sample was divided into a test category based on the schematic above.
The test categories were rotated among the palates to randomize the groupings.

Samples in the control group were wrapped in a saline soaked paper towel,
sealed in a plastic bag filled halfway with saline to maintain tissue moisture, and put on a
shaker plate at room temperature. Samples in the buffer group were injected with 0.5 mL
of the buffer solution using a 22 g, 1” needle. The injections were administered about
halfway down the length of the sample. The needle was inserted at an angle of
approximately 30 degrees from the horizontal. The reagent was delivered with uniform
pressure over five seconds. The sample was wrapped in a saline soaked paper towel,
placed in a sealable plastic bag halfway filled with saline, and put on a shaker plate at
room temperature. Samples in the genipin group were injected with 0.5 mL of the
genipin reagent using a 22 g, 1” needle. The injections were administered about halfway
down the length of the sample. The needle was inserted at an angle of approximately
30 degrees from the horizontal as demonstrated in Figure 3.12. The reagent was
delivered with uniform pressure over five seconds. The sample was wrapped in a saline
soaked paper towel, placed in a sealable plastic bag halfway filled with saline, and put

41

on a shaker plate at room temperature. Pre-treatment sample height, length, and width,
as well as injection time were recorded.

Figure 3.12: The needle was placed about halfway down the length of the sample. The reagent was
uniformly injected as the needle was pulled back out of the sample to ensure even coverage and to
prevent pillowing of the palate.

All samples remained on the shaker plate overnight for 12-15 hours at room
temperature to allow the genipin plenty of time to diffuse. After incubation, all samples
were necked down to approximately 1 cm wide by 1 cm long in the middle using a
circular metal punch as seen in Figure 3.13. Necking height, length, and width were
recorded.

Figure 3.13: After incubating overnight, the soft palate samples were necked down to ensure failure
in the middle during the tensile test.

3.3.4 Mechanical Testing Protocol
All samples were mechanically tested using a materials test system (Test
Resources 100R1000) via a protocol including hysteresis, stress relaxation and tensile
loading to failure tests, as shown in Appendix B3. The sample was loaded into the
tensile testing machine and secured using the grips at a gauge length of 42 mm. To

42

prevent slippage, both ends of the tissue were wrapped in a Chem-Wipe to reduce
wetness and increase grip.
The hysteresis test was performed first. A force of 10 N was loaded onto the
sample. The test resources machine was then set up to perform a hysteresis test of 20
cycles with a displacement of +/- 3mm from the starting point at a rate of 5 mm/s. The
time (s), stroke (mm), load (N), torque (N-mm) and angle (deg) were recorded at a
sampling rate of 50 Hz.
The stress relaxation test was performed next. Again, a force of 10 N was applied
to the sample. The sample was then held at that constant displacement for five minutes.
Upon completion of the five minutes, the force was reduced to zero, and the sample
rested for one minute. Again, the time (s), stroke (mm), load (N), torque (N-mm) and
angle (deg) were recorded at a sampling rate of 25 Hz.
Finally, the tensile test to failure was performed. Starting from 0 N, the machine
loaded the tissue in tension until failure at 1 mm per second. The time (s), stroke (mm),
load (N), torque (N-mm) and angle (deg) were recorded at a sampling rate of 50 Hz.
After the genipin samples failed, the approximate percent of blue fibers in the failure
region was noted by looking at the surface fibers of the torn region.
3.3.5 Mechanical Testing Analysis
Hysteresis was calculated as the area between the loading up and loading down
curves for each sample. To determine the change in hysteresis and the hysteresis ratio,
the time (s), stroke (mm) and load (N) data from the mechanical test was utilized. The
starting point was used to offset the stroke data to find the absolute displacements. For
example, if the starting point was -42 mm, the stroke data was offset by 42 mm. Then,
strain was determined by dividing the displacement by gauge length. Finally, stress in
MPa was calculated by dividing the load by the cross-sectional area of the tissue.
To determine the 1st and 20th cycles of the hysteresis plot, the cyclical loading was
plotted with load in Newton on the y-axis and time in seconds on the x-axis as shown in
Figure 3.14. The first cycle was determined to be from the first local minimum to the
second local minimum as shown in red. The last cycle was determined to be from the
19th local minimum to the 20th local minimum as shown in black. Then, the
corresponding local minimum points were extracted and graphed to create the individual
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cycle hysteresis curves with stress on the y-axis and strain on the x-axis. For the first
cycle, the stress and strain were plotted from corresponding values at the 1st local
minimum point to the 2nd local minimum point as shown in Figure 3.15. For the last
cycle, the stress and strain were plotted from corresponding values at the 19th local
minimum point to the 20th local minimum point as shown in Figure 3.15, as well. Finally,
the entire hysteresis curve was plotted with strain on the x-axis and stress on the y-axis
as shown in Figure 3.17. The 1st and 20th cycles were highlight in red and black
respectively.

Figure 3.14: To determine the location of the 1st and 20th cycles of the hysteresis curve, the loading
st
st
nd
cycles versus time were plotted. The 1 cycle was taken from the 1 local minimum to the 2 local
th
th
th
minimum, and the 20 cycle was calculated form the 19 local minimum to the 20 local minimum.

st

th

Figure 3.15: The 1 and 20 cycles were plotted in relation to stress and strain to determine the
hysteresis.
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st

th

Figure 3.16: The entire hysteresis curve was plotted with the 1 and 20 cycles highlighted to see
their relation to the rest of the cycles.

Finally, the contribution toward the hysteresis calculation for each individual set of
adjacent data points was calculated using Equation 2, with stress point 1 and stress
point 2 representing the individual stress points throughout the hysteresis cycling.
𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐻𝑦𝑠𝑡𝑒𝑟𝑒𝑠𝑖𝑠 =

!"#$%% !"#$% !!!"#$%% !"#$% !
!

∗ (𝑆𝑡𝑟𝑎𝑖𝑛 2 − 𝑆𝑡𝑟𝑎𝑖𝑛 1) (Eq. 2)

Once all of the individual hysteresis values were calculated, the total hysteresis for the
loading curve and the total hysteresis for the unloading curve were calculated for the 1st
load-unload cycle. The total hysteresis for the loading curve was calculated by adding
together all of the individual hysteresis values from the 1st local minimum to the 1st cycle
maximum. The total hysteresis for the unloading curve was calculated by adding
together all of the individual hysteresis values form the 1st cycle maximum to the 2nd local
minimum. Then, the difference between the loading curve total hysteresis and the
unloading curve hysteresis was calculated to determine the area between the curves.
This was repeated for the 20th cycle. Finally, the change in hysteresis between the 1st
and 20th cycles was calculated by subtracting the 20th cycle hysteresis from the 1st cycle
hysteresis. Additionally, the hysteresis ratio was calculated by dividing the 20th cycle
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hysteresis by the 1st cycle hysteresis. Examples of hysteresis calculations are shown in
Appendix B4.
Using the load (N), time (s), and stroke (mm) data from the stress relaxation test,
the stress relaxation was calculated as the decrease in stress over a five-minute period.
First, the offset displacement was added to the stroke to find total displacement, and
then the displacement divided by the gauge length was used to determine the strain.
Next, stress in MPa was calculated by dividing the load by the cross-sectional area.
Using the stress in MPa and time in seconds, the stress relaxation curve was plotted as
demonstrated in Figure 3.17. Then, stress relaxation was calculated by subtracting the
minimum stress value from the maximum stress value. Next, relaxation modulus was
calculated by dividing the stress by the constant strain according to Equation 3, and then
the overall relaxation modulus was determined by subtracting the minimum modulus
value from the maximum modulus value. Finally, normalized relaxation modulus was
calculated by normalizing the strain used in Equation 3 by dividing the individual sample
strain by the average strain for each test group.
𝑅𝑒𝑙𝑎𝑥𝑎𝑡𝑖𝑜𝑛 𝑀𝑜𝑑𝑢𝑙𝑢𝑠 (𝑡) =

!(!)
!

(Eq. 3)

Examples of the stress relaxation test calculations are shown in Appendix B5.

Figure 3.17: The stress relaxation graph for each sample was plotted to demonstrate the relaxation
of the specimen over time.
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The tensile test to failure data was utilized to calculate a variety of elastic-plastic
parameters using stroke (mm) and load (N), including ultimate tensile stress, ultimate
tensile strain, Young’s modulus, toe region slope, yield point stress, yield point strain,
toughness and resilience. Using the stroke (mm) from the mechanical testing data, the
values were offset based on the starting stroke. For example, if the test begins at -42
mm, the stroke values were offset by 42 mm to get the actual deformation of the
specimen. Then the strain was calculated by dividing the deformation by the gauge
length. Using the load (N) data from the mechanical test, stress was calculated by
dividing it by the smallest cross-sectional area of the specimen. The maximum stress
was used to determine the ultimate tensile stress. The ultimate tensile strain was the
strain at the maximum stress point. The ultimate tensile stress and strain occurred at
the maximum point in the graph as illustrated in Figure 3.18 by the black arrow.
Next, the stress versus strain graph was plotted with stress on the y-axis and
strain on the x-axis to find the next parameters as demonstrated in Figure 3.18. First,
the toe region was calculated by plotting the points from the first non-zero stress value to
0.05 MPa and adding a polynomial trend line raised to the 2nd power. The toe region
slope, which measured the straightening of the collagen fibers as they began to
experience load, was the slope of the toe region trend line as shown in purple. Next, the
start of the linear region was determined by moving 50 values past the last value of the
toe region. The linear region was determined to be the next 150-200 values past the
starting point, as long as there was no obvious break in linearity in the graph as shown in
green. A linear trend line was plotted for this region. Young’s modulus, which measured
the stiffness of the tissue, was considered to be the slope of the linear region trend line.
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Figure 3.18: The ultimate tensile stress and strain were determined by the maximum location on the
graph as illustrated by the black arrow. The toe region slope and Young's modulus were also
determined from the toe region and linear region, respectively.

Then, the linear region trend line was offset by 0.2% strain, and the resulting line
was plotted. From the intersection of the offset strain line and the stress-strain curve,
the yield point was calculated as the point that the tissue begins to plastically deform
leading to permanent tissue damage as shown in Figure 3.19. The x and y values at the
yield point were the yield strain and yield stress as demonstrated by the black arrow.
The toughness was defined as the ability to deform the tissue up to the fracture point,
and the area under the entire stress-strain curve calculated it as demonstrated by the
orange highlighting in Figure 3.20. From the toughness value, the energy required to
deform the tissue was calculated by multiplying the toughness by the cross-sectional
area. Likewise, the resilience was defined as the ability of a material to absorb energy
when it is deformed elastically, and it was calculated by determining the area under the
stress-strain curve up to the yield point as shown by the red highlighting in Figure 3.21
[66-68]. Examples of the tensile test to failure calculations are shown in Appendix B6.
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Figure 3.19: The yield point was determined by offsetting the linear region line by 0.2% strain and
calculating the intersection point of the two lines, as demonstrated by the arrow in the graph.

Figure 3.20: Toughness was calculated by the area under the stress-strain curve as represented in
orange.
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Figure 3.21: Resilience was calculated as the area under the stress strain curve up to the yield point
as highlighted in red.

After all of the parameters were calculated for each sample, the outliers,
determined by the three-sigma rule, were removed from the data set. Any samples that
had results more than three standard deviations away from the mean were noted as
outliers in that category. If a sample had more than five total outliers across all
categories, the sample was determined to be an overall outlier and removed from the
analysis.
The averages and standard deviations for each parameter were calculated for
individual control, buffer, and genipin groups. Likewise, each group was broken down
into the tops group and the bottoms group, corresponding to the position of the sample
relative to the soft palate as previously demonstrated in Figure 3.10, and the averages
and standard deviations for each parameter were also calculated. Percent differences
between the parameters of the different groups were computed using Equation 4.
%𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =

(!"#$!%# !"#$%! !"#"$%&%#!!"#$!%# !"#$%! !!"!#$%$")
!"#$!%# !"#$%! !"#"$%&%#

∗ 100 (Eq. 4)

Any parameters with a percent difference greater than 30% were noted.
Statistical analysis was completed to determine if the means of the different
groups were statistically significant. The first group compared was the control samples
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versus the buffer treated samples, comparing the top samples only, the bottom samples
only, and all of the samples combined. This was used to verify that there was no
significant difference in the mechanical properties caused by the buffer treatment alone.
The same statistical comparisons were compared for the buffer samples versus the
genipin treated samples. This comparison was used to determine any significant
differences in the mechanical properties as a result of the genipin treatment.

Either a

two-sample t-test with independent sample groups or a non-parametric Mann-Whitney
test was completed based on the results of the F test.
The two-sample t-test with independent groups determined whether the means of
two groups were different. To complete a two-sample t-test, the following assumptions
were made [70]:
•

The two groups were independent variables.

•

Each observation within the group was independent of the other
observations in the group.

•

The variables followed a normal distribution with the same variance.

The Mann-Whitney test compared the median differences between the two
groups. The assumptions followed for the Mann-Whitney were [70]:
•

The two groups were independent of one another.

•

The results were ordinal.

•

The samples within each group were independent.

•

The variables did not have to be normally distributed.

To decide the appropriate statistical analysis test for each group, the F-test was
completed to determine if the sample variances of the two populations were equal.
Equation 5 was used to calculate the F statistic [70].
𝑑𝑓! ∗ 𝑆!!
) 𝑑𝑓!
𝜎!!
𝐹=
𝑑𝑓 ∗ 𝑆 !
( !" ! ! ) 𝑑𝑓!
𝜎!
(

(𝐸𝑞. 5)

Then, the Fcrit value was determined using an F-table. If the F value was greater than
the Fcrit value, the variances were considered to be different. If the F value was less than
the Fcrit value, the variances were considered to be the same. For the comparisons that

51

passed the F-test, a t-test was completed because all assumptions of the t-test could be
met. For comparisons that failed the F-test, a Mann-Whitney test was completed
because the sample variances were determined to be different resulting in not being
able to meet all of the t-test assumptions.
4. Results and Discussion
This section discusses the results of the pilot equine in vivo study and the soft
palate mechanical testing study. Throughout this chapter, the results from the wind
tunnel study conducted previously by Dr. Kuo, as discussed in Chapter 1, are referenced
in relation to the results of the in vivo and mechanical testing studies.
4.1 Pilot in vivo Study Results
This section goes into further detail about the results of the pilot equine in vivo
study, including the outcomes of dynamic endoscope examinations and the respiratory
audio recordings.
4.1.1 Voice Recorder Design Testing
Prior to conducting tests on the in vivo study horses, the recorder design integrity
was tested using eight non-study horses to verify that the recorder could distinguish a
variety of breathing noises in various exercising conditions. All eight of the non-study
horses were equipped with the recorder on the side of the halter and exercised at a
walk, trot, and canter as shown in Figure 4.1. The recordings took place in windy
conditions and in calm conditions. The recorder was able to pick up a variety of exhales,
snorts, coughs, and other respiratory noises. Additionally, the design of the recorder
was sturdy enough to withstand being smacked against a gate by one of the horses.
Overall, the recorder was determined to be successful because it could pick up a variety
of noises in different environmental conditions, as well as withstand physical abuse by
the horses throwing or moving their heads.
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Figure 4.1: The recording device was tested on non-study horses to ensure the integrity of the
device at a walk, trot and canter.

4.1.2 Study Enrollment
Despite DDSP being relatively prevalent in racehorses, most afflicted horses are
quietly euthanized, making it difficult to find the three horses to enroll in the study. Dr.
Sprayberry provided a list of over 300 qualified equine veterinarians in Kentucky that
were called or emailed to potentially help find horses with DDSP. From that list, only a
handful of local veterinarians were willing to help locate horses with DDSP. Overall, the
process took six months to find just three DDSP horses to enroll in the study.
The first horse enrolled was a 7-year-old thoroughbred mare that was previously
diagnosed with DDSP via a dynamic endoscope examination. She displaced frequently
at a walk, trot, and canter. She had no previous surgeries or treatments for DDSP. She
was a pet with no previous racing history. This horse was withdrawn from the study, due
to logistical issues and feasibility concerns about the study.
The next horse enrolled was a 7-year-old thoroughbred gelding, BH. At 2 years
old, he underwent a preventative tieback surgery despite having a normal epiglottis and
soft palate at the time. At 3 years old, the tieback was released, and he began
displacing a few months later. At that point, he was diagnosed with DDSP and retired
from racing. A tie forward procedure was completed at 5 years old. At 6 years old, the
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edge of his soft palate was trimmed with a laser. Currently, he has been turned out to
pasture due to frequent displacement of his soft palate. BH has no surgical or treatment
options left for DDSP.
The third horse was TH, a 3-year-old Standardbred gelding. TH was not
previously diagnosed with DDSP, but he exhibited all of the classic symptoms, including
roaring, snoring, and exercise intolerance. During races, TH would produce a loud
roaring noise and then stop, gasping for air. TH did not undergo any surgeries, but he
did unsuccessfully try the Cornell Collar. TH was actively being raced in Standardbred
harness races at the start of the study.
The final horse was MV, a 2-year-old Standardbred mare. MV was never formally
raced, but she was in training to be a Standardbred harness racehorse. During training,
MV often would roar and experience shortness of breath.
One donated control was a 25-year-old quarter horse gelding with no history of
breathing abnormalities. The other donated control was a 17-year-old quarter horse
gelding with no history of breathing abnormalities. The final control horse was purchased
from a horse dealer in KY. This control was a 6-year-old quarter horse mix gelding with
no history of breathing abnormalities.
After all six horses were enrolled in the study; horse identification numbers were
assigned as shown in Table 4.1
Table 4.1: Identification numbers assigned to safety and efficacy phase horses enrolled in the study.

Horse

Animal Name

Gender

Age

Study Phase

1

BH

Gelding

8

Efficacy - DDSP

2

TH

Gelding

3

Efficacy - DDSP

3

MV

Filly

2

Efficacy - DDSP

4

Donation #1

Gelding

16

Safety – Control

5

Donation #2

Gelding

23

Safety – Control

6

Purchased Horse

Gelding

6

Safety - Control

ID
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4.1.3 Pre Treatment Examinations
An outside veterinarian completed a dynamic endoscope examination on Horse
#1 using a dynamic endoscope within the last year. The report of the study concluded
that Horse #1 had a completely paralyzed and thickened left arytenoid. Also, the left
arytenoid was partially scarred and located out of the way due to a previous tieback
surgery that was released. DDSP occurred readily, and the palate was displaced
through 90% of the examination. The epiglottis was moderately flaccid and normal
sized. See Appendix C1 for full pre treatment endoscopic examination for Horse #1.
Horse #2 and Horse #3 were both examined for DDSP by Dr. Woodie using a
dynamic endoscope as demonstrated in Figure 4.2. Horse #2 was evaluated using the
equine treadmill at Rood and Riddle Equine Hospital, in Lexington, KY. Horse #2 was
diagnosed as having a normal upper airway at rest. While pacing at high-speed
exercise, Horse #2 displaced his palate and was diagnosed with DDSP. Horse #3 was
evaluated using a portable dynamic endoscope at Red Mile Racetrack, in Lexington, KY.
See Appendix C2 for complete diagnosis from the pre treatment endoscopic examination
for Horse #2.

Figure 4.2: Dynamic endoscope examinations were completed using an equine treadmill for Horse
#2 (left) and a portable dynamic endoscope at a remote location for Horse #3 (right).

The pre treatment respiratory recording for Horse #1 was completed on a lunge
line at a walk, trot, and canter for 20 minutes. The recorder was attached to the left side
of his halter with the microphone placed near his nostril as shown in Figure 4.3. During
the recording, Horse #1 did not displace or make any abnormal breathing sounds at a
walk or trot. However, at a canter, Horse #1 snored frequently and experienced exercise
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intolerance. At least once, Horse #1 came to a complete stop and snorted loudly to
correct his displaced palate. The audio recordings for Horse #1 had excess wind noise
because of slight movement of the halter during exercise.

Figure 4.3: Attaching the recording device to the side of the halter allowed the audio recordings for Horse #1 to
be recorded. During the recordings, the recorder moved slightly with the movement of the halter.

Horse #2 was recorded while exercise harness racing for 20 minutes. Per his
owner, Horse #2 was pacing at his top racing capabilities. Due to interference with the
bridle and riding equipment, the recorder was attached to the front of his bridle with the
microphone near his nostrils as shown in Figure 4.4. During the recording, Horse #2
snored loudly throughout the exercising, with increased snoring towards the end of the
race.

Figure 4.4: The recording device was attached to the front of Horse #2's bridle to record his respiratory
noises.

Horse #3 was recorded while exercise harness racing, as well. The trainer
completed a full practice race with Horse #3 for 20 minutes. Again, due to potential
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interference with the tack, the recorder was attached to the front of her bridle with the
microphone near her nostrils as shown in Figure 4.5. During the pre treatment recording,
Horse #3 snored while trotting at high speeds and had multiple occasions where her
breathing was completely interrupted for about ten second intervals.

Figure 4.5: For Horse #3, the recording device was attached to the front of the bridle to record any
respiratory noises.

4.1.4 Soft Palate Treatment
Even for an experienced veterinarian, injecting the soft palate proved to be a
difficult procedure. The soft palate is a flimsy material, making it difficult to insert the
needle and maintain the correct position to administer the reagent. Therefore, the
injections were completed so that the needle trajectory crossed the center of the soft
palate to help maintain the correct needle position. When the endoscope was inserted
into the right nostril, the 7:00 palate injection was completed on the left side, and when
the endoscope was inserted into the left nostril, the 5:00 palate injection was completed
on the right side. A digital display video endoscope was unable to be obtained for this
study, so a simple endoscope with only a standard viewing port was used for the
injections. Dr. Aristizabal had to look through the 1-meter long viewing port, which is
similar to looking through the body tube of a microscope, to see the injection location
and needle placement. As one would expect, looking through a 1-meter long tube made
the injection area very small and challenging to see, thus increasing the difficulty of
placing the needles in the correct position, as shown in Figure 4.6. If a digital display
video endoscope had been available, some of the difficulties associated with this type of
injection would have been greatly reduced.
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Also, the 1-meter long transendoscopic injection needle required a 0.5 mL
loading dose to fill the needle tube plus an additional 1 mL of the reagent to advance the
desired amount into the soft palate. The 1 ml advancing substance was overlooked
when preparing for the study and extra reagent was not available. Therefore, Dr.
Aristizabal suggested to use a column of approximately 1 mL of air to push the entire
reagent volume into the soft palate as demonstrated in Figure 4.7. Dr. Aristizabal had
previously used air to advance reagents for other equine applications in peripheral
tissues, and he did not believe it would cause any issues. Due to the compressibility of
air under pressure, using 1 mL of air to advance the reagent would result in less than 1
mL of reagent being injected. During each of the soft palate injections the soft palate
readily expanded to accommodate the extra volume, causing a ‘pillow’ filled with the
reagent and perhaps a small volume of air to form at the injection site. This was most
likely due to the fact that the soft palate has insufficient elasticity to withstand the
injection without incurring moderate tissue damage as further discussed in Section 4.1.7.

Figure 4.6: The endoscope had a viewing window that allowed the soft palate to be viewed (left).
However, because the endoscope was 1 meter long, the soft palate appeared very small (right).
When viewing the soft palate in real time, it appeared clear and in focus. The image on the right is
only out of focus because it was taken with a camera through the endoscope port.
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Figure 4.7: The reagent was advanced into the soft palate using a column of air after ensuring the
needle was in the correct position.

The protocol called for each horse to receive two 1 mL injections of the genipin
buffered reagent into the 5:00 and 7:00 positions on the soft palate. Five of the six
horses received two 1 mL injections in these positions. Horse #5 was the first horse
treated, and he received two 1.5 mL injections by mistake because the full amount was
accidentally injected into the soft palate. Also, during the first injection for Horse #1, the
needle slipped out of the soft palate as the reagent was being delivered, causing it to be
sprayed topically on the soft palate. Horse #1 then received two more 1 mL injections
into the 5:00 and 7:00 positions. All individual horse injection details and notes are
included in Table 4.2
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Table 4.2: Notes from soft palate treatment and volume of reagent injected for each horse.

Injection Horse Injection
Order
1

ID

Spot
5

2
3

4

4
5

1

6

7

3

8
9

2

10
11
12

6

Volume

Procedure Notes

Injected (mL)

5:00

1.5

7:00

1.5

5:00

1.0

7:00

1.0

5:00

1.0

7:00

1.0

5:00

1.0

7:00

1.0

5:00

1.0

7:00

1.0

5:00

1.0

7:00

1.0

• Injected too much
reagent by mistake
• Very tough palate –
difficult to insert needle
• 1 mL of reagent sprayed
topically on soft palate
• Very flimsy soft palate
• Palate displaced during
injection
• Normal palate
• Very soft and flimsy soft
palate
• Injected both 5:00 and
7:00 locations from one
nostril

Post treatment, the horses were examined every hour for 72 hours. Initially, a
few of the horses cleared their throat or coughed, but not excessively. Horse #3
experienced mild hypersalivation and a reduced appetite 24 hours post treatment as
shown in Figure 4.8. These symptoms subsided within 24 hours. Otherwise, all of the
horses recovered unremarkably. Table 4.3 in Appendix C3 lists the post treatment
clinical observations for each horse in more detail.
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Figure 4.8: Horse #3 experienced hypersalivation for 24 hours post treatment, as noted by the white
foam coming from the horse's mouth.

Seven days after treatment, the safety phase control horses were sedated with
Detomidine (0.02 mg/kg) and Butorphanol (0.03 mg/kg), and euthanized with Fatal Plus
(1 mL/4.5 kg). Their soft palates were then removed, stored on dry ice and shipped to
Orthopeutics, LP for analysis. The animal carcasses were appropriately disposed of by
SRC. Twelve days after treatment, the efficacy phase horses were returned to their
owners for post treatment examinations.
4.1.5 Post Treatment Examinations
Immediately after returning home, follow up phone calls were made to the
efficacy phase horse owners for updates on the well being, breathing sounds, and
exercise tolerance. Per Horse #1’s owner, Horse #1 was recovering well and showing
no signs of abnormal noises. Horse #1 had not been exercised, so the status of
abnormal noises and exercise intolerance were unknown. In general, Horse #2 was
recovering well and showing no signs of abnormal noises at rest. However, when
exercising at high speeds, Horse #2 showed variable results. Sometimes when
exercised, he would breathe normally with no abnormal noises or noticeable
displacements. Other times, he would snore throughout his entire exercise session and
displace his soft palate at the end during high speed exercising. Overall, Horse #3
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recovered well from the genipin treatment and demonstrated no abnormal breathing
sounds or exercise intolerance.
Approximately one month after treatment, the efficacy phase horses underwent
post treatment dynamic endoscope examinations and respiratory audio recordings. Post
treatment, Horse #1 underwent a portable dynamic endoscope examination by Dr.
Woodie at a walk, trot and canter on a lunge line. At rest, Horse #1 had a paralyzed and
thickened left arytenoid and evidence of a previous left ventriculocordectomy. Horse #1
did not displace his palate at rest. While exercising, he did not displace his soft palate or
make any abnormal respiratory noises at a walk, trot or canter. He did experience
intermittent epiglottic entrapment. For the full post treatment diagnosis, see Appendix
C1.
The post treatment dynamic endoscopic examination was completed on Horse
#2 while exercise harness racing using a portable dynamic endoscope. At rest, the soft
palate and upper airway were within normal limits. During high-speed exercise, he
displaced his soft palate. For full post treatment diagnosis, see Appendix C2.
Horse #3 did not have a post treatment dynamic endoscope examination
completed due to logistical issues. Horse #3 resides over two hours away and the
owner was unable to make the round trip to bring the horse to Lexington, KY for the
examination.
Respiratory audio recordings were completed on all three horses post treatment.
For the post treatment audio recording for Horse #1, the halter was again placed on the
left side of the halter with the microphone near the nostril. Horse #1 was lunged at a
walk, trot and canter for 20 minutes. During this time, the Horse #1 did not make any
abnormal respiratory noises or snoring. Also, Horse #1 did not show any exercise
intolerance or stop exercising because of palatal displacements.
Horse #2 had a post treatment audio recording completed while exercise harness
racing with the recorder attached to the center of the bridle with the microphone near the
nostril. During the post treatment audio, Horse #2 did not displace his soft palate,
however, audible snoring noises were still present towards the end of his race. Per his
owner, Horse #2 paced his fastest mile to date, showing an improvement in exercise
intolerance.
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The post treatment respiratory recording for Horse #3 was completed during an
exercise harness race at full trotting speed. The recorder was attached to the center of
bridle with the microphone near the nostril. During the post audio treatment, Horse #3
did not make any abnormal respiratory noises or experience any breathing issues.
Based on the breathing recording, Horse #3 did not displace her palate or show any
exercise intolerance after the genipin treatment.
Based on the dynamic endoscopic examinations and the audio respiratory
recordings, two of the three horses have showed improvement in snoring loudness and
palatal displacement. Horse #1 and #3 both exercised post treatment with no abnormal
breathing noises or exercise intolerance. Horse #2 showed inconsistent results with
limited improvement in snoring loudness. Therefore, it appears that the genipin
treatment reduced snoring loudness and palatal displacement; however, more research
should be completed to determine the appropriate dosage and concentration to produce
desirable results in all horses.
4.1.6 Respiratory Audio Analysis
In the pre treatment and post treatment respiratory recordings, the horses were
exercised for the same amount of time and at the same exertion rate to remove as many
discrepancies as possible between the recordings. To analyze the respiratory audio
files, the samples were cut down using Audacity 2.1.1 (Computer Program, 2015), an
audio editor and recording program, to remove the extraneous noises associated with
attaching and detaching the recorder and warming the horse up. The resulting audio
files consisted of about five minutes of the horses exercising at maximum speed. For
Horse #1, full speed was cantering on a lunge line; for Horse #2, full speed was highspeed pacing while harness racing; and for Horse #3, full speed was high-speed trotting
while harness racing. Then, the points of palatal displacements or snoring were noted
for each sound file, as listed in Table 4.4. For Horse #1, the clearest pre treatment
snoring sounds occurred between 0:59-1:06 minutes. For Horse #2, the clearest
pretreatment snoring sounds appeared during the 5:05-5:50 minute range with snoring
occurring with each exhale. For Horse #3, the clearest pretreatment displacement
locations were from 2:45-2:59 minutes because there was a time interval when the horse
completely stopped breathing during this span. Using the location of the palatal
displacements, the audio files were further broken down into one exhale (1E), three
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exhales (3E) and 20 exhales (20E) sections that contained the DDSP snoring or
breathing gaps when present.
Table 4.4: DDSP snoring locations for each horse with clear snores highlighted in bold

Audio File

Snoring Locations
(in mins)

Horse #1: Pre Treatment

0:59-1:06; 2:43-2:50; 4:27-4:33; 5:34-5:49

Horse #1: Post Treatment

None

Horse #2: Pre Treatment

0:24; 0:56; 2:51; 3:54; 4:28; 4:53-4:59; 5:055:50

Horse #2: Post Treatment

1:10-1:12; 1:36-1:39; 4:17-4:24; 5:03-5:05

Horse #3: Pre Treatment

0:19; 0:58-1:00; 2:30; 2:45-2:59; 5:32-5:34

Horse #3: Post Treatment

2:32*; 3:09*
*Possible snoring noises, but difficult to be
conclusive with respiratory audio alone
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Next, the 3E and 20E audio files were analyzed using custom program codes
developed in Matlab in the time domain. The 3E files were used to compare amplitudes
between pre treatment and post treatment audio files. For each graph, the pre treatment
audio recordings are shown in red and the post treatment audio recordings are shown in
blue. As shown in Figure 4.9, Horse #1 has about the same amplitude peaks for the pre
treatment and post treatment breathing, however, the breathing pattern is much more
uniform post treatment. This is also true for Horse #2 and Horse #3, who demonstrated
smaller amplitude peaks in the post treatment graphs as shown in Figures 4.10 and
4.11, respectively. The reduction in amplitude for all three horses relates to a reduction
in snoring loudness. In all three time domain graphs, there is also evidence of an
approximately 10 Hz oscillation in the pre treatment exhales. For Horse #1 and Horse
#3, this low frequency vibration is not present in the post treatment exhales, which
corresponds to a decrease in palatal snoring. Additionally, for Horse, #1, the breathing
rate post treatment is twice as fast as the breathing rate pre treatment. Since the audio
files were taken at approximately the same time into the warm up routine, it could be
assumed that the horse is able to work harder post treatment, thus increasing his
breathing rate. Overall, the time domain graphs for all three horses support the dynamic
endoscope examination results because they show a decrease in snoring loudness and
an increase in exercise tolerance based on the decrease in amplitude peaks and the
increased breathing rates. Horse #1 and Horse #3 no longer experience any DDSP
symptoms, which is evident in their time domain graphs because there is a decrease in
post treatment amplitude peaks and a decrease in the 10 Hz oscillations associated with
palatal vibration. For Horse #2, there was a decrease in amplitude peaks; however, the
10 Hz oscillations are still present in the post treatment time domain graph, supporting
the results of the dynamic endoscopic examination with a reduction in snoring loudness
but the presence of palatal vibrations.
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Figure 4.9: The time domain graph for Horse #1 for 3E shows a reduction in the 10 Hz oscillations, as
well as an ability to work harder based on the faster breathing rate.

Figure 4.10: Horse #2 demonstrates a reduction in the amplitudes in the post treatment time domain
graph, relating to a reduction in snoring loudness.
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Figure 4.11: The post treatment time domain graph for Horse #3demonstrated a decrease in both the
amplitude peaks and the 10 Hz oscillations, relating to a reduction in snoring loudness and palatal
vibrations.

The 20E files were analyzed to determine any irregularities in the breathing
pattern because the larger number of exhales allowed patterns to be easily noticed. In
general, for all three horses, the pre treatment time domain graphs were not uniform in
amplitude peak heights. Additionally, in the pre treatment graphs, there is evidence of
irregular breathing patterns, with short inhales, long exhales, and gaps caused by airway
obstruction, as demonstrated in particular by Horse #1 in Figure 4.12. For all horses,
each individual exhale in the pre treatment graphs is much longer, causing the breathing
rate to be slower than in the post treatment graphs. This is especially evident for Horse
#2, as seen in Figure 4.13. Horse #3 also shows evidence of a large breathing gap in
the pre treatment audio between 10 and 12 seconds as shown in Figure 4.14. Any gaps
in the breathing pattern indicate apneic events, as previously described in the study by
Azarbarzin and Moussvi [42]. In the post treatment graphs, breathing patterns are more
regular with a uniform peak height for all three horses. Also, any breathing gaps caused
by airway obstruction are also non-existent. Overall, the 20E time domain graphs are
useful to determine the location of soft palate displacements as indicated by the gaps in
the breathing pattern.
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Figure 4.12: The 20E time domain graphs for Horse #1 show varying lengths of inhales and exhales
in the pre treatment graph. In the post treatment graph, the breathing rhythm is more uniform.

Figure 4.13: For Horse #2, the 20E pre treatment time domain graph has a much slower breathing
rate due to each exhale requiring more force to overcome palatal vibration. The post treatment
graph has a faster, more uniform, breathing rate.
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Figure 4.14: The 20E pre treatment time domain graph for Horse #3 has a large gap from 10-12
seconds, corresponding to an airway obstruction. In the post treatment graph, there is no evidence
of any palatal obstructions.

Then, spectrogram graphs were created in Matlab using the 3E audio files. The
spectrograms showed changes in amplitude across a variety of frequencies. For the
spectrograms, the x-axis represented time, the y-axis represented frequency, and the
red squares represented high amplitudes at -40 V while the blue squares represented
low amplitudes at -120 V. Horse #1 and Horse #3 both showed a noticeable reduction
in the quantity of high amplitude red squares in the high frequency range in the post
treatment spectrogram graph compared to the pre treatment graph as demonstrated in
Figure 4.15 and Figure 4.17, respectively. Additionally, Horse #3 had a reduction in the
area of red squares in the low frequency range. Horse #2 did not have an obvious
decrease in the number of red squares representing high amplitudes for any frequency
between the pre treatment and post treatment spectrogram graphs as shown in Figure
4.16. Based on the spectrogram graphs, the genipin treatment seemed to have caused
a decrease in amplitude in the high frequency range, which corresponds to a decrease
in palatal vibration and whistling. This is supported by the results of the dynamic
endoscope examinations and owner reports that had a reduction of DDSP symptoms for
Horse #1 and Horse #3.

69

Figure 4.15: The spectrogram for Horse #1 shows a reduction in high amplitude red squares in the
high frequency range in the post treatment graph (bottom) compared to the pre treatment graph
(top).

Figure 4.16: The pre treatment (top) and post treatment (bottom) spectrogram graphs for Horse #2
did not show an obvious difference in the area of high amplitude red squares for any frequency
range.
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Figure 4.17: The pre treatment spectrogram graph (top) showed more high amplitude red squares
than the post treatment spectrogram graph (bottom) across all frequency ranges for Horse #3.

Using ImageJ image analysis software, the area of high amplitude red squares
was calculated and compared pre and post treatment to determine the percent
differences. Each spectrogram graph was loaded into ImageJ and analyzed using the
green color channel to count the number of red squares. The green color channel was
used because it best represented the area of the red squares due to the filter applied
when separating the channels. The green color channel graphs for each spectrogram
are shown in Figures 4.18, 4.19 and 4.20 with the pre treatment and post treatment
spectrogram graphs represented. Using the color channel graphs, the area of red
squares was calculated by counting the number of black particles in the green color
channel graphs, as summarized in Table 4.5. Figure 4.21 shows the differences for
each horse in the area of red squares, representing high amplitude sounds across all
frequencies. Using these values, the percent difference between the area of red
squares in the pre treatment spectrogram and the post treatment spectrogram was
calculated for each horse and plotted in Figure 4.22. On average, there was a 39%
decrease in the number of red squares in the post treatment respiratory recordings
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compared to the pre treatment respiratory recordings. Horse #1 and #3 both had a
reduction of greater than 50% in the number of high amplitude squares relating to a
reduction in sounds associated with snoring an palatal displacement, which correlates
with the observations made at the post treatment evaluations and with the horse owner
post treatment assessments.

Figure 4.18: The green color channel graphs from Image J representing the pre treatment
spectrogram (left) and post treatment spectrogram (right) for Horse #1 showed a decrease in high
frequency amplitudes.

Figure 4.19: The green color channel graphs from Image J representing the pre treatment
spectrogram (left) and post treatment spectrogram (right) for Horse #2 showed a slight decrease in
the area of red squares.
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Figure 4.20: The green color channel graphs from Image J representing the pre treatment
spectrogram (left) and post treatment spectrogram (right) for Horse #3 showed a decrease in the
area of red squares across all frequency ranges.

Table 4.5: The ImageJ results included the total area of red squares as well as the percent area.
Using these values, the percent difference was calculated for the pre treatment and post treatment
spectrograms for each horse.

Audio File

Total

Percent

Percent Difference in

Area

Area Red

area of red squares in
post treatment
spectrogram

Horse #1: Pre Treatment

48605

32.33%

Horse #1: Post

19400

12.87%

Horse #2: Pre Treatment

45344

30.16%

Horse #2: Post

41612

27.89%

Horse #3: Pre Treatment

54399

23.13%

Horse #3: Post

27196

11.56%

60.20% decrease

Treatment
7.54% decrease

Treatment

Treatment
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50.01% decrease

Figure 4.21: For each horse, the percent area of red squares decreased after treating the soft palate
with the genipin reagent as shown in the bar graph.

Figure 4.22: Each horse had at least a 5% decrease in the area of red squares in the post treatment
recording compared to the pre treatment recording.

Finally, the 1E and 3E audio files were analyzed using the frequency domain in
the high frequency and low frequency ranges. The one exhale (1E) and three exhale
(3E) sections were chosen based on the location of DDSP snores and palatal
displacements as described in Table 4.4. The 1E sound files were used to see the
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changes in the frequency domain between pre and post treatment audio files for just a
single exhale at a time. The 3E sound files were used to see the post treatment
changes as an average of a few exhales at a time. For both the 1E and 3E graphs, the
entire frequency range between 0 Hz and 4000 Hz were evaluated first in order to see
the general frequency distribution of each audio segment with the pre treatment audio
recordings in red and the post treatment audio recordings in blue as shown in Figures
4.23-4.28. Comparing the 1E graphs to the 3E graphs for the pre treatment and post
treatment files, the shapes of the graphs are generally the same for all three horses.
Also, based on visual examination alone, it appeared that there was a reduction in
higher frequency amplitudes for the post treatment audio files, as demonstrated in
Figures 4.23 and 4.24. Additionally, there seems to be a decrease in amplitudes in the
lower frequency range as shown in Figures 4.25-4.28, corresponding to a reduction in
snoring loudness.

Figure 4.23: The frequency domain graphs for the pre treatment and post treatment audio recordings
for Horse #1 show a general reduction in amplitudes, especially in the high frequency range, for the
1E files.
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Figure 4.24: The frequency domain graphs for the pre treatment and post treatment audio
recordings for Horse #1 show a large reduction in amplitudes, especially in the high frequency
range, for the 3E files.

Figure 4.25: For Horse #2, the pre and post treatment frequency domain graphs show a general
decrease in amplitude for the 1E files, especially in the low frequency range.
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Figure 4.26: In the 3E files, the frequency domain graphs also show a general reduction in amplitude
for the post treatment files for Horse #2, especially in the low frequency domain.

Figure 4.27: In general, Horse #3 had a reduction in amplitudes of the frequency domain graphs from
pre treatment to post treatment for the 1E files, particularly in the low frequency range.
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Figure 4.28: Again, the 3E file graphs for Horse #3 show a general reduction in amplitude for the post
treatment frequency domain graph from the pre treatment graph, particularly in the low frequency
range.

The frequency domain graphs were filtered using the moving average to aid in
the quantitative analysis by removing any background noise or outlier peaks. The
filtered frequency domain graphs, in pink, were plotted over top of the original data, in
black, to display the changes in the graphs. As predicted, the large outlier peaks were
removed when filtered using the moving average for all 1E and 3E frequency domain
graphs, as shown in Figures 4.29-4.34 below.
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Figure 4.29: Using the moving average to filter the frequency domain graphs, the large outlier peaks
were smoothed in the1E pre treatment and post treatment graphs for Horse #1.

Figure 4.30: The moving average filter removed the large outlier peaks and background noise for
Horse #1 in the 3E pre treatment and post treatment graphs.
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Figure 4.31: For Horse #2, smoothing the frequency domain graphs using the moving average
method diminished the large outlier peaks in the 1E pre treatment and post treatment graphs.

Figure 4.32: For the 3E pre treatment and post treatment graphs for Horse #2, the large outlier peaks
were reduced after filtering.
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Figure 4.33: Filtering the frequency domain graphs for Horse #3 using the moving average method
removed the outlier peaks from the 1E pre treatment and post treatment audio files.

Figure 4.34: For the 3E pre treatment and post treatment audio files, the moving average method
removed the outlier peaks for Horse #3.
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After filtering, the frequency domain graphs were broken down into the high
frequency range from 500 to 4000 Hz for 1E files and 3E files. The high frequency
domain analysis started at 500 Hz because that was the cut off frequency for the laser
used in the wind tunnel study. The Nyquist frequency, which is the minimum rate that a
signal can be sampled without introducing errors, was 4000 Hz, making that the
maximum point in the frequency domain. For all graphs, the pre treatment audio is
shown in red and the post treatment audio is shown in blue. Horse #1 showed a
substantial decrease in amplitudes in the high frequency range as shown in Figure 4.35.
Horse #2 did not have any obvious decreases in the high frequency range as
demonstrated in Figure 4.36. Horse #3 exhibited a slight decrease in amplitudes in the
high frequency range, but not nearly as drastic as the reduction for Horse #1 as seen in
Figure 4.37. Since Horse #1 has been clinically evaluated to no longer having DDSP
after the genipin treatment based on the dynamic endoscope testing, the reduction in the
high frequency whistling noises could be associated with the elimination of palatal
displacement in the equine model. This is further supported by the high frequency range
results for Horse #2 because that horse did not have any reduction in the high frequency
range amplitude, and that horse still has clinically validated DDSP based on the post
treatment dynamic endoscopic examination. Horse #3 did not undergo a post treatment
dynamic endoscope, but based on owner reports, the horse is not experiencing any
DDSP symptoms, which supports that the decrease in high frequency amplitudes is
associated with a reduction in palatal displacement.

Figure 4.35: The frequency domain graphs from 500-4000 Hz for Horse #1 show a substantial
decrease in amplitudes in the high frequency range after the genipin treatment for both the 1E graph
(left) and 3E graph (right).

82

Figure 4.36: Horse #2 shows a slight reduction in the 1E graph (left) in the post treatment amplitudes
in the high frequency range, but no reduction in the 3E graph (right), indicating that the selection of
exhales can influence the outcome.

Figure 4.37: Horse #3 had a slight decrease in amplitudes in the high frequency range as shown by
the 1E graph (left) and the 3E graph (right).

The filtered frequency domain files were examined in various low frequency
ranges to determine the reduction in amplitude peaks correlating to a decrease in
snoring loudness and soft palate vibrations. The ranges used were 0-500 Hz, 0-200 Hz
and 0-100 Hz, correlating to various frequency ranges commonly used to analyze
snoring sounds. The areas under the frequency domain curve were calculated as a
representation of the spectral density of the audio file, and then the percent difference
was determined to quantify a difference between the pre treatment and post treatment
amplitude files. The trapz function in Matlab was used to determine the area under the
curve for the 1E and 3E files, and the specific area used for each frequency range was
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highlighted as shown in Figures 4.38-4.43. The pre treatment graph is shown in red and
the post treatment graph is shown in dark blue. The area under the curve (AUC) from 0500 Hz is shaded in light blue, the AUC from 0 -200 Hz is highlighted in green, and the
AUC from 0-100 is colored in yellow.

Figure 4.38: The areas under the curve for the Horse #1 for the 1E pre treatment (top) and post
treatment (bottom) files were calculated for the various frequency ranges.

Figure 4.39: The areas under the curve for the Horse #1 for the 3E pre treatment (top) and post
treatment (bottom) files were calculated for the various frequency ranges.
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Figure 4.40: The areas under the curve for the Horse #2 for the 1E pre treatment (top) and post
treatment (bottom) files were calculated for the various frequency ranges.

Figure 4.41: The areas under the curve for the Horse #2 for the 3E pre treatment (top) and post
treatment (bottom) files were calculated for the various frequency ranges.
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Figure 4.42: The areas under the curve for the Horse #3 for the 1E pre treatment (top) and post
treatment (bottom) files were calculated for the various frequency ranges.

Figure 4.43: The areas under the curve for the Horse #3 for the 3E pre treatment (top) and post
treatment (bottom) files were calculated for the various frequency ranges.
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The filtered frequency domain files were examined in the low frequency range
from 0 to 500 Hz. A limit of 500 Hz was chosen because it was the cutoff frequency for
the laser used in the wind tunnel study. In the graphs, the pre treatment audio data is
shown in red, and the post treatment data is shown in blue. As demonstrated by all
three horses, there is a reduction in the low frequency range amplitudes between 0-500
Hz. Horse #1 also shows a decrease in amplitudes, but it is less evident in the 3E graph
than in the 1E graph as shown in Figure 4.44. Horse #2 and Horse #3 show a definitive
reduction that is evident in both the 1E graphs and 3E graphs, as demonstrated in
Figures 4.45 and 4.46. The reduction in low frequency domain amplitudes supports the
reduction in steady-state displacements, or vibration amplitudes, as seen in the wind
tunnel study.
As previously shown in Figures 4.38-4.43, the area under the frequency domain
curves was determined for each audio file as a representation of the spectral density of
the audio file. Table 4.6 highlights the calculated areas under the curves, and the
associated percent difference between the pre treatment values and post treatment
values for each individual horse. Figure 4.47 and 4.48 show the differences in the areas
under the curve between the pre treatment and post treatment audio files for the 1E and
3E files, respectively. Finally, Figure 4.49 plots the percent differences between the
area under the curve for the pre treatment file and post treatment file for each horse in
the 1E and 3E files. Overall, for the 1E files, there was an average 31.6% reduction in
amplitudes from 0-500 Hz. For the 3E files, there was an average 15.6% reduction in
amplitudes form 0-500 Hz. In the 3E files, Horse #1 had a slight increase in the area
under the curve for the post treatment curve. Based on clinical observations, Horse #1
no longer experiences any DDSP related snoring, so the increase in area under the
curve for the post treatment audio file could be the result of background noise that was
not fully filtered out or due to increased airflow because of an elevated level of exercise
available to the horse now that the breathing disorder has been corrected. The reduction
in amplitudes in the low frequency range from 0-500 Hz relates to a decrease in snoring
loudness, which further supports the wind tunnel study results that showed an average
23% reduction in steady state soft palate vibration amplitudes for the 100 mM genipin
concentration injections.
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Figure 4.44: Horse #1 shows a post treatment reduction in amplitudes in the 1E graph (left) in the
frequency domain graph from 0-500 Hz, with a less obvious reduction in amplitudes in the 3E graph
(right). A majority of the reduction in amplitudes occurs in the frequencies below 200 Hz.

Figure 4.45: For Horse #2, there is a large reduction in amplitudes in both the 1E (left) and 3E (right)
post treatment curves compared to the pre treatment curves, with the greatest amplitude decrease
occurring below 200 Hz.
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Figure 4.46: The 1E (left) and 3E (right) post treatment amplitudes demonstrated a slight reduction
from the pre treatment amplitudes, especially below 150 Hz, for Horse #3.

Table 4.6: This table shows the spectral density of the audio data represented by the areas under the
curve in the frequency domain for the 1E and 3E audio files from 0-500 Hz and the percent
differences calculated between the pre treatment and post treatment graphs.

1E
𝝎!𝟓𝟎𝟎

𝑨𝟏𝑬 𝚫𝝎
Audio File

𝝎!𝟎

%Difference
between Pre

A1E=Audio

and Post

Amplitude for 1E

Treatment
Audio

Horse #1: Pre

1.10E+04

Treatment
Horse #1: Post

9.62E+03

3E

𝝎!𝟓𝟎𝟎

𝑨𝟑𝑬 𝚫𝝎
𝝎!𝟎

A3E=Audio
Amplitude for
3E

%Difference
between Pre
and Post
Treatment
Audio

1.56E+04
12.46%
decrease

19.29% increase
1.86E+04

Treatment
Horse #2: Pre

9.12E+03

Treatment
Horse #2: Post

4.68E+03

1.62E+04
48.74%
decrease

1.05E+04

35.15%
decrease

Treatment
Horse #3: Pre

4.33E+03

Treatment
Horse #3: Post

2.88E+03

7.42E+03
33.46%
decrease

Treatment
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5.13E+03

30.90%
decrease

Figure 4.47: The spectral density of the audio data represented by the areas under the frequency
domain curve demonstrate a reduction in post treatment amplitudes for all horses from 0-500 Hz for
the 1E files, relating to a reduction in snoring loudness and soft palate vibrations.

Figure 4.48: The spectral density of the audio data represented by the areas under the frequency
domain curve demonstrate a reduction in post treatment amplitudes for two horses from 0-500 Hz
for the 3E files, relating to a reduction in snoring loudness and soft palate vibrations. Although no
longer experiencing DDSP symptoms, Horse #1 had an increase in amplitudes for the 3E file from 0500 Hz, which could be attributed to an increase in breathing rate post treatment.
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Figure 4.49: Comparing the percent differences in the amplitudes of the pre treatment and post
treatment spectral densities for the 1E and 3E files from 0-500 Hz, shows an average 31.6% decrease
for the 1E file and 15.6% decrease for the 3E files.

Similarly, the audio data was analyzed in the low frequency range from 0 to 200
Hz for the 1E and 3E files. A cutoff of 200 Hz was used because the common frequency
range to analyze human snoring sounds is from 0 to 200 Hz, which is associated with
snoring and the soft palate vibrations, as previously stated. In all graphs, the pre
treatment audio files are represented in red and the post treatment audio files are
represented in blue. In general, all three horses experienced a decrease in the
amplitudes of frequency domain graphs from 0 to 200 Hz in the 1E files. For Horse #1
the reduction in amplitudes was noticeable in the 1E graph, but less noticeable in the 3E
graph, as shown in Figure 4.50. Most of the reduction in amplitudes for Horse #1
occurred below 100 Hz, which is associated specifically with a reduction in soft palate
vibrations. Horse #2 and Horse #3 both reflected large reductions in amplitude from 0 to
200 Hz for the 1E and 3E files as demonstrated in Figures 4.51 and 4.52, relating to a
reduction in snoring loudness and soft palate vibrations.
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The areas under the pre treatment and post treatment frequency curves were
calculated for each horse, as a representation of the spectral density of the audio data,
and the percent difference between the two was determined. As previously shown,
Figures 4.38-4.43 highlight the areas under the curves that were calculated, and these
results are displayed in Table 4.7. Figure 4.53 and 4.54 show the areas under the curve
for pre treatment and post treatment graphs for each horse for the 1E files and 3E files,
respectively. Finally, Figure 4.55 plotted the percent differences between the pre
treatment and post treatment audio files for each horse for the 1E and 3E files. Overall,
there was an average 47.2% decrease in amplitude for the 1E post treatment audio files,
and an average 25.4% decrease in amplitude for the 3E post treatment audio files.
Again, Horse #1 experienced a slight increase in the post treatment area under the
curve from 0-200 Hz for the 3E file, most likely due to an increase in breathing rate
because of a reduction in exercise exertion after curing his breathing disorder. Based
on the reduction of the amplitudes in the 0-200 Hz frequency range, it can be concluded
that all three horses experienced a decrease in snoring loudness due to the correlation
with human snoring frequencies. This conclusion is in agreement with the individual
reports from the owners who stated that all three horses had a decrease in snoring
loudness while exercising. Also, it is supported by the dynamic endoscope results from
Horse #1, who was diagnosed as no longer having DDSP after the genipin treatment.

Figure 4.50: The areas under the pre treatment and post treatment curves for Horse #1 show a
reduction in amplitude from 0-200 Hz for the 1E files (left) and for the 3E files (right), especially in the
frequency range below 100 Hz relating to a reduction in soft palate vibration.
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Figure 4.51: The areas under the pre treatment and post treatment curves for Horse #2 show a large
reduction in amplitude for the 1E files (left) and 3E files (right) from 0-200 Hz, relating to a reduction
in snoring loudness and soft palate vibration.

Figure 4.52: The areas under the pre treatment and post treatment curves for Horse #3 demonstrate
a reduction in amplitude for the 1E files (left) and 3E files (right) from 0-200 Hz, especially in the
range from 0-100 Hz, representing a reduction in soft palate vibration.
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Table 4.7: This table shows the spectral density of the audio data represented by the areas under the
curve in the frequency domain for the 1E and 3E audio files from 0-200 Hz and the percent
differences calculated between the pre treatment and post treatment graphs.
Audio File

𝝎!𝟐𝟎𝟎

1E
𝑨𝟏𝑬 𝚫𝝎

𝝎!𝟎

A1E=Audio
Amplitude for 1E

%Difference
between Pre and
Post Treatment

𝝎!𝟐𝟎𝟎

3E
𝑨𝟑𝑬 𝚫𝝎

𝝎!𝟎

A3E=Audio
Amplitude for 3E

Audio
Horse #1: Pre

4.09E+03

%Difference
between Pre and
Post Treatment
Audio

5.06E+03

Treatment
Horse #1: Post

2.99E+03

27.04% decrease

5.98E+03

18.11% increase

Treatment
Horse #2: Pre

4.01E+03

Treatment
Horse #2: Post

6.99E+03
62.11% decrease

49.94% decrease

1.52E+03

3.50E+03

2.17E+03

3.19E+03

Treatment
Horse #3: Pre
Treatment
Horse #3: Post

52.36% decrease
1.03E+03

44.29% decrease
1.78E+03

Treatment

Figure 4.53: All three horses experienced a reduction in the amplitudes for the areas under the
frequency domain curves, which represented spectral density, from 0-200 Hz for the 1E graphs,
relating to a reduction in snoring loudness and palatal vibrations.
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Figure 4.54: Two of the three horses experienced a reduction in the amplitudes for the areas under
the frequency domain curves, which represented spectral density, from 0-200 Hz for the 3E graphs,
relating to a reduction in snoring loudness and palatal vibrations. Horse #1 had a slight increase in
the post treatment amplitudes.

Figure 4.55: Comparing the percent differences in the amplitudes of the pre treatment and post
treatment spectral densities for the 1E and 3E files from 0-200 Hz, shows an average 47.2% decrease
for the 1E file and 25.4% decrease for the 3E files.
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Additionally, the audio data was analyzed in the low frequency range from 0 to
100 Hz for the 1E and 3E files to correlate to vibrations associated with the soft palate.
Snoring sounds detected by trained individuals are typically heard in the 0-50 Hz range,
thus analyzing the audio files from 0-100 Hz would correspond to snoring loudness, as
well. In all graphs, the pre treatment audio files are represented in red and the post
treatment audio files are represented in blue. In general, all three horses experienced a
decrease in the amplitudes of frequency domain graphs from 0 to 100 Hz in the 1E files.
For Horse #1, the reduction in amplitudes were noticeable in the 1E graph, but less
noticeable in the 3E graph, as shown in Figure 4.56. Horse #2 and Horse #3 both
reflected large reductions in amplitude from 0 to 100 Hz for the 1E and 3E files as
demonstrated in Figures 4.57 and 4.58, relating to a reduction in snoring loudness and
soft palate vibrations. The largest reduction in amplitudes for Horse #1 and Horse #3
happened below 50 Hz, which corresponds to a reduction in soft palate vibration that
occurs around 25 Hz. These results coincide with the post treatment dynamic
endoscope examinations and owner updates that report these horses as no longer
experiencing any DDSP symptoms, including soft palate displacements and snoring.
The areas under the pre treatment and post treatment frequency curves were
calculated for each horse, as a representation of the spectral density of the audio data,
and the percent difference between the two curves was determined for the 0-100 Hz
frequency range. As previously shown, Figures 4.38-4.43 highlight the areas under the
curves that were calculated, and these results are displayed in Table 4.8. Figure 4.59
and 4.60 show the areas under the curve for pre treatment and post treatment graphs for
each horse for the 1E files and 3E files, respectively. Finally, Figure 4.61 plots the
percent differences between the pre treatment and post treatment audio files for each
horse for the 1E and 3E files. Overall, there was an average 55.0% decrease in
amplitude for the 1E post treatment audio files, and an average 35.6% decrease in
amplitude for the 3E post treatment audio files. Again, Horse #1 experienced a slight
increase in the post treatment area under the curve from 0-100 Hz for the 3E file, most
likely due to an increase in breathing rate because of a reduction in exercise exertion
after curing his breathing disorder. Based on the reduction of the amplitudes in the 0100 Hz frequency range, it can be concluded that all three horses experienced a
decrease in snoring loudness due to the correlation with human snoring frequencies.
Additionally, based on the reduction in amplitudes below 50 Hz, it can be determined
that the horses also had a reduction in soft palate vibrations. These conclusions agree
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with the individual owner reports and the dynamic endoscope examination results that
showed a reduction in snoring loudness and palate vibration for two of the horses while
exercising. Although, Horse #2 still experienced intermittent DDSP symptoms post
treatment, his frequency domain graph from 0-100 Hz still shows a reduction in snoring
loudness and palatal vibrations. In this case, the 56.9% reduction in the 1E file and
53.80% reduction in the 3E file for Horse #3 may not have been sufficient to completely
rid all of the DDSP snoring and palate displacement symptoms.

Figure 4.56: The areas under the frequency domain curve for the 1E (left) file shows a reduction in
amplitudes from the pre treatment to the post treatment graphs, relating to a reduction in snoring
loudness for Horse #1. The 3E (right) file shows a reduction in frequencies below 50 Hz, relating to a
reduction in soft palate vibrations.

Figure 4.57: The areas under the frequency domain curve for the 1E (left) and 3E (right) files show a
reduction in amplitudes from the pre treatment to the post treatment graphs, relating to a reduction
in snoring loudness for Horse #2.
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Figure 4.58: The areas under the frequency domain curve for the 1E (left) and 3E (right) files show a
reduction in amplitudes from the pre treatment to the post treatment graphs, relating to a reduction
in snoring loudness for Horse #3.

Table 4.8: This table shows the spectral density of the audio data represented by the areas under the
curve in the frequency domain for the 1E and 3E audio files from 0-100 Hz and the percent
differences calculated between the pre treatment and post treatment graphs.

Audio File

𝝎!𝟐𝟎𝟎

1E
𝑨𝟏𝑬 𝚫𝝎

𝝎!𝟎

A1E=Audio
Amplitude for
1E

%Difference
between Pre
and Post
Treatment

𝝎!𝟐𝟎𝟎

3E
𝑨𝟑𝑬 𝚫𝝎

𝝎!𝟎

A3E=Audio
Amplitude for
3E

Audio
Horse #1: Pre

1.65E+03

Treatment
Horse #1: Post

9.70E+02

%Difference
between Pre
and Post
Treatment
Audio

1.93E+03
41.46%
decrease

2.07E+03

7.37% increase

Treatment
Horse #2: Pre

1.22E+03

Treatment
Horse #2: Post

5.26E+02

2.30E+03
56.93%
decrease

1.06E+03

53.80%
decrease

Treatment
Horse #3: Pre

1.29E+03

Treatment
Horse #3: Post

4.29E+02

1.86E+03
66.68%
decrease

Treatment

98

7.36E+02

60.48%
decrease

Figure 4.59: All three horses experienced a reduction in the amplitudes for the areas under the
frequency domain curves, which represented spectral density, from 0-100 Hz for the 1E graphs,
relating to a reduction in snoring loudness and palatal vibrations.

Figure 4.60: Two of the three horses experienced a reduction in the amplitudes for the areas under
the frequency domain curves, which represented spectral density, from 0-100 Hz for the 3E graphs,
relating to a reduction in snoring loudness and palatal vibrations. Horse #1 had a slight increase in
the post treatment amplitudes.
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Figure 4.61: Comparing the percent differences in the amplitudes of the pre treatment and post
treatment spectral densities for the 1E and 3E files from 0-100 Hz, shows an average 55% decrease
for the 1E file and 35.6% decrease for the 3E files.

Finally, the 1E files were analyzed from 20 to 80 Hz in the 0-100 Hz frequency
domain graphs to correspond with the previous study completed by Franklin et al. In this
study, a common ‘DDSP’ peak was located at 41 ± 21Hz for the in vitro horses and at 53
± 24 Hz for in vivo, as shown in Figure 4.62 [55]. The frequency domain graphs were
analyzed for all three horses to see if the ‘DDSP’ peak existed in the pre treatment audio
graph, and to see if it disappeared in the post treatment audio graph. As shown in
Figure 4.63, Horse #1 had two prominent peaks in the 40-50 Hz range and in the 60-70
Hz range in the pre treatment frequency domain curve, which could correspond with the
‘DDSP’ peak because both of these peaks fall near the average peak location from
Franklin’s study. In the post treatment curve, both of these peaks have disappeared for
Horse #1. This supports the dynamic endoscope examination results because Horse #1
was cured of DDSP, therefore, any ‘DDSP’ peaks should be nonexistent in the post
treatment frequency domain graph. Horse #2 had a medium peak around 35 Hz and a
large peak around 70 Hz in the pre treatment frequency domain graph as shown in
Figure 4.64. Both of these peaks disappear in the post treatment curve; however, a
new, smaller amplitude peak appears around 60 Hz. Horse #2 was diagnosed with still
having DDSP in the post treatment dynamic endoscope examination; therefore, the
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appearance of a new peak in the post treatment curve corresponds with these results.
Finally, for Horse #3, there was a prominent peak between 70-90 Hz in the pre treatment
curve as shown in Figure 4.65. In the post treatment curve, all of the peaks are
noticeably decreased from the pre treatment curve, including the potential ‘DDSP’ peak
between 70-90 Hz, corresponding with the owner’s reports that Horse #3 is no longer
experiencing any DDSP symptoms.

Figure 4.62: From the Franklin et al study, the top graph demonstrates the ‘DDSP’ peaks found for in
vitro cadaveric horses, and the bottom graph shows the ‘DDSP’ peak found for the in vivo exercising
study horses with DDSP [55].

Figure 4.63: Horse #1 had two prominent peaks in the 20-80 Hz range in the pre treatment audio file
that could be related to the ‘DDSP’ Peak. Both of these peaks disappeared in the post treatment
curve, relating to a non DDSP dynamic endoscope diagnosis.
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Figure 4.64: Horse #2 had two prominent peaks in the 20-80 Hz range in the pre treatment audio file
that could be related to the ‘DDSP’ Peak. In the post treatment audio file, both of the original peaks
disappeared, but a new ‘DDSP’ peak appeared, leading one to believe that the horse still experienced
DDSP, as confirmed by the dynamic endoscope results.

Figure 4.65: Horse #3 had a prominent peak in the pre treatment graph corresponding to a potential
‘DDSP’ peak. In the post treatment curve, all of the prominent peaks have disappeared, supporting
the owner’s report that Horse#3 no longer experiences any symptoms of DDSP.
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4.1.7

Histological Analysis

The three soft palates from the safety phase horses were harvested upon
completion of the in vivo study. Upon thawing, the three palates were observed and
divided into six sections per palate as previously described. The soft palate from Horse
#4, as shown in Figure 4.66, had two noticeable thickened and elevated ‘pillow-like’
regions around the injection site. When cutting into these areas, the tissue was a dark
blue color, indicating that it had been crosslinked by the genipin reagent. This was most
likely due to either the ‘pillowing’ or inflation effect of the soft palate that occurred during
the injections or to an errant injection in which the needle was not fully inserted into
tissue, causing the reagent to be injected closer to the respiratory mucosal layer. The
palate from Horse #5 had a small area of necrosis, but otherwise looked normal as
demonstrated in Figure 4.67. The necrotic area from palate of Horse #5 was crosslinked
blue from the genipin treatment on the inside. Similarly, Horse #6’s palate showed a
large region of necrotic tissue on the surface of the soft palate encircled by a fibrotic
encapsulation around the injection area, as seen in Figure 4.68. Inside of this necrotic
tissue, the region had a small area of dark blue crosslinking, but otherwise it appeared to
be non-crosslinked, unhealthy, damaged tissue.
Once all observations were complete, the palates were cut in half into left (L) and
right (R) sections, and then three segments were cut from each half: top (T), middle (M),
bottom (B) with the top closest to the epiglottis and the bottom closest to the hard palate.
From each half, at least one of the segments was taken from a perceived untreated
section as indicated by an apparent absence of blue coloration. This produced 18
segments total: 4LT, 4LM, 4LB (untreated), 4RT, 4RM, 4RB (untreated), 5LT, 5LM, 5LB
(untreated), 5RT, 5RM, 5RB (untreated), 6LT (untreated), 6LM, 6LB, 6RT (untreated),
6RM, and 6RB. These samples were then fixed in 10% formalin for six days, then
placed in 70% ethanol and shipped to IDEXX BioResearch Pathology Services for
histological analysis.
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Epiglottis

Hard
palate
Figure 4.66: The soft palate from Horse #4 showed two large regions of distended ‘pillowed’ tissue
as demonstrated in the full soft palate picture on the left. Upon cutting into these regions, it was
discovered that the inside tissue was a dark blue color as shown by the yellow arrow, indicating that
it had been crosslinked by the genipin treatment as shown in the picture on the right.

Epiglottis

Hard
palate
Figure 4.67: The soft palate from Horse #5 had a small necrotic region in the top area as highlighted
by the yellow circle in the picture on the left. Inside this region, the tissue was crosslinked blue as
pointed out by the white arrow surrounded by a small pocket of apparent light gray necrotic tissue
as shown by the yellow arrow in the picture on the right.
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Epiglottis

Hard
palate
Figure 4.68: The soft palate from Horse #6 had a large region of gray necrotic tissue surrounded by a
fibrotic encapsulation as seen in yellow circle in the picture on the left. Inside of this region, the
tissue had some evidence of blue crosslinking, but it also had evidence of damaged tissue as seen
in the picture on the right.

Dr. Cynthia Besch-Williford, a licensed veterinary pathologist, completed the
histological analysis. Each sample was processed for paraffin infiltration, blocked,
sectioned, stained with H&E and examined microscopically. A few of the samples were
too large to fit in one cassette, so they were bisected and placed into two cassettes.
Observed microscopic changes were described to the extent and grade of inflammation
using terms including minimal, mild, moderate, and marked.
Overall, there was no specific trend in the severity or extent of inflammatory
infiltrates related to the treated sections. However, the inflammatory response was
linked to the extent of tissue necrosis. Two untreated samples, 4RB and 6LT, had tissue
damage, fibroplasia and inflammatory responses similar to the treated tissues,
suggesting to Dr. Besch-Williford that the crosslinking reagent had migrated to these
regions despite the lack of any blue coloration. It is not likely that Dr. Besch-Williford
came to the correct conclusion in this regard, being unfamiliar with the direct link
between genipin penetration and the presence of blue coloration. In all samples, there
was a moderate to extensive region of tissue disruption and necrosis in the middle or the
core of the soft palate with abundant neutrophils associated with regions of tearing and
lesions as shown in Figures 4.69 and 4.70. These results were most likely due to the
consistently observed expansion, or pillowing of the tissue during the injections to
accommodate the two 1 mL volumes of reagent (or 1.5 mL in the case of Horse #5) plus
any aberrant amount of air used to push the reagent into the tissue, which caused the
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tissue to be disrupted. Figure 4.71 demonstrated expanded vessels in the submucosa,
caused by edema formed from mechanical disruption or tissue freezing. Bacteria
colonized the necrotic region on the exterior of the soft palate from Horse #6, with
encysted Sarcocystis bradyzoites also observed in the viable muscle as seen in Figure
4.72. The inflammation and fibroplastic responses of this tissue were most likely
increased as a result of the bacteria present. Summaries of inflammation and fibroplasia
scores for each section are listed in Table 4.9, and detailed histological analysis
descriptions from IDEXX are listed in Appendix C4.
Based on the disruptive reagent delivery technique, it is unclear to what extent
the tissue disruption, inflammatory response and scar tissue formation was due to the
mechanics of the injections or due to the genipin reagent. By the presence of tissue
disruption, inflammatory and fibroplastic responses in the control regions of the soft
palate that had not been contacted by the genipin crosslinker, it is clear that the injection
technique itself contributed to these histological observations. Additionally, the
inadvertent creation of fibrotic tissue as a result of the disruptive delivery technique could
have assisted in stiffening the soft palate, thus preventing dorsal displacement of the soft
palate and causing a reduction in snoring. Due to the effects of the adverse reagent
delivery technique, the relative contribution of the genipin agent itself has yet to be fully
determined. Also, the histologic results are at a single, seven-day time point post
injection and may not adequately reflect the long-term responses of the treatment and
fibrotic tissue formation.
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Table 4.9 Relative scores of inflammation and fibroplasia for each sample with 0=no significant
change noted, 1=minimal, 2=mild, 3=moderate, and 4=marked.

Sample ID

Group

Inflammation Inflammation

Central Tissue

Severity

Extent

Necrosis

Fibroplasia

4LT

Treated

4

3

4

2

4LM

Treated

3

3

2

2-3

4LB

Control

0

0

0

0

4RT

Treated

4

4

4

2-3

4RM

Treated

4

4

4

3

4RB

Control

4

4

4

3

5LT

Treated

4

4

4

3

5LM

Treated

4

4

4

3

5LB

Control

0

0

0

0

5RT

Treated

3

4

3

2-3

5RM

Treated

3

4

2

2-3

5RB

Control

0

0

0

0

6LT

Control

2

2

1

1

6LM

Treated

4

3

4

2-3

6LB

Treated

4

4

4

3

6RT

Control

0

0

0

0

6RM

Treated

4

4

4

3

6RB

Treated

4

4

4

3
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Figure 4.69: An image taken at 20X magnification from sample 4LM shows abundant neutrophils in
the core of the biopsy with a mild to moderate zone of necrotic tissue. In this sample, degenerated
palatine muscle with fibroplasia is also evident.

Figure 4.70: The 20x magnification image of sample 4RT showed an extensively necrotic core with
distended blood vessels. The surrounding tissue had an abundant amount of neutrophil infiltrates
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Figure 4.71: The connective tissue fibrils of the 4LT sample at 20x magnification were widely
separated from edema, perhaps secondary to mechanical disruption, or tissue freezing as indicated
by the arrows in the picture. Otherwise, the sample had necrotic collagenous stroma that was
moderately infiltrated with neutrophils.

Figure 4.72: The 20x magnification image of the 6LM sample showed an extensively necrotic core
surrounded by a region of fibroplasia. This sample had a few neutrophils present as well.
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4.2 Soft Palate Mechanical Testing Study
The soft palate mechanical testing study examined the effects of the genipin
treatment in cadaveric equine samples on the mechanical properties of the soft palate.
The results of the hysteresis, stress relaxation, and tensile loading to failure tests were
summarized in this section. Additionally, statistical analysis for each sample were
completed and described.
4.2.1

Sample Preparation

Twelve cadaveric equine soft palates were obtained from Conboy Enterprises,
Inc. in Lexington, KY. Each palate was thawed for 24 hours and extracted from the
surrounding tissue. Then, two to four sections were cut from each palate following the
Figure 3.10 from Chapter 3 with two top sections cut closest to the edge contacting the
epiglottis and with two bottom sections cut closest to the hard palate. Palates #5, #6,
and #9 only had two sections cut from it, and Palate #1 only had three sections cut from
it due to size and quality issues with the individual palate specimens. The remaining
palates had four sections cut from them. The palate sections were then divided into 3
test groups. The control group had 14 total samples, with 8 top sections and 6 bottom
sections. The buffer group had 12 total samples, with 6 top sections and 6 bottom
sections. The genipin group had 17 total samples, with 9 top sections and 8 bottom
sections.
Each sample was then treated with the appropriate reagent or left untreated
based on their specific test group based on Figure 3.11 from Chapter 3. The reagents
were delivered into the middle of the sample at an approximately 30-degree angle from
the horizontal. The best way to ensure even coverage of the reagent, based on trial and
error injection tests, was to insert the needle slightly toward one end but adjacent to the
halfway point of the length of the sample, and then dispense the reagent as the needle
was being pulled out. The needle was inserted to about half of the depth of the tissue,
then the reagent was injected with even pressure at a rate of approximately 0.1 mL per
second as the needle was being slowly extracted. This method allowed the reagent to
cover a larger cross-sectional area and helped to prevent any expansion of the tissue to
accommodate the liquid. If the entire reagent volume was injected entirely in one
location, then the tissue would expand like a ‘pillow’ to accommodate the extra fluid. As
noted, in the histology results from the in vivo study, the ‘pillowing’ effect was associated
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with tearing and lesions within the tissue leading to neutrophil invasion and necrotic
tissue in and around the injected area, so the ‘pillowing’ effect was avoided in the
mechanical testing study. The injection time and location on the soft palate were noted
for each sample. After incubation, the samples were necked down to approximately 1 cm
wide, which was about half of the starting width of each sample. The length, width and
depth of the entire sample and necking region were measured using a ruler and
recorded. For the genipin samples, the area of blue visible on the outside surface of the
sample was also measured using a ruler and recorded. In most of the top samples, the
genipin reagent covered the entire cross-sectional area of the necking region based on
observations of the outside edges of the specimen. In thicker samples, the volume of
genipin injected was not sufficient to cover the entire cross-sectional area of the tissue;
therefore, the blue crosslinked region would be located more towards the top layer of the
samples only. All pertinent information and testing notes for the soft palate mechanical
testing study is included in Table 4.10 in Appendix D1.
4.2.2

Mechanical Testing

Each sample first underwent the hysteresis test. For all samples, a load of 10 N
was applied, and then the sample was displaced ± 3 mm from the starting point for 20
cycles. One sample, SP8BLB, underwent the hysteresis test twice because the 10 N
preload was not applied in the first one. Using the time (s), stroke (mm), and load (N)
values recorded from the tensile testing machine, the 1st cycle hysteresis, 20th cycle
hysteresis, change in hysteresis and hysteresis ratio were calculated. Additionally, the
1st and 20th cycle hysteresis curves, as well as the entire hysteresis graph, were plotted
for each specimen. Example 1st cycle, 20th cycle, and entire hysteresis curves for a
control, buffer and genipin sample are shown in Figures 4.73 – 4.78. In general, based
on the graphs, the genipin treated experienced a trend of more hysteresis in the 1st
cycle, but the difference was not statistically significant. Additionally, the genipin treated
samples experienced a larger change in hysteresis over the course of the 20 cycles, but
the difference was not statistically significant. The hysteresis test parameter results for
all individual samples are shown in Table 4.11 in Appendix D2.
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Figure 4.73: The 1 and 20 cycles for the hysteresis curve for the control sample show a reduction
in the area between the curves for the two cycles.
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Figure 4.74: The entire hysteresis curve for the control samples demonstrates where the 1 and 20
cycle are in relation to the rest of the curve. It also demonstrates the reduction in maximum stress
as the cycle number increases.
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Figure 4.75: The 1 and 20 cycles for the hysteresis curve for the buffer sample show a large
difference in the area between the curves for the two cycles.
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Figure 4.76: The entire hysteresis curve for the buffer samples demonstrates where the 1 and 20
cycle are in relation to the rest of the curve. It also demonstrates the reduction in maximum stress
as the cycle number increases.
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Figure 4.77: The 1 and 20 cycles for the genipin sample show a smaller difference in the area
between the curve compared to the buffer and control samples.
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Figure 4.78: The entire hysteresis curve for the genipin samples demonstrates where the 1 and 20
cycle are in relation to the rest of the curve. It also demonstrates a longer toe region when applying
load during cyclical loading for the genipin samples.
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Next, each sample underwent the stress relaxation test, where the sample was
preloaded with 10 N and held at a constant deformation for 5 minutes. One sample,
SP3TRB, underwent the stress relaxation test twice because the first set of data was not
recorded. Using the time (s), stroke (mm), and load (N) values recorded from the tensile
testing machine, the minimum stress, maximum stress, stress relaxation, relaxation
modulus, and normalized relaxation modulus were calculated, and the respective graphs
were plotted. Examples of stress relaxation graphs for the control, buffer and genipin
samples are shown in Figure 4.79. Based on the figure, the buffer specimen appears to
have a larger stress relaxation, however, the differences between the three groups was
not statistically significant as further discussed below in Section 4.2.3.

Figure 4.79: Typical stress relaxation curves for the buffer, genipin, and control groups.

Also, the relaxation modulus and normalized relaxation modulus were calculated
for each sample. The normalized relaxation modulus was calculated by dividing the
individual sample strain by the average strain for that test group. The averages for the
control group, buffer group and genipin group were 0.2771 MPa, 0.3027 MPa, 0.2355
MPa, respectively. The normalized relaxation modulus in general showed an increase
for the genipin and buffer treated samples as shown in Figure 4.80, but the differences
were not statistically significant. The stress relaxation test results for individual samples
are shown in Table 4.11 in Appendix D2.
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Figure 4.80: The normalized relaxation modulus, which was normalized to the individual averages for each test
group, displayed an increase for the genipin and buffer treated samples, although the differences were not
statistically significant.

Finally, each sample underwent a tensile load to failure test at a rate of 1
mm/second. During the SP4TLG sample’s tensile test, the tissue slipped out of the grips
during the early loading phase before any failure was observed, thus requiring the test to
be repeated. In general, the samples failed diagonally along the outer layer fibers in the
middle of the sample for 34 of the 44 samples, or 77% of the time. The remaining
samples failed outside of the middle region, closer to the grips. Using the time (s),
stroke (mm), and load (N) values recorded from the TestResources system, tensile
stress and strain parameters were determined. Then, the stress-strain curve was
plotted, and from that, the toe region slope, Young’s Modulus, yield stress, yield strain,
toughness, energy, and resilience were calculated. Examples of stress strain curves for
the control, buffer and genipin samples are shown in Figures 4.81-4.83. In general, the
different treatment groups all had similar stress-strain profiles, with a defined toe region,
linear region and yield point. The tensile test results for individual samples are shown in
Table 4.11 in Appendix D2.
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Figure 4.81: The stress strain curve allowed many important parameters to be calculated for each
test group. This sample stress strain curve for the control group shows an obvious yield point at
the intersection of the curve and the offset strain line.

Figure 4.82: The stress strain curve allowed many important parameters to be calculated for each
test group. This sample stress strain curve for the buffer group highlights the toe region and linear
region, as well as the offset strain line, that were used to calculate the respective slopes and yield
point.
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Figure 4.83: The stress strain curve allowed many important parameters to be calculated for each
test group. This sample stress strain curve for the genipin group demonstrates how the maximum
point on the graph is usually not equal to the yield point, as shown by the offset strain line
intersection with the stress strain curve.

4.2.3

Mechanical Testing Analysis

Once all of the parameters were determined for each sample, the outliers were
removed using the three-sigma rule, meaning that any sample with results more than
three standard deviations away from the mean in a specific parameter was considered to
be an outlier for that category. Any sample that had five category outliers was
considered to be an overall outlier, and removed from the data set. There were five
outliers in total: SP1TLG, SP7TLG, SP12BLG, SP3TRB, and SP10TRC. The three
genipin samples, SP1TLG, SP7TLG, and SP12BLG, all failed above the blue,
crosslinked region, meaning the tensile testing data did not test the genipin treated area.
The buffer sample, SP3TRB, was an outlier because the stress relaxation test was
repeated twice, leading to different mechanical testing results because of the collagen
fibers were more relaxed. The control sample, SP10TRC, was a very flimsy and
unhealthy sample. This left 12 samples in the control group, with 6 tops and 6 bottoms;
11 samples in the buffer group with 5 tops and 6 bottoms; and 14 samples in the genipin
group with 8 tops and 6 bottoms. A summarized chart of the samples in each group
and their values for all parameters is included in Table 4.12 in Appendix D3.
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All of the viscoelastic and elastic-plastic parameter averages and standard
deviations were calculated for each test group, as well as for the separated top samples
and bottom samples. The top samples data was analyzed separately from the bottom
samples because the thickness of the soft palate varies significantly when moving from
the free end of the soft palate toward the hard palate. Therefore, the thinner top
samples cut closest to the free end of the palate had a larger density of crosslinking
treatment compared to the thicker bottom samples cut closer to the hard palate because
the collagen content decreases when moving from the epiglottis to the hard palate,
causing there to be a large variation in the results among test groups. Separating the
top and bottom samples allowed for smaller standard deviations for each parameter.
The averages and standard deviations for each group with the outliers removed are
summarized in Table 4.13 in Appendix D4.
Using the averages for each parameter, the percent differences were
determined. First, the percent differences between the control group and buffer group
were calculated to see if injection of the buffer alone had any effect on the mechanical
properties of the soft palate, as summarized in Table 4.14. Any statistically significant
percent difference greater than 25% were noted in red. The percent differences between
the buffer group and genipin group were calculated to determine the effect of the genipin
treatment on the mechanical properties of the soft palate. Any statistically significant
percent difference greater than 25% were highlighted in red, as summarized in Table
4.15. Some differences were expected between the buffer-only treated samples and the
control samples due to the dramatically increased hydration in these samples. Using
these differences, the effect of the genipin injection could be deduced based on the
effects of the increased hydration caused by the injection of the solvent on the
mechanical properties.
For the statistical analysis, either a t-test or Mann-Whitney U non-parametric test
were completed based on whether the variance of the sample groups could be
considered the same, as determined by the F-test. To complete the F-test, first the
critical F-value (Fcrit) was determined for each comparison using an F-table. Then, the F
value was calculated. If the F value was less than the Fcrit value, then the variances
were considered to be the same and the t-test was used. If not, then the Mann Whitney
U test was used. The Fcrit values for each comparison are shown in Table 4.16, and the
individual F values for each parameter are listed in Table 4.17 in Appendix D5. All F
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values that are larger than the Fcrit value for that comparison are highlighted in red.
Based on the results of the F-test, the t-test could be applied to the buffer versus control
comparison for the overall samples and the top only samples, and to the buffer versus
genipin comparison for the tops only samples because the variances were assumed to
be the same with an alpha of 0.05. For the remaining comparisons, the Mann-Whitney
U non-parametric test was completed because the variances could not be assumed to
be the same based on the failure of the F-test with an alpha of 0.05. Statistically
significant parameters are marked with an asterisk (*) in Tables 4.14 and 4.15.
Individual p-values for each parameter are shown in Table 4.18 in Appendix D6.
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Table 4.14: COMPARISON OF BUFFER-ONLY GROUP TO CONTROL GROUP – The percent
differences for the buffer samples compared to the control samples for each parameter were broken
down into the top samples only, bottom samples only and overall samples. The results were
reported based on how the buffer group average relates to the control group average. Statistically
significant results with a p value less than 0.05 with α=0.05 are marked with an asterisk and
highlighted in red (*).

Parameter
Cross Sectional Area

Top Samples

Bottom Samples

Only

Only

14.64 %

Overall Samples

22.90 % decrease

18.57 % decrease

decrease
Ultimate Tensile Stress

6.40 % decrease

65.88 % increase*

16.24 % increase

Ultimate Tensile Strain

6.49 % decrease

33.08 % increase

11.14 % increase

Yield Strain

3.24 % increase

12.14 % increase

7.10 % increase

Yield Stress

4.48 % increase

34.54 % increase

14.02 % increase

Young’s Modulus

4.42 % decrease

11.35 % increase

0.26 % decrease

Resilience

20.11 %

276.07 % increase

49.67 % increase

decrease
Toe Region Modulus

17.28 % increase

30.61 % decrease

6.55 % decrease

Toughness

56.17 %

140.94 %

35.29 % decrease

decrease

increase*

58.63 %

92.34 % increase

34.49 % decrease

Energy to Failure

decrease
1st Cycle Hysteresis

4.44% increase

17.66% increase

8.52% increase

Change in Hysteresis

9.48 % increase

16.63 % increase

11.38 % increase

Hysteresis Ratio

13.94 %

4.47 % decrease

10.09 % decrease

decrease
Stress Relaxation

19.39 % increase

48.98 % increase

29.98 % increase

Relaxation Modulus

24.36 % increase

30.22 % increase

26.69 % increase

Normalized Relaxation

78.16% increase

42.26% increase

58.32% increase

Modulus
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Table 4.15: COMPARISON OF GENIPIN AND BUFFER-ONLY INJECTED GROUPS – The percent
differences for the genipin samples compared to the buffer samples for each parameter were broken
down into the top samples only and overall samples. The results were reported based on how the
genipin group average relates to the buffer group average. Statistically significant results with a p
value less than 0.05 with α=0.05 are marked with an asterisk and highlighted in red(*).

Parameter

Top Samples

Overall Samples

Only
Cross Sectional Area

11.95 %

20.49 % decrease

decrease
Ultimate Tensile Stress

51.67 %

31.20 % increase

increase*
Ultimate Tensile Strain

Yield Strain

32.89 %

30.88 %

decrease

decrease*

34.57 %

30.65 % decrease

decrease
Yield Stress

53.04 %

42.69 % increase*

increase*
Young’s Modulus

63 % increase*

56.02 % increase*

Resilience

6.43 % decrease

27.51 % decrease

Toe Region Modulus

118.34 %

118.33 % increase

increase
Toughness

11.99 % increase

9.71 % increase

Energy to Failure

6.60 % increase

6.99 % decrease

1 Cycle Hysteresis

10.31% increase

23.41% increase

Change in Hysteresis

1.08 % decrease

14.88 % increase

Hysteresis Ratio

30.20 % increase

23.24 % increase

Stress Relaxation

4.09 % increase

9.19 % increase

Relaxation Modulus

74.10 % increase

71.54 % increase

Normalized Relaxation

96.28% increase

69.61% increase

st

Modulus

When comparing the buffer samples to the control samples, it was expected that
an increase in hydration would have an effect on the mechanical properties of the buffer-
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only treated samples, however, there should not be many parameters with a statistically
significant difference of more than 25%. Based on the results summarized in Table
4.14, the tops only buffer treated group and the overall buffer treated group had no
parameters that had statistically significant differences from the control group. Since the
tops only and the overall category did not have any statistically significant differences
between the buffer treated samples and the control samples, it proves that the buffer
treatment alone does not have any significant effect on the mechanical properties of the
soft tissue for these test groups, despite the increase in hydration. This means that
when the buffered genipin reagent is injected into the soft palate, the crosslinking affect
caused by the genipin is presumed to be the primary contributor towards any changes in
the mechanical properties.
On the other hand, the bottom only group had two parameters with statistically
significant differences between the buffer treated group and the control group. Due to
the statistically significant differences for two of the parameters, the bottom only group
was determined to demonstrate a change in the mechanical properties when treated
with the buffer only group. An effect by the buffer only treatment could be evident in the
bottom only samples due to the large variation in the collagen content compared to the
tops only samples. Additionally, the thicker samples may have retained more of the
injected water, causing an increase in hydration that had an effect on the tissue’s
properties. Finally, since the bottom samples were thicker, the volume of genipin
reagent injected may not have been able to adequately cover the entire cross-sectional
area of the tissue compared to the thinner samples. Therefore, the bottom only samples
were not used to compare the effect of the genipin treatment on the soft palate.
Finally, the genipin samples were compared to the buffer samples to determine
the effect of the genipin treatment on the mechanical properties of the soft palate.
Again, only the tops-only and the overall groups were statistically analyzed due to the
bottoms-only group showing significant effects caused by a variety of reasons, as
previously explained. The tops-only groups had statistically significant differences from
the buffer treated samples in three parameters: ultimate tensile stress, yield stress and
Young’s modulus. The overall group had statistically significant differences for three
categories as well: ultimate tensile strain, yield stress, and Young’s Modulus.
None of the parameters from the hysteresis test demonstrated a statistically
significant difference between the genipin treated samples and the buffer treated
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samples. Similarly, the stress relaxation test did not produce any parameters with
statistically significant differences. Consequently, there was no measurable effect of the
genipin crosslinker on the viscoelastic properties of the soft palate.
The tensile test produced three parameters with statistically significant
differences between the genipin treated group and the buffer treated group. Ultimate
tensile stress (p=0.021) and strain (p=0.006) had statistically significant results for the
tops only group and the overall group, respectively. The increase in ultimate tensile
stress shows an increase in strength for the genipin treated samples, which is supported
by a previous study that crosslinked spinal discs with genipin and demonstrated a
statistically significant 20.7% increase in ultimate tensile strength (p=0.036) [19].
Another study that treated equine tendons produced statistically significant results in the
ultimate tensile stress (p<0.0001) and strain (p=0.01) for genipin treated tissues [71].
The decrease in ultimate tensile strain showed an increase in stiffness. Both of these
results enhance the soft palate, making it stronger and stiffer, and thus better able to
resist displacement. Similarly, Young’s modulus had a statistically significant (p=0.026
for tops-only and p=0.014 for overall) increase, demonstrating that the treated tissue is
stiffer due to the genipin crosslinking, which was supported by an increase Young’s
modulus for the genipin treated samples in the tendon study (p<0.0001) [71].
As previously mentioned, yield stress and strain are important parameters in soft
tissue applications because they mark the point at which the material begins to
plastically deform, resulting in permanent deformation or injury to the tissue. The yield
stress showed a statistically significant (p=0.017 for tops-only and p=0.049 for overall)
increase in the strength of the genipin treated tissue for both the tops only and overall
groups. This result was supported by previous studies that utilized genipin to crosslink
spinal discs, which showed a statistically significant increases in yield stress (p=0.012)
[19-20]. Yield strain was not statistically significant, but appeared to trend more than
25% lower for both the tops-only and overall groups.
Also, the statistically significant increase in yield stress without a statistically
significant change in resilience suggests that there was no increase in the brittleness of
the tissue compared to the buffer-only samples. The percent differences for resilience
supported this because they were all less than 15%, showing that the energy required to
plastically deform the genipin treated tissues was not statistically different than the
control samples. Similar studies conducted in the tendon and intervertebral disc showed
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statistically significant increases in the resilience (p=0.01 and p=0.019, respectively),
meaning that genipin typically increases the resilience in tissues with a higher
percentage of collagen content [19-20,71]. Since the soft palate has less collagen
present, it makes sense that the resilience would not necessarily be as affected by the
genipin treatment. Similarly, the energy required to permanently deform the tissue
increased, but it was not statistically significant meaning that the toughness of the soft
palate tissue was not affected by the genipin treatment. This was supported by similar
tests in the disc that showed an increase in toughness, without statistical significance
(p=0.170), meaning that genipin does not negatively affect the toughness of the tissue
[19-20]. Based on these results, the genipin treatment created statistically significant
differences in the ultimate tensile stress, ultimate tensile strain, yield stress and Young’s
modulus categories, exhibiting an increase in strength and stiffness of the soft palate.
5. Conclusions
Snoring and OSA are sleep disorders caused, in part, by mechanical degradation
of the soft palate due to accumulated damage from snoring. Some current treatments
focus on preventing snoring and OSA by increasing stiffness through fibrotic tissue
formation, even though fibrosis formation leads to inferior mechanical properties. A
genipin reagent was used as a treatment for the soft palate to prevent snoring and
deformations and to also improve the mechanical properties by crosslinking the native
collagen fibers. The genipin treatment was tested using a pilot equine in vivo study and
a soft palate mechanical testing study.
The success of the pilot equine in vivo study relied upon the results of the
respiratory audio recording, the dynamic endoscope examinations and the owner’s
reports. At least one of the horses was diagnosed as no longer having DDSP, and no
longer shows any symptoms associated with the disorder. Another horse did not have a
post treatment dynamic endoscope examination completed; however, based on the
audio analysis and the owner’s update, the horse is no longer experiencing any DDSP
symptoms, including snoring, palatal displacements, or exercise intolerance. The final
horse was diagnosed with DDSP still, but has showed improvements in exercise
tolerance and snoring loudness. Histological results showed no specific inflammatory
infiltrate trends. However, there was evidence of adverse responses due to errant
injections, such as the necrotic tissue on the mucosal surface and the tearing and
lesions due to the ‘pillowing’ of the soft palate during transnasal endoscopic injections.
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The histology samples also had an appearance of fibroplasia, which could mean that the
effective treatment of the DDSP horses may be due to a combination of the inadvertent
fibroplastic response to the over-extension of the soft palate during injection and of the
mechanical effects of the genipin treatment.
Future in vivo studies should focus on reduced injection volumes and alternative
delivery methods to avoid errant injections and the over-extension of the soft palate
during injections. Using the 1-meter long endoscope proved to be difficult to inject the
soft palate due to issues with controlling the endoscope and clearly seeing the injection
site. New possibilities for delivery methods include using coated sutures to release the
genipin and to avoid errant injections, or using reduced injection volumes and multiple
injection sites to avoid the ‘pillowing’ effect. Also, a video endoscope could be used to
make viewing the injection area easier. Likewise, a larger in vivo study should be
completed to test the effectiveness of the genipin treatment at different volumes and
concentrations. Eventually, the genipin treatment should be tested in human trials to
test the efficacy of the genipin injections for snoring and OSA applications.
The soft palate mechanical testing study produced statistically significant results
in four categories for the genipin treated samples compared to the buffer treated
samples, with an increase in ultimate tensile stress, yield stress, and Young’s modulus
and a decrease in yield strain. These results demonstrate an increase in tissue strength
and stiffness, leading to an increase in tissue stability.

The location of the samples in

relation to the hard palate proved to have an effect on the results of the mechanical
tests. The samples taken closer to the epiglottis produced statistically significant
improvements in the mechanical properties due to their higher collagen content
compared to the samples closer to the hard palate, thus indicating that the preferred
treatment location is closer to the free edge of the soft palate near the epiglottis.
Future research should focus on standardizing the reagent delivery method.
There is a large learning curve when it comes to injecting the reagent uniformly
throughout the entire cross-section of the sample. Therefore, research should be done
to determine the ideal injection angle, pressure and location. Similarly, the appropriate
volume of the reagent to administer should be determined based on the cross-sectional
area of the specific sample since the thickness of the soft palate increases from the free
edge near the epiglottis to the hard palate. Finally, the mechanical testing study should
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be repeated with human soft palates to determine the effects of the genipin treatment on
human soft palate mechanical properties.
Overall, the in vivo study and mechanical testing study supported the hypothesis
by showing reduction of aberrant vibrations and displacements while also improving the
mechanical properties of the soft palate. The reduction in snoring loudness and palatal
displacement in the in vivo study agreed with the increase in tissue stiffness from the
mechanical testing study. The increase in tissue strength suggests that the stability of
the tissue was increased by the genipin treatment. The histology results suggested that
the microstructural and compositional integrity could be conserved with proper reagent
delivery. This was further supported by the maintenance of the viscoelastic properties of
soft palate as demonstrated by the hysteresis and stress relaxation tests. In essence,
the genipin treatment demonstrated an increase in tissue strength, stiffness and stability
based on the results from the in vivo study and the mechanical testing study, suggesting
that genipin-based treatments should be further evaluated, and could become an
effective and safe treatment for snoring and OSA applications.
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APPENDIX A1: Dr. Sprayberry’s questions and answers for in vivo study
Answers by Dr. Kim Sprayberry in bold
General Questions:
1. What needs to be done to obtain the DDSP horses?
• What is necessary is to contact either trainers or veterinarians in
the Illinois/Indiana/Missouri region who have horses with DDSP
and would be willing to transport them to the study center.
• I do not know many trainers or vets in those areas, and the few
contacts I do have, have not been able to summon up any
affected horses.
2. What needs to be done to obtain the thoroughbreds?
• Same answer: the Thoroughbreds are the DDSP horses, and we
need to contact people in the area of the contract researcher so
we can enroll some horses. The problem is that this is a region
of the country where racehorses are less numerous than in
Kentucky, and I do not have many contacts there.
Pre-Treatment Exam:
1. Can this be done at the horse’s barn prior to sending the horse to Missouri or
does this need to be completed at Missouri?
• A horse with DDSP would likely have already had an endoscopic
exam to confirm the diagnosis. So yes, this pretreatment exam
COULD be done at the horse’s home barn. However, for the
purposes of recording ‘before’ and ‘after’ pictures and
comparing, it would be more uniform and repeatable if the B & A
photos were done with the same equipment.
2. What does the exam all need to include?
a. Endoscopic exam? Yes.
b. General exam? Yes.
c. Record breathing? Yes, although the abnormal breathing heard
with DDSP typically is only audible during exercise, not at rest.
3. Can their regular veterinarian complete this exam or do all exams need to be
completed by you?
• Any veterinarian with an endoscope can do this. The only caveat
is if we are going to be using B&A images to judge or score
results. Then we’d run into a confounding factor with image
variability stemming from different scopes, light sources, and
other factors.
Transportation:
1. Is there a certain company you recommend to transport the horses to
Missouri?
• Not really; any company or individual with experience in hauling
horses should be fine.
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Timeframe:
1. Approximate dates of study that would work for you?
• I can spend 2 days at a time, and would most easily be available
for this beginning mid July. I am teaching summer school in the
first session, meaning I’ll be tied up from mid June until mid
July. After that, I am very flexible and relatively uncommitted. I
will also be in Lexington for 3-5 days sometime in late July or
early August.
2. How many days would you want the horses there before the study?
• Just 1.
3. Any health requirements?
a. Shots required? No
b. Coggins? Only as required for transport across state lines.
c. Health Certificate? Ditto
Breathing Recording:
1. Should the horse’s breathing be recorded just during exercise or during both
exercise and rest?
• Both
2. How long to record the horse’s breathing during exercise? i.e. is 5 minutes
sufficient or do you suggest shorter or longer?
• 5 minutes should be sufficient. We may find that a trainer will
relate that his/her horse only begins making the noise after being
on the track for 10 minutes, and in this regard, horses can vary
among individuals. But most horses are on the track for no more
than 10 minutes in the mornings, and that is when the abnormal
sound associated with DDSP are heard.
3. How strenuous should the horse be exercising? i.e. walk, jog, lope, gallop,
etc.
• Galloping
4. Does the breathing recording need to be completed within a certain
timeframe? Does a week before study work or would a day before the study
be sufficient?
• Either interval would be fine
5. Do you think a microphone attached to the halter/bridle be sufficient data to
record DDSP frequency?
• The best way of objectively confirming that any given horse has
DDSP is to have a dynamic endoscope in place while the horse is
galloping and record real-time images of the laryngeal
abnormality. This equipment is increasingly in use.
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APPENDIX A2: Digital voice recorder specifications
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APPENDIX A3: in vivo study consent form

AGREEMENT FOR EXPERIMENTAL EQUINE TREATMENT
AND OWNER’S INFORMED CONSENT
This AGREEMENT FOR EXPERIMENTAL EQUINE TREATMENT AND OWNER’S INFORMED CONSENT
(referred to as “Agreement and Consent”) is between:
______________________________________, having an address of______________________________________
(referred to as “Owner”);
Orthopeutics, LP, a Kentucky limited liability company, having an address of 1501 Bull Lea Rd. #103, Lexington, KY
40511 (referred to singly as “Orthopeutics” and collectively with Sinclair Research Center, LLC as “OrthopeuticsSinclair”); and
Sinclair Research Center, LLC, a Missouri biomedical research facility at the University of Missouri, having an address of
562 Missouri DD, Auxvasse, MO 65231 (referred to singly as “Sinclair” and collectively with Orthopeutics, LP as
“Orthopeutics-Sinclair”).
Owner, Orthopeutics, and Sinclair are referred to collectively as the “Parties”. The Effective Date of this Agreement and
Consent is the date it is signed by the Parties.
BACKGROUND
NEXT stands for Nonsurgical Exogenous crosslink Therapy. NEXT, sometimes referred to herein as NEXT Technology
is a chemically made device formed following injection of a crosslinking agent into the soft palate of an animal, such as a
horse, which interacts with the native proteins (e.g., collagen) causing the tissue to reduce its flaccidity and vibration and
to increase its strength, resilience, toughness and fatigue resistance. Strengthening the soft palate may help horses
diagnosed with dorsal displacement of the soft palate (DDSP), which involves a form of awake snoring and apnea.
The therapeutic effect of NEXT Technology typically begins within 30 minutes of application, and provides mechanical
stabilization of the tissue within 24 hours of application.
Orthopeutics’ spin out company, Equinext, LLC holds a worldwide exclusive license for NEXT technology for all animal
applications. With potential commercialization benefits for Equinext, Orthopeutics-Sinclair are conducting the second
stage of a First in Equine (FIE) study of the effects of NEXT on horses (referred to as the “Study”).
Owner voluntarily elects to have the horse identified in Schedule 1 (referred to as “Horse”) participate in the Study for the
treatment of DDSP and the soft palate. Orthopeutics has determined that the Horse fits the NEXT treatment protocol, and
Orthopeutics-Sinclair are willing to enroll the Horse in the Study subject to the agreements and Informed Consent
expressed herein.
Accordingly, the Parties agree and state as follows:
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AGREEMENTS
1. Orthopeutics-Sinclair in their sole discretion, may remove the Horse from the Study at any time. Owner may remove
the Horse from the Study with a 14-day notice to Orthopeutics-Sinclair.
2. Owner shall be responsible for all normal and typical veterinary-related costs incurred before, during, and after the
Horse’s participation in the Study.
3. It is the Owner’s sole responsibility, before agreeing to allow the Horse’s participation in the Study, to obtain
professional input from the Horse’s veterinarian about whether NEXT Technology is reasonably likely to promote healing
effects on the soft palate of the Horse, and whether the likely benefit justifies participation when weighed against possible
adverse outcomes or side effects.
4. Owner shall follow the recommendations provided by the Horse’s veterinarian regarding care, evaluation, and
rehabilitation following the administration of NEXT Technology, including but not limited to periodic clinical and
endoscopic evaluations, and other types of pre-operative and post-operative evaluations as appropriate. Owner, not
Orthopeutics-Sinclair, shall be responsible for the costs of all forms of care, evaluation, and rehabilitation contemplated
by this paragraph.
5. Orthopeutics-Sinclair may use any and all clinical or laboratory data related to the Horse and the NEXT Technology
for any purpose, provided that the Horse’s and the Owner’s identity are kept confidential. Owner shall maintain the
confidentiality of all clinical and non-clinical outcomes in association with the NEXT Technology, unless otherwise made
public by Orthopeutics within its sole discretion according to this paragraph.
6. ORTHOPEUTICS-SINCLAIR DISCLAIM ANY AND ALL EXPRESS AND IMPLIED WARRANTIES IN
CONNECTION WITH NEXT TECHNOLOGY AND THE AGENTS USED IN NEXT THERAPY, INCLUDING BUT
NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A
PARTICULAR PURPOSE.
7. Liability of Orthopeutics-Sinclair, if any, is limited to the cost of the agents utilized in the NEXT Technology on the
Horse, and Owner’s recovery and remedies are limited to such cost. All further liability for all actual, direct, indirect,
special, compensatory, and punitive damages, including but not limited to lost profits and consequential damages, which
may occur for any reason are expressly disclaimed by mutual agreement of the Parties.
8. For the duration of this study, owner agrees to not utilize any other alternative treatment therapies on the Horse.
Owner agrees to follow after care instructions and rehabilitation program as provided by Orthopeutics-Sinclair.
9. Owner understands that the Horse must be shipped to the Sinclair Research Center in Missouri and acknowledges the
inherent risks that are involved in shipping and transporting horses. These risks may include but are not limited to, illness,
disease, trauma, injury, or death of the Horse. Owner understands that Orthopeutics-Sinclair and the associated
transporting company do not provide insurance. Owner hereby holds Orthopeutics, Sinclair, and the transporting
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company harmless for any liability that could incur for property damage or bodily injury to any horse and/or patrons while
loading, transporting, unloading or handling the Horse.
10. In the event that the horse requires veterinary care while in transport, Orthopeudics-Sinclair will immediately notify
Owner. If the Owner cannot be reached, Orthopeudics-Sinclair will contact the first available licensed veterinarian.
Owner shall be responsible for all fees listed by said veterinarian, with no liability to Orthopeudics, Sinclair, or the
transporting company.
11, This Agreement and Informed Consent shall be governed by the laws of the Commonwealth of Kentucky, without
regard to Kentucky’s or any other state’s rules concerning conflicts of law. The Parties agree that Kentucky Courts shall
have jurisdiction over them personally as well as over the subject matter of any dispute that arises in connection with this
Agreement and Informed Consent. Any lawsuit filed in connection with this Agreement must be commenced in Fayette
County, Kentucky.

INFORMED CONSENT
1. The experimental nature of NEXT Technology has been fully explained to Owner and/or Owner’s agent. Further,
Owner is aware that potential risks, side effects, and adverse complications of NEXT Technology (referred to as
“Complications”) may include, without limitation, lack of repair, deterioration of condition, soft palate damage,
infection, inflammation, and bleeding. However, the possibility of other unexpected responses including the
possible need to euthanize the animal is not excluded. Owner is aware that Complications may be either
anticipated or unanticipated, and may be either immediately known or not immediately knowable. While it is
expected that Complications, if any, will be minimal, no guarantees or warranties of any kind are being provided
regarding the outcome of the Study and/or the effects of NEXT Technology on the Horse.
2. Owner understands that NEXT Technology on the Horse may include mild sedation, injection of a local
anesthetic, and one or more injections of Genipin, and consents to same.
3. The Parties acknowledge that Owner’s decision to allow the Horse to participate in the Study is entirely
voluntary.
4. By signing below, I, as the Owner or the Owner’s agent, acknowledge that I have read this Agreement and
Informed Consent in its entirety, I have been provided with a description of the NEXT Technology, I have had the
opportunity to ask further questions of Orthopeutics-Sinclair, and that the risks of potential Complications have
been explained to my satisfaction. I give informed consent to the administration of NEXT Technology to the
Horse in connection with the Study.
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Signatures
IN WITNESS WHEREOF, the parties have accepted and agreed to the above by and through their authorized agents as of
the Effective Date:
On Behalf of Owner,

On Behalf of

_______________________ :

Orthopeutics, LP:

_______________________________

_____________________________

Name: _______________________________

Name: ______________________________

Title: ________________________________

Title:

______________________________

Date: ________________________________

Date:

______________________________

On Behalf of:
Sinclair Research Center, LLC:
___________________________
Name: _____________________________
Title: ______________________________
Date: ______________________________
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1. SCHEDULE 1
Information about horse:
Name:____________________________________ Discipline:______________________________
Breed:________________ Sex: Mare

Gelding Stallion

Age:______________

Veterinarian:__________________________ Vet phone:____________________ Email:______________________
Date of DDSP ("Snoring") Onset:______________ Frequency of Displacement:____________________
Loudness of “Snoring”: _____________
Previous Health Conditions/Surgeries: _______________________________________________________________
Work Level of Horse:____ Pasture (no work) ____ light work

____ moderate work ____ full work (1 hr/5 days wk)

Purchase price of horse: ____________
Declared Value of Horse:______________________ Insured:
Has insurance company been contacted?

Yes

Yes

No

No

If insured, please provide following information:
Insurance Co:_______________________ Phone:____________________ Contact:______________________
Owner Information:
Name/Address:___________________________________________
___________________________________________
___________________________________________
Cell phone:____________________________________ Email:_________________________________
Information provided by:_____________________________________ Date:_______________

5
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APPENDIX A4: in vivo study donation form

!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!
!
!
AGREEMENT FOR DONATION OF EQUINE FOR EXPERIMENTAL EQUINE TREATMENT
This AGREEMENT FOR DONATION OF AN EQUINE FOR EXPERIMENTAL EQUINE
TREATMENT (referred to as “Agreement”) is between:
_____________________________________, having an address of ______________________________
(referred to as “Owner”); and
Orthopeutics, LP, a Kentucky limitied liability company, having an address of 1501 Bull Lea Rd. #103,
Lexington, KY 40511 (referred to as “Orthopeutics”).
Owner and Orthopeutics are referred to collectively as the “Parties.” The Effective date of this Agreement is
the date it is signed by the Parties.
AGREEMENTS
1. Owner voluntarily donates the horse identified in Schedule 1 (referred to as “Horse”) to Orthopeutics to
be used in the study for the treatment of dorsal displacement of the soft palate (DDSP) in equines
(referred to as “Study”) at Sinclair Research Center at the University of Missouri (referred to as
“Sinclair”).
2. The Owner relinquishes all rights and responsibilities pertaining to the Horse to Orthopeutics.
3. The Owner acknowledges that the Horse will be used for scientific research as a part of the Study,
including but not limited to, anesthesia, soft palate injections, sound recordings, or endoscope
examinations.
4. Orthopeutics will be responsible for ensuring humane care of the Horse throughout the study.
5. The Owner acknowledges that the Horse will be humanely euthanized at the conclusion of the study by
licensed veterinarians at Sinclair.
6. Owner acknowledges that there will be no money compensation for the donation of the Horse to
Orthopeutics for the Study.

!
1
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!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!
!
!
SIGNATURES
IN WITNESS WHEREOF, the parties have accepted and agreed to the above by and through their authorized
agents as of the Effective Date:
On Behalf of Owner,
____________________________________:
_______________________________________
Name: ________________________________________
Title: _________________________________________
Date: _________________________________________
On Behalf of
Orthopeutics, LP:
_________________________________________
Name: _________________________________________
Title: __________________________________________
Date: __________________________________________

!
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!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!
!
!
1. SCHEDULE 1
Information about horse:
Name:____________________________________ Discipline:______________________________
Breed:________________ Color: _____________ Sex: Mare Gelding Stallion

Age:______________

Veterinarian:_______________________ Vet phone:_________________ Email:______________________
Previous Health Conditions/Surgeries:
_______________________________________________________________
Work Level of Horse:____ Pasture (no work) ____ light work ____ moderate work ____ full work (1
hr/5 days wk)
Purchase price of horse: ____________
Declared Value of Horse:______________________ Insured: Yes
Has insurance company been contacted?

Yes

No

No

If insured, please provide following information:
Insurance Co:______________________ Phone:____________________ Contact:______________________
Owner Information:
Name/Address:___________________________________________
___________________________________________
___________________________________________
Cell phone:____________________________________ Email:_________________________________
Information provided by:_____________________________________ Date:______________________

!
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APPENDIX A5: Veterinary transcript for DDSP horses

Hello Dr. [INSERT VET NAME HERE],

I am a graduate student in the Department of Biomedical Engineering at the University of
Kentucky. I am currently working on an in vivo study on dorsal displacement of the soft
palate, or DDSP, in horses. The study consists of injecting the soft palate with a natural
substance to stiffen it and decrease vibrations, thus reducing the frequency of soft palate
displacement. The study is being funded by a National Institute of Health SBIR Phase 1
grant.

I am actively searching for three horses with DDSP to be used in our study in the next
couple of weeks. The DDSP horses in the study would be transported to the Sinclair
Research Center in Missouri. The study would consist of an initial exam, including
recording their breathing noises while running and an endoscopic evaluation. Then, the
horse will be sedated and their soft palates injected using a transendoscopic injection
needle. Finally, a post exam, similar to the initial exam, would be completed. The
horses would then be returned to their owners at the end of the study. Licensed
veterinarians at Sinclair Research Center would monitor the horses throughout the
study.

Do you know of any horses that would be good candidates for the study? If you do not,
do you know of anyone that could possibly help me?

Please feel free to email me or call me with any questions or concerns. I look forward to
hearing from you.

Thank you,
Stephanie Hunt
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APPENDIX A6: Reagent calculations for in vivo study

Genipin Calculations: 100 mM
100 𝑚𝑚𝑜𝑙
1 𝑚𝑜𝑙
226.22 𝑔
1𝐿
2 𝑚𝐿
𝑔
𝑚𝑔
𝑥
𝑥
𝑥
𝑥
= 0.045244
= 45.24
1𝐿
1000 𝑚𝑚𝑜𝑙
1 𝑚𝑜𝑙
1000 𝑚𝐿 1 𝑏𝑜𝑡𝑡𝑙𝑒
𝑏𝑜𝑡𝑡𝑙𝑒
𝑏𝑜𝑡𝑡𝑙𝑒

Buffer Calculations: 10% DMSO, 45 mM EPPS-P
22.5 mL EPPS-P
22.5 mL Distilled Water
5 mL DMSO
100 𝑚𝑀 𝐸𝑃𝑃𝑆 − 𝑃𝑥

!!.! !" !""#!!
! !"##$%

𝑥

! !"##$%
!" !"

= 45 𝑚𝑀 𝐸𝑃𝑃𝑆 − 𝑃
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APPENDIX A7: Respiratory audio analysis Matlab codes
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149

150
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APPENDIX A8: ImageJ Protocol

1.
2.
3.
4.
5.
6.

Open ImageJ
Import image
Select image from the menu bar à color à split channels
Using the green channel, select image à adjust à threshold
Use the default values, then press okay.
Select analyze à analyze particles

The output will provide the count of the red squares, the area, and the percent area of
red squares.
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APPENDIX B1: Reagent calculations for mechanical testing study

Genipin Reagent: 50 mM
50 𝑚𝑚𝑜𝑙
1 𝑚𝑜𝑙
226.22 𝑔
1𝐿
2 𝑚𝐿
𝑔
𝑔
𝑥
𝑥
𝑥
𝑥
= 0.0226
= 22.6
1𝐿
1000 𝑚𝑚𝑜𝑙
1 𝑚𝑜𝑙
1000 𝑚𝐿 1 𝑣𝑖𝑎𝑙
𝑣𝑖𝑎𝑙
𝑣𝑖𝑎𝑙

Saline Buffer: 0.9% NaCl
4.5 𝑔 𝑁𝑎𝐶𝑙 1000 𝑚𝐿
𝑔
𝑥
=9
500 𝑚𝐿
1 𝑣𝑖𝑎𝑙
𝑣𝑖𝑎𝑙

Saline-Phosphate Buffer: 50 mM tri-sodium phosphate
!" !!"#
!!

𝑥

! !"#
!""" !!"#

𝑥

!"#.!" !
! !"#

𝑥

!!
!""" !"

𝑥

!""" !"
! !"#$

= 19.01
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APPENDIX B2: Soft palate extraction protocol
Soft Palate Extraction
1. Soft palates will arrive with trachea and surrounding tissues.

2. Locate the epiglottis. Flip the epiglottis tip below the notch of the soft palate.

epiglottis

Soft palate
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3. Cut the tissue directly above the soft palate along the median.

4. Open the tissue you just cut to expose the epiglottis, soft palate and larynx.

Larynx

Epiglottis
Soft Palate

5. Cut along the outer edges of the soft palate to separate the excess tissue. The tissue
along the edge of the soft palate will be very thin and transparent – this is a good place
to cut along to ensure the entire palate is included.
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6. Cut along the bones below the epiglottis to remove the pant legs.

7. Trim any excess tissue from soft palate.
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APPENDIX B3: Mechanical testing protocol
Mechanical Testing Protocol
Hysteresis Test
1. Load Sample
2. Preload 10 N
3. Set up program
a. Show Cycling Panel: Axial: Stroke, Mean: ht of sample, Amplitude: 3 mm, Freq:
0.5, Phase:0, Cycles:20, Sine, mean down
4. Set up DAQ file at a sampling rate of 50 Hz
5. Start recording
6. Start cycle
7. Stop recording
8. Export data
Stress Relaxation Test
1. Load Sample
2. Preload 10 N
3. Create program
a. Step 1: ramp up to 10 N, rate 1 mm/s
b. Step 2: hold 300 s
c. Step 3: Idle
4. Set up DAQ file. Change DAQ Rate to 25 Hz
5. Start Recording
6. Start cycle
7. Stop recording
8. Export data
Tensile Test
1. Load sample
2. Return displacement to 0 and wait 30 seconds
3. Set up function generator
a. Axial mode: stroke, target point: 39, ramp 1mm/s
4. Set up DAQ at a sampling rate of 50 Hz
5. Start recording
6. Start ramp
7. Stop recording
8. Export data
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APPENDIX B4: Hysteresis Parameter Calculations
Hysteresis Calculations:
First, the starting point was used to offset the stroke data to find the absolute displacements.
For example, if the starting point was 42 mm, the stroke data was offset by 42 mm. Then, strain
was calculated by dividing the displacement by the gauge length. Next, stress in MPa was
calculated by dividing the load by the cross-sectional area of the sample. Finally, stress in Pa
was calculated by raising the stress in MPa values to the sixth power.
Once the strain and stress in Pa were calculated, the hysteresis graphs were plotted. First, the
cyclical loading was plotted with load on the y-axis and time on the x-axis to determine the
location of the 1st and 20th cycles. The 1st cycle was determined to be from the first local
minimum to the second local minimum as shown in red in Figure 1. The 20th cycle was
determined to be from the 19th local minimum to the 20th local minimum.

Figure 1: Hysteresis Cycles shown as load versus time to determine location of 1st and 20th cycles.

Then, the corresponding local minimum points were extracted and graphed to create the
individual cycle hysteresis curves with stress on the y-axis and strain on the x-axis. For
the 1st cycle, the stress and strain were plotted from corresponding values at the 1st local
minimum point to the 2nd local minimum point as shown in Figure 2. For the 20th cycle,
the stress and strain were plotted from corresponding values at the 19th local minimum
point to the 20th local minimum point as shown in Figure 3.

Figure 2: 1st cycle hysteresis curve

159

Figure 3: 20th Cycle hysteresis curve

Then, the entire hysteresis cycle was plotted with strain on the x-axis and stress on the y-axis as
shown in Figure 4. The 1st and 20th cycle curves were highlighted in red and black respectively.

Figure 4: Hysteresis Curve for all Cycles

Finally, the hysteresis for each point was calculated using the equation below.

𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐻𝑦𝑠𝑡𝑒𝑟𝑒𝑠𝑖𝑠 =

𝑆𝑡𝑟𝑒𝑠𝑠 𝑃𝑜𝑖𝑛𝑡 1 + 𝑆𝑡𝑟𝑒𝑠𝑠 𝑃𝑜𝑖𝑛𝑡 2
∗ (𝑆𝑡𝑟𝑎𝑖𝑛 2 − 𝑆𝑡𝑟𝑎𝑖𝑛 1)
2

Once all of the individual hysteresis points were calculated, the total hysteresis for the cycle up
and the total hysteresis for the cycle down were calculated for the 1st curve. The total
hysteresis for the cycle up was calculated by adding together all of the individual hysteresis
values from the 1st local minimum to the 1st cycle maximum. The total hysteresis for the cycle
down was calculated by adding together all of the individual hysteresis values form the 1st cycle
maximum to the 2nd local minimum. Then the difference between the cycle up total hysteresis
and the cycle down hysteresis was calculated to determine the area between the curves. This
was repeated for the 20th cycle.
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APPENDIX B5: Stress relaxation parameter calculations
The stress relaxation graphs were analyzed for the relaxation force and for the relaxation
modulus. First, the stress relaxation graph was plotted with time on the x-axis and stress in MPa
on the y-axis as shown in Figure 1. From this graph, the maximum and minimum stresses were
determined. Then the relaxation force was calculated by calculating the difference between the
maximum and minimum.

Stress RelaxaUon
0.08
0.07
Stress (MPa)

0.06
0.05
0.04

Stress Relaxa^on

0.03

Poly. (Stress Relaxa^on)

0.02
0.01
0
0

50

100

150

200

250

300

350

Time (sec)
Figure 5: Stress Relaxation Graph

Finally, the stress relaxation modulus was calculated at each point using Equation 1. Then, the
maximum and minimum relaxation modulus values were determined, and the relaxation
modulus difference was calculated by subtracting the minimum value from the maximum value.
𝑅𝑒𝑙𝑎𝑥𝑎𝑡𝑖𝑜𝑛 𝑀𝑜𝑑𝑢𝑙𝑢𝑠 =
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!(!)
!

(Equation 1)

APPENDIX B6: Tensile test parameter calculations
Tensile Test
Goal: Find the Peak Stress, Strain, Toughness, Energy to Peak, Toe Region Slope, Young’s
Modulus and Yield Point.
1. Using the stroke data offset the values by the starting point. For example, if all data
starts at -42mm, offset the values by 42 mm.
2. Find the strain by dividing the offset stroke by the length.
3. Find the stress by dividing the load by the cross sectional area.
4. Find the peak stress by finding the absolute maximum stress.
5. The strain at peak is determined by finding the strain at the absolute peak stress value.
6. Plot the stress vs. strain graph.
7. Plot the toughness values from the start of the graph to the final non zero point. Add a
trendline with the equation and R2 value. The trendline should be raised to the 3rd
power.
8. Determine the toughness by dividing each part of the toughness equation by the strain
raised to the respective power and adding them together.
9. Calculate the energy for the entire curve by multiplying the toughness by the cross
sectional area.
10. Locate the toe region by highlighting from the first non-zero value in the stress region
to 0.05 MPa.
11. Plot the toe region and add a trendline with the equation and R2 value. The equation
should be raised to the 2nd power.
12. Find the slope of the toe region by taking the derivative of the equation.
13. Find the start of the linear region by adding 50 points onto the end of the toe region.
Take the end of the linear region to be about 150-200 points from the beginning, unless
there is an obvious break from linearity in the graph.
14. Plot the linear region and trendline with the equation and R2 value. The Young’s
Modulus is the slope of the linear region.
15. To determine the yield point, first find the offset strain line by taking the linear region
equation and offsetting it by .02.
16. Plot the offset strain line and determine the point of intersection with the curve. The y
value of the intersection point is the yield point.
17. Find resilience by calculating the area under the curve to the yield point.
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APPENDIX C1: Bright Humor’s dynamic endoscope diagnoses

Pre Treatment:

Natanya M. Nieman, DVM
3241 Pisgah Pike
Versailles, KY 40383
(859)537-5000

BRIGHT HUMOR
Scope report
March 23, 2014Left arytenoid completely paralyzed and thickened, partially scarred up out of the
airway (previous tieback surgery that was released. Dorsal displacement of the soft
palate-displaced 90% of the exam. Epiglottis is moderately flaccid and of normal
size.
Previous surgeries:
Tie Back
Tie Back Release
Tie Forward
Laser edge of soft palate
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Post Treatment:
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APPENDIX C2: Talladega Hall’s dynamic endoscope diagnoses
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APPENDIX C3: Post treatment clinical observations
Table 4.3: Post treatment clinical observations from in vivo study for each horse
Study
ID

Study
Day

1

1
0

1

Time

Clinical Observations

13 hr post

clearing throat repeatedly but not excessive

15 hr post

slight teeth grinding and licking

1 hr post

still slightly sedated

25 hr post

slight clear nasal discharge bilaterally, breathing normally

28 hr post

licking occasionally

29 hr post

twitching lips and licking occasionally

59 hr post

laying down

68 hr post

mild mucoid nasal discharge from both nares

1 hr post

still slightly sedated

2 hr post

licking/chewing

21 hr post

mild hypersalivation, reduced appetite

22 hr post

eating normally

23 hr post

mild hypersalivation, licking side of stall, breathing normally

24 hr post

occasional licking

25 hr post

mild hypersalivation, licking back of stall, breathing normally

28 hr post

slight clear nasal discharge from right nostril, breathing normally, eating well

43 hr post

some feed remaining

11 hr post

smacking continuously

12 hr post

continues to smack

14 hr post

clearing throat repeatedly but not excessive

15 hr post

constantly chewing and licking, no respiratory difficulty

16 hr post

small amount licking

19 hr post

clearing throat repeatedly

43 hr post

laying down

1 hr post

still slightly sedated

2

3

0

3
1

2
0

4
1

2

0
11 hr post
5

good amount of smacking and tongue movement in and out, cleared throat several times

55 hr post

chewing

57 hr post

chewing

13 hr post

laying down quietly

16 hr post

laying down quietly

2

6

1
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APPENDIX C4: Detailed histological analysis for individual samples

HISTOPATHOLOGY REPORT
4LT 1-2

Two sections through the treated palate 4LT are examined. The biopsy has intact mucosa on both the
respiratory and oral sides. The core of the biopsy is necrotic and connective tissue fibrils are widely
separated. The separation may be from edema or from expansion associated with tissue freezing. Few
muscular fascicles adjacent to the necrotic core retain their striations and are diffusely basophilic.
Surrounding the necrotic core is a marked zone of abundant neutrophils, many of which have
degenerated into basophilic smears (degenerated chromatin). In the palatine muscles adjacent to the
necrotic core, neutrophil infiltrates widely separate muscle fibers within fascicles. Muscle fibers are
swollen and most retain striations. Some myofibers have granular cytoplasm with large clear vacuoles.
The vacuoles may be from freezing artifact as similar cytoplasmic vacuoles are observed in the control
palate sections. Outside of the neutrophils, a wide zone of the collagenous stroma is necrotic.
Between the necrotic core and the viable submucosa of the oral mucosal epithelium is a moderate band
of spindloid cells with plump nuclei interpreted to be fibroblasts and mild amounts of irregular bands of
collagen. Mild numbers of eosinophils infiltrate the viable submucosa and a few small lobules of mucous
glands are observed. The stratified epithelium of the oral mucosa is unremarkable.
On the respiratory side, the necrotic collagenous stroma is moderately infiltrated with neutrophils. In the
submucosa are variably-sized clear spaces lined with a simple endothelium and filled with a minimal
amount of flocculent eosinophilic material. These clear spaces may represent vessels (lymphatic and
/or vascular) that may have expanded because of freezing. Also in the submucosa are mild to moderate
numbers of eosinophils. The respiratory mucosa is mildly infiltrated with granulocytes and cilia are not
observed. The lack of cilia may be associated with the transition of respiratory to oral mucosa.

4LM 1-2

Two sections through the treated palate 4LM are examined. The biopsy has intact mucosa on both the
respiratory and oral sides. The core of the biopsy contains abundant neutrophils. Surrounding the core
of neutrophils is a mild to moderate zone of necrotic collagenous stroma.
Neutrophil infiltrates occasionally extend through the necrotic stroma and surround degenerated lobules
of mucous glands on the oral side. Between the necrotic stroma and the viable submucosa of the oral
mucosa is a moderate band of spindloid cells with plump nuclei interpreted to be fibroblasts and
abundant dense irregular collagen. In some regions, collagenous fibers are separated by pale
eosinophilic material (suggestive of edema or freezing artifact). The submucosa is infiltrated with mild to
moderate numbers of neutrophils and lymphocytes that extend to the basal cells of the mucosa. Few
inflammatory cells infiltrate mildly edematous rete pegs of the mucosa.
Many muscle fascicles adjacent to the necrotic stroma on the respiratory side have myofibers with
single cytoplasmic vacuoles (freezing artifact). A minor number of muscle fascicles contain small
myofibers separated by mild numbers of spindloid cells and mild amounts of irregular collagenous
fibers, which are changes associated with fibroplasia. Many of the small myofibers have central plump
nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle and
the submucosa are moderate bands of plump spindloid cells or fibroblasts, with occasional mitotic
figures, with moderate amounts of irregular collagen fibrils. Between the regions of fibroplasia and the
mucosa are numerous lobules of mucous glands that have an edematous interstitial stroma. In the
submucosa are variably-sized clear spaces lined with a simple endothelium and filled with a minimal
amount of flocculent eosinophilic material. These clear spaces may represent vessels (lymphatic and
/or vascular) that may have expanded because of freezing. Also in the submucosa are mild to moderate
numbers of eosinophils. The respiratory mucosa contains small vacuoles that separate epithelial cells.

4LB 1-2

Two sections of the control palate 4LB are examined. No significant lesions are observed. The
pseudostratified columnar ciliated epithelium on the respiratory side of the palate is intermittently folded
to form glandular-like pockets. The submucosa is moderately populated with tubuloalveolar mucous
glands in a well-vascularized stroma of fine collagenous fibrils. Around the base of the mucous glands
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and diffusely within the stroma are mild infiltrates of lymphocytes and plasma cells. Deep to the
submucosa are moderately-sized arteries and bands of dense collagen, tendons and fascicles of the
palatine skeletal muscles. Skeletal myofibers occasionally contain cytoplasmic clear vacuoles which
are most likely a consequence of ice crystal formation associated with freezing. Toward the oral side of
the palate, abundant large lobules of mucous glands are adjacent and occasionally separate the
muscular fascicles. Glandular lobules are separated from each other by thick bands of dense
connective tissue. Closer to the mucosal surface and within the dense collagenous stroma of the
submucosa are multiple lymph nodules, each with multiple germinal centers. Interspersed between
lymphoid nodules are smaller bands of skeletal muscle and cross-section of ducts – likely from the
mucous glands. The oral mucosa is slightly folded and composed of acanthotic non-keratinized
stratified squamous epithelium with prominent rete pegs.
4RT 1-2

Two sections through the treated palate 4RT are examined. The biopsy has mostly intact mucosa on
both the respiratory and oral sides. The core of the biopsy is extensively necrotic. Vessels in the
necrotic core are distended and contain fibrillar eosinophilic material which may represent fibrin.
Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the zone of neutrophils,
a wide zone of the collagenous stroma is necrotic.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a mild band of
spindloid cells with plump nuclei interpreted to be fibroblasts and mild amounts of dense collagen. The
submucosa is infiltrated with mild numbers of eosinophils and lymphocytes. The mucosa is
unremarkable.
On the respiratory side, neutrophil infiltrates widely separate muscle fibers within many fascicles.
Muscle fascicles contain swollen and fragmented myofibers separated by moderate numbers of
spindloid cells (fibroblasts) and mild amounts of collagenous fibers, which are changes associated with
fibroplasia. Between the injured muscle and the submucosa are degenerated mucous glands, moderate
infiltrates of plump fibroblasts, mild deposits of irregular collagen and mild to moderate infiltrates of
eosinophils and lymphocytes. Neutrophil infiltrates within the necrotic stroma extend to the submucosa
in many regions. The submucosa is mildly edematous. In a few regions of the submucosa are variablysized clear spaces lined with a simple endothelium and filled with a minimal amount of flocculent
eosinophilic material. These clear spaces may represent vessels (lymphatic and /or vascular) that may
have expanded because of freezing. In the respiratory mucosa are minimal inflammatory cells. Cilia are
not observed.

4RM 1-2

Two sections through the treated palate 4RM are examined. The biopsy has mostly intact mucosa on
both the respiratory and oral sides. The core of the biopsy is extensively necrotic. Vessels in the
necrotic core are distended and contain fibrillar eosinophilic material which may represent fibrin.
Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the zone of neutrophils,
a wide zone of collagenous stroma is necrotic.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a moderate
band of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense
irregular collagen. Lobules of mucous glands are degenerated with loss and attenuation of glandular
epithelium. The submucosa is edematous and infiltrated with moderate numbers of eosinophils and
lymphocytes. Occasional inflammatory cells are within the mucosa and occasional mitoses are
observed in basal epithelial cells.
Neutrophil infiltrates widely separate muscle fibers within many fascicles on the respiratory side. Muscle
fascicles contain swollen and fragmented myofibers separated by moderate numbers of spindloid cells
(fibroblasts) and mild deposits of irregular collagen, which are changes associated with fibroplasia.
Many muscle fascicles adjacent to the necrotic stroma contain small myofibers with central plump
nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle and
the submucosa are moderate bands of plump fibroblasts with moderate irregular collagen deposits.
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Between the regions of fibroplasia and the mucosa are numerous lobules of mucous glands. Neutrophil
infiltrates of the necrotic stroma extend to the submucosa in many regions. In most of the biopsy, the
submucosa is mildly edematous and moderately infiltrated with lymphocytes, neutrophils and few
eosinophils. The respiratory mucosa is mildly infiltrated with granulocytes and cilia are not observed.
The lack of cilia may be associated with the transition of respiratory to oral mucosa.
4RB 1-2

Two sections through the control palate 4RB are examined. The biopsy has mostly intact mucosa on
both the respiratory and oral sides. The core of the biopsy is extensively necrotic which may be from
carryover from the treated sites. Vessels in the necrotic core are distended and contain fibrillar
eosinophilic material which may represent fibrin. Surrounding the necrotic core are abundant infiltrates
of neutrophils.. Outside of the abscess, a wide zone of the collagenous stroma is necrotic.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a moderate
band of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate deposits of dense
irregular collagen. Lobules of mucous glands are degenerated with loss and attenuation of glandular
epithelium. The submucosa is edematous and infiltrated with moderate numbers of eosinophils and
lymphocytes. Occasional inflammatory cells are within the mucosa and occasional mitoses are
observed in basal epithelial cells.
On the respiratory side, necrosis of the stroma with moderate neutrophil infiltrates extends to the
submucosa in many regions. Neutrophil infiltrates widely separate muscle fibers within many fascicles.
Muscle fascicles contain swollen and fragmented myofibers separated by moderate numbers of
spindloid cells (fibroblasts) and mild amounts of collagenous fibers, which are changes associated with
fibroplasia. Many muscle fascicles adjacent to the necrotic stroma contain small myofibers with central
plump nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle
and the submucosa are moderate bands of plump fibroblasts with moderate irregular collagen deposits.
Between the regions of fibroplasia and the mucosa are numerous lobules of mucous glands within an
edematous interstitial stroma. The submucosa is mildly edematous and moderately infiltrated with
lymphocytes, neutrophils and few eosinophils. The respiratory mucosa is mildly infiltrated with
granulocytes.

5LT

One section through the treated palate 5LT is examined. The biopsy has a limited amount of mucosa
on the respiratory and oral sides. The core of the biopsy is extensively necrotic. Within the necrotic
tissue are scattered bacterial colonies. Moderate to marked infiltrates of neutrophils surround the
necrotic core. Outside of the neutrophilic zone, a wide zone of the collagenous stroma is necrotic.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense
collagen. These bands of fibroplasia frequently surround foci of necrotic stroma and extend up to the
level of the mucous glands. Mild infiltrates of neutrophils are among the fibroblasts at the interface of
the necrotic stroma and many small blood vessels are observed within the fibroplastic tissue. The
submucosa and oral mucosa are within normal limits.
On the respiratory side, necrosis of stroma and muscular fascicles with moderate to marked neutrophil
infiltrates extend to the submucosa and occasionally to the base of the mucosa. Some mucous glands
are degenerated and infiltrated with mild numbers of lymphocytes and plasma cells. Muscle fascicles
contain swollen and fragmented myofibers separated by moderate numbers of spindloid cells and mild
amounts of collagenous fibers, which are changes associated with fibroplasia. On the periphery of the
necrotic tissue, muscle fasicles are separated by moderate amounts of dense and fine collagen fibrils
with fewer and smaller spindloid cells (interpreted to be fibrocytes) and minimal inflammatory cell
infiltrates. This expanded stroma may represent artifactual separation associated with freezing. The
mucous glands in this region are mildly infiltrated with lymphocytes and plasma cells. In the submucosa
are multiple variably-sized clear spaces lined with a simple endothelium and rarely filled with a minimal
amount of flocculent eosinophilic material. These clear spaces may represent vessels (lymphatic and
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/or vascular) that may have expanded because of freezing. The submucosa has mild to moderate
numbers of lymphocytes that often extend to the base of the mucosa. The respiratory mucosa
occasionally contains small vacuoles that separate epithelial cells. No cilia are observed.
5LM

One section through the treated palate 5LM is examined. The biopsy has a limited amount of mucosa
on the respiratory and oral sides. The core of the biopsy is extensively necrotic at one margin.
Surrounding the necrotic core are mild to moderate infiltrates of neutrophils. Outside of the neutrophilic
zone are multiple regions of necrotic collagenous stroma.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense
irregular collagen. Mild infiltrates of neutrophils are among the fibroblasts at the interface of the necrotic
stroma and many small blood vessels are observed within the fibroplastic tissue. Mucous glands in the
region with the most inflammation and fibroplasia have mild interstitial edema. The submucosa in the
region of inflammation has mild numbers of infiltrating eosinophils, plasma cells and lymphocytes. The
oral mucosa is unremarkable.
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa
and base of the mucosa. Some mucous glands in this region are moderately to markedly degenerated
and infiltrated with mild numbers of neutrophils, lymphocytes and plasma cells. Muscle fascicles
contain swollen and occasionally fragmented myofibers separated by moderate numbers of spindloid
cells, interpreted to be fibroblasts, mild to moderate amounts of irregular collagen and mild infiltrates of
neutrophils and occasionally eosinophils. On the periphery of the necrotic tissue, muscle fasicles are
separated by moderate amounts of dense and fine irregular collagen fibrils with fewer and smaller
spindloid cells (interpreted to be fibrocytes) and minimal inflammatory cell infiltrates. This expanded
stroma may represent artifactual separation of normal stroma associated with freezing. Mild interstitial
infiltrates of lymphocytes and plasma cells are observed in the mucous glands in this region. In the
submucosa are multiple variably-sized clear spaces, most of which are lined with a simple endothelium.
These clear spaces may represent vessels (lymphatic and /or vascular) that may have expanded
because of freezing. The submucosa has mild to marked numbers of lymphocytes that often extend to
the base of the mucosa. The respiratory mucosa occasionally contains small vacuoles that separate
epithelial cells. No cilia are observed.

5LB

One section of the control palate 5LB is examined. No significant lesions are observed. The surface
epithelium on the respiratory side of the palate is intermittently folded to form glandular-like pockets and
overlays multiple large submucosal lymphoid nodules, each composed of lymphoid aggregates with
prominent germinal centers. The epithelium overlying the nodules is a simple low columnar epithelium
while that of the infolded regions is pseudostratified and columnar. Between and beneath the lymphoid
nodules are mucous glands in a well-vascularized stroma of fine irregular collagenous fibrils. Around
the base of the mucous glands and diffusely within the stroma are mild infiltrates of lymphocytes and
plasma cells. Deep to the mucous glands is a broad band of dense regular collagen populated with
medium-sized arteries and multiple small clusters of lymphocytes. Beneath this layer is a fascial plane
composed of mild amounts of collagen surrounding arteries, nerves and clusters of adipose tissue. The
core of the biopsy contains a moderate band of large dense collagenous fascicles interpreted to be the
tendon aponeurosis. Between the tendon aponeurosis and the oral side of the palate are abundant
lobules of mucous gland. Few bands of collagen associated with ductal structures extend from the
submucosa into the glands. Closer to the mucosal surface and within the dense collagenous stroma of
the submucosa are multiple lymph aggregates and ducts. The oral mucosa is slightly folded,
nonkeratinized stratified squamous epithelium with prominent rete pegs.

5RT 1-2

Two sections through the treated palate 5RT are examined. One portion of the biopsy (5RT1) is
interpreted to be within normal limits and is not described. Changes are observed on section 5RT2. The
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core of the biopsy is necrotic with moderate neutrophilic infiltrates at one margin. Outside of the
neutrophilic zone are multiple regions of necrotic collagenous stroma.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense
irregular collagen. Mild to moderate infiltrates of neutrophils are among the fibroblasts at the interface
of the necrotic stroma and many small blood vessels are observed within the fibroplastic tissue. Mucous
glands in the region with the most inflammation and fibroplasia have mild interstitial fibrosis, edema (or
freezing artifact) and mild infiltrates of lymphocytes and plasma cells. The submucosa in the region of
inflammation has minimal numbers of infiltrating eosinophils, plasma cells and lymphocytes. The oral
mucosa is unremarkable.
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa
and base of the mucosa. Some mucous glands in this region are mildly to moderately degenerated and
infiltrated with mild numbers of neutrophils, lymphocytes and plasma cells. Muscle fascicles contain few
myofibers separated by moderate numbers of spindloid cells, interpreted to be fibroblasts, mild to
moderate amounts of irregular collagen and mild infiltrates of neutrophils and occasionally eosinophils.
Many muscle fascicles adjacent to the necrotic stroma contain small myofibers with central plump and
peripheral nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating
muscle and the submucosa are moderate bands of fibroblasts with moderate irregular dense collagen
deposits. Mild interstitial infiltrates of lymphocytes and plasma cells are observed in the mucous glands
in this region. In the submucosa are multifocal variably-sized clear spaces, most of which are lined with
a simple endothelium. These clear spaces may represent vessels (lymphatic and /or vascular) that may
have expanded because of freezing. The submucosa has mild diffuse to marked focal numbers of
lymphocytes that often extend to the base of the mucosa. The respiratory mucosa occasionally contains
small vacuoles that separate epithelial cells. No cilia are observed.

5RM 1-2

Two sections through the treated palate 5RM are examined. One portion of the biopsy (5RM2) is
interpreted to be within normal limits and is not described. Changes are observed on section 5RM1. The
core of the biopsy is mildly necrotic with moderate to marked neutrophilic infiltrates at one margin.
Outside of the neutrophilic zone are multiple regions of necrotic stroma.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense
irregular collagen. Mild to moderate infiltrates of neutrophils are among the fibroblasts at the interface
of the necrotic stroma and many small blood vessels are observed within the fibroplastic tissue. Mucous
glands in the region with the most inflammation and fibroplasia have mild interstitial fibrosis, edema (or
freezing artifact) and mild infiltrates of lymphocytes and plasma cells. The submucosa in the region of
inflammation has minimal numbers of infiltrating eosinophils, plasma cells and lymphocytes. The oral
mucosa is unremarkable.
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa
and base of the mucosa. Some mucous glands in this region are mildly to moderately degenerated and
infiltrated with mild numbers of neutrophils, lymphocytes and plasma cells. Many muscle fascicles
adjacent to the necrotic stroma contain small myofibers with central plump and peripheral nuclei, a
change associated with muscle hyperplasia or repair. Viable muscle fascicles frequently contain few
myofibers separated by moderate numbers of spindloid cells, interpreted to be fibroblasts, mild to
moderate amounts of irregular collagen and mild infiltrates of neutrophils and occasionally eosinophils.
Between the regenerating muscle and the submucosa are moderate bands of plump fibroblasts with
moderate irregular collagen deposits. Mild interstitial infiltrates of lymphocytes and plasma cells are
observed in the mucous glands in this region. In the submucosa are multifocal variably-sized clear
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spaces, most of which are lined with a simple endothelium. These clear spaces may represent vessels
(lymphatic and /or vascular) that may have expanded because of freezing. The submucosa also has
mild diffuse to marked aggregates of lymphocytes that often extend to the base of the mucosa. No cilia
are observed on respiratory mucosal epithelia.
5RB

One section of the control palate 5RB is examined. No significant lesions are observed. The oral
mucosa is slightly folded nonkeratinized stratified squamous epithelium with prominent rete pegs. The
submucosa contains dense collagenous stroma with multiple lymph aggregates and ducts of mucous
glands. Few bands of collagen associated with ductal structures extend from the submucosa into the
glands. Between the submucosa are abundant lobules of mucous glands. No respiratory mucosa is
present in the section.

6LT

One section of the control palate 6LT is examined. The pseudostratified columnar ciliated epithelium on
the respiratory side of the palate is absent in half of the section. The submucosa is moderately
populated with tubuloalveolar mucous glands in a well-vascularized stroma of fine collagenous fibrils. In
the region missing the mucosa, the submucosa contains several foci of necrotic stroma surrounded by
and infiltrated with mild numbers of neutrophils. It is likely this is carryover damage from the treated
portions of the same soft palate. Around the base of the mucous glands and diffusely within the stroma
are mild infiltrates of lymphocytes and plasma cells. Deep to the submucosa are moderately-sized
arteries and bands of dense collagen, tendons and abundant fascicles of skeletal muscle. Toward the
oral side of the palate are many large lobules of mucous glands. Glandular lobules are separated from
each other by small bands of dense connective tissue. Closer to the mucosal surface and within the
dense collagenous stroma of the submucosa are multiple cross-sections of ducts – likely from the
mucous glands. The oral mucosa is occasionally folded and composed of acanthotic non-keratinized
stratified squamous epithelium with prominent rete pegs.

6LM

One section through the treated palate 6LM is examined. The biopsy has mostly intact mucosa on the
oral side. No mucosa is observed on the respiratory side. The core of the biopsy is extensively necrotic.
Vessels in the necrotic core are distended and contain fibrillar eosinophilic material which may
represent fibrin. Within the necrotic area are moderate numbers of coccobacillary bacterial colonies.
Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the neutrophil infiltrates,
a wide zone of the collagenous stroma is necrotic.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a mild band of
spindloid cells with plump nuclei interpreted to be fibroblasts and mild amounts of dense irregular
collagen. The submucosa is infiltrated with mild numbers of eosinophils and lymphocytes. Multifocal
lymphoid nodules with lymphoid aggregates and germinal centers are observed. The mucosa is
unremarkable.
Neutrophil infiltrates and collagen fibrils widely separate muscle fibers within many fascicles adjacent to
the necrotic core on the respiratory side. Muscle fibers are small, most retain striations and have central
nuclei consistent with regeneration. Some muscle fascicles contain myofibers separated by moderate
numbers of fibroblasts and mild deposits of irregular collagen fibers, which are changes associated with
fibroplasia. There is minimal submucosa and no respiratory mucosa present in the section.
In the palatine muscles distant from the treatment site is an intracytoplasmic cyst filled with bananashaped protozoal organisms consistent with Sarcocystis. No inflammation was associated with the
presence of the encysted protozoa.

6LB 1-2

Two sections through the treated palate 6LB are examined. The biopsy has a small portion of intact
mucosa on the respiratory side and a limited amount of oral mucosa. The core of the biopsy is
extensively necrotic. Within the necrotic tissue are multiple mineralized foci and coccobacillary bacterial
colonies. Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the zone of
neutrophils is a wide zone of necrotic collagenous stroma. On the respiratory side is a broad region of
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diffuse basophilia (representing degeneration) of muscle, fascia and mucosa. A small portion of viable
respiratory mucosa is on one section.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a moderate
band of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense
irregular collagen. Some lobules of mucous glands are degenerated with loss and attenuation of
glandular epithelium. The submucosa is infiltrated with mild numbers of eosinophils and lymphocytes.
Occasional inflammatory cells are within the mucosa.
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa
and base of the mucosa. In this area, muscle fascicles are separated by moderate numbers of
fibroblasts and mild deposits of irregular collagen which are changes associated with fibroplasia. Many
myofibers in fascicles adjacent to the necrotic stroma are absent and some are small with central plump
nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle and
the submucosa are moderate bands of plump fibroblasts with moderate irregular collagen deposits.
Between the regions of fibroplasia and the mucosa are numerous lobules of mucous glands, some with
degenerated glandular epithelium, and all with moderate interstitial infiltrates of lymphocytes,
neutrophils and few eosinophils. The submucosa is mildly edematous and moderately infiltrated with
lymphocytes, plasma cells, neutrophils and few eosinophils. The respiratory mucosa is mildly infiltrated
with granulocytes.
6RT

One section of the control palate 6RT is examined. No significant lesions are observed. The
pseudostratified columnar ciliated epithelium on the respiratory side of the palate is intermittently folded
to form glandular-like pockets. The submucosa is moderately populated with tubuloalveolar mucous
glands in a well-vascularized stroma of fine collagenous fibrils. Around the base of the mucous glands
and diffusely within the submucosa are minimal infiltrates of lymphocytes, plasma cells and occasional
eosinophils. Deep to the submucosa are moderately-sized arteries and bands of dense collagen,
tendons and abundant fascicles of skeletal muscle. Skeletal myofibers occasionally contain
cytoplasmic clear vacuoles which are most likely a consequence of ice crystal formation associated with
freezing. Toward the oral side of the palate, abundant large lobules of mucous glands are adjacent to
and occasionally separate the muscular fascicles. Glandular lobules are separated from each other by
thick bands of dense connective tissue. Closer to the mucosal surface and within the dense
collagenous stroma of the submucosa is an aggregate of lymphocytes, smaller bands of skeletal muscle
and cross-section of ducts – likely from the mucous glands. The oral mucosa is slightly folded and
composed of acanthotic non-keratinized stratified squamous epithelium with prominent rete pegs.

6RM 1-2

Two sections through the treated palate 6RM are examined. One portion of the biopsy (6RM2) is
interpreted to be within normal limits and is not described. Changes are observed on section 6RM1.
The core of the biopsy is extensively necrotic. Within the necrotic tissue are multiple mineralized foci
and coccobacillary bacterial colonies. Surrounding the necrotic core are abundant infiltrates of
neutrophils. Outside the zone of neutrophils on the respiratory side is a broad region of diffuse
basophilia (representing degeneration) of muscle, fascia and portions of mucosa.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a large region
of stroma composed of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate
amounts of dense irregular collagen. In this area are a few muscle fascicles with mild to moderate
interstitial infiltrates of plump fibroblasts, mild amounts of irregular collagen fibrils and mild infiltrates of
plasma cells and lymphocytes. Between the fibroplastic regions and mucosa is abundant regular
collagenous stroma with a single lobule of mucous glands. Stroma and submucosa are infiltrated with
minimal numbers of eosinophils and lymphocytes.
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa
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and base of the mucosa. In this area, muscle fascicles are separated by moderate numbers of spindloid
cells or fibroblasts and mild deposits of irregular collagenous fibers. Many myofibers in fascicles
adjacent to the necrotic stroma are absent and some are small with central plump nuclei, a change
associated with muscle hyperplasia or repair. Between the regenerating muscle and the submucosa are
moderate bands of plump fibroblasts with moderate irregular collagen deposits. Between the regions of
fibroplasia and the mucosa are numerous lobules of mucous glands, some with degenerated glandular
epithelium, and all with mild interstitial infiltrates of lymphocytes, neutrophils and few eosinophils. The
submucosa is mildly edematous and moderately infiltrated with lymphocytes, plasma cells, neutrophils
and few eosinophils. The respiratory mucosa shows the transition from pseudostratified columnar to
stratified squamous epithelium in this region. The mucosa is mildly infiltrated with granulocytes.
In the palatine muscles distant from the treatment site is an intracytoplasmic cyst filled with bananashaped protozoal organisms consistent with Sarcocystis. No inflammation was associated with the
presence of the encysted protozoa.
6RB

One section through the treated palate 6RB is examined. The core of the biopsy is extensively necrotic.
Within the necrotic tissue are multiple mineralized foci. Surrounding the necrotic core are abundant
infiltrates of neutrophils. Outside the zone of neutrophils on the respiratory side is a broad region of
diffuse basophilia (representing degeneration) of muscle, fascia and portions of mucosa.
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a large region
of stroma composed of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate
amounts of dense irregular collagen. In this area are a few muscle fascicles with mild to moderate
interstitial infiltrates of plump spindloid cells, mild amounts of collagenous fibers and mild infiltrates of
plasma cells and lymphocytes. Between the fibroplastic regions and mucosa is abundant regular
collagenous stroma. Stroma and submucosa are infiltrated with mild numbers of plasma cells,
lymphocytes and minimal numbers of eosinophils.
On the respiratory side, necrosis of the stroma with moderate neutrophil infiltrates partially extends to
the submucosa only in the region with viable mucosa. In this area, muscle fascicles are separated by
moderate numbers of fibroblasts and mild to moderate deposits of irregular collagenous fibers. Many
myofibers in fascicles adjacent to the necrotic stroma are absent and some are small with central plump
nuclei, a change associated with muscle hyperplasia or repair. Between the regions of fibroplasia and
the mucosa are numerous lobules of mucous glands, one with degenerated glandular epithelium and
the others with mild interstitial infiltrates of lymphocytes, neutrophils and few eosinophils. The
submucosa is moderately infiltrated with lymphocytes, plasma cells, neutrophils and few eosinophils.
The respiratory mucosa shows the transition from pseudostratified columnar to stratified squamous
epithelium in this region. The mucosa is mildly infiltrated with granulocytes.
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APPENDIX D1: Mechanical testing study notes
Table 4.10: Mechanical testing study sample notes
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APPENDIX D2: Mechanical testing study raw data
Table 4.11: Raw data from mechanical testing study for each individual sample
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APPENDIX D3: Summarized data with outliers removed
Table 4.12: Individual sample data with outliers removed from mechanical testing study
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APPENDIX D4: Averages and standard deviations of data
Table 4.13: Averages and standard deviations for each parameter. The percent differences comparing each group
are also listed.
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APPENDIX D5: F-test results for each parameter

Table 4.16: Critical F values for each comparison for the mechanical testing study

Table 4.17: F-test results for each individual parameter. Values that do not pass the test are highlighted in pink
with red text.
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APPENDIX D6: p-value results for each parameter
Table 4.18: p-value results for each parameter. The categories that failed the F-test were analyzed with the MannWhitney U non-parametric test, and those that passed were analyzed with the t-test. Statistically significant values
with a p value < 0.05 at α = 0.05 are highlighted in red and pink.
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